canoboi的个人主页 - 老虎社区

canoboi

暂无个人介绍

IP属地：未知

614关注

28粉丝

0主题

0勋章

2022-01-02

Like n comment

If I Could Buy Only 1 Stock in 2022, This Would Be It

2021-12-30

Like and comment..thanks

抱歉，原内容已删除

2021-12-28

Like and comment thanks

Toplines Before US Market Open on Tuesday

2021-12-27

Like and comment thanks

Santa Claus Rally watch: What to know this week

2021-12-26

Like and comment thanks

Can This Top Blue Chip Stock Handle Soaring Inflation?

2021-12-23

Like and comment thks

Allakos rebounds amid bearish views on trial setback

2021-12-22

Like and comment thanks

Read Why Loop Capital Slashed Twitter Price Target By 22%

2021-12-19

Like and comment thanks

Novavax, Vir among healthcare gainers, Pfizer posts best rally in a decade

2021-12-18

Like n comment. Thks

Wall Street ends down after mostly negative week

2021-12-10

Like and comment. Thanks

STI down as investors weigh faster Fed taper

2021-12-09

Like and comment. Thanks

Is Roku Too Good To Pass Up at This Price?

2021-12-08

Like and comment. Thks

Airlines and cruise line stocks jumped in morning trading

2021-12-03

Like n comment thanks

5 Warren Buffett Stocks Are Screaming Buys in December

2021-11-30

Like and comment thanks

抱歉，原内容已删除

2021-11-29

Like and comment. Thanks

Toplines Before US Market Open on Monday

2021-11-14

Ok

Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.

2021-10-15

Like and comment.

Crypto stocks jumped in morning trading

2021-10-14

Like and comment thanks

抱歉，原内容已删除

2021-10-09

Like pls thks

Is the stock market open on Columbus Day? Yes! But the bond market isn't--Here's why

2021-10-08

Like and comment. Thanks

抱歉，原内容已删除

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":3554895157968981,"uuid":"3554895157968981","gmtCreate":1592223580332,"gmtModify":1592223580332,"name":"canoboi","pinyin":"canoboi","introduction":"","introductionEn":"","signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":28,"headSize":614,"tweetSize":161,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"35ec162348d5460f88c959321e554969-1","templateUuid":"35ec162348d5460f88c959321e554969","name":"精英交易员","description":"证券或期货账户累计交易次数达到30次","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"60.14%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.18","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":692490252,"gmtCreate":1641127475987,"gmtModify":1641127476362,"author":{"id":"3554895157968981","authorId":"3554895157968981","name":"canoboi","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like n comment","listText":"Like n comment","text":"Like n comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/692490252","repostId":"2200444738","repostType":4,"repost":{"id":"2200444738","pubTimestamp":1641099600,"share":"https://www.laohu8.com/m/news/2200444738?lang=&edition=full","pubTime":"2022-01-02 13:00","market":"us","language":"en","title":"If I Could Buy Only 1 Stock in 2022, This Would Be It","url":"https://stock-news.laohu8.com/highlight/detail?id=2200444738","media":"Motley Fool","summary":"Our favorite stock picks for the coming year.","content":"<html><head></head><body><p>We&#39;re firm believers in the benefit of owning a diversified portfolio of stocks. However, we all have our favorite stocks.</p><p>We asked some of our Fool.com contributors to whittle their favorites down to their top choice to buy in 2022 if they could only pick <a href=\"https://laohu8.com/S/AONE.U\">one</a>. Here&#39;s why <b><a href=\"https://laohu8.com/S/MMM\">3M</a></b> (NYSE:MMM), <b>Brookfield Asset Management </b>(NYSE:BAM), and <b>Brookfield Renewable</b> (NYSE:BEP)(NYSE:BEPC) topped their lists as the one stock they&#39;d buy this year. </p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/a909bb3cfb7abaedc74cfef9296edc0a\" tg-width=\"700\" tg-height=\"423\" width=\"100%\" height=\"auto\"/><span>Image source: Getty Images.</span></p><h2>A diversified giant that&#39;s still on sale</h2><p><b>Reuben Gregg Brewer (3M):</b> Benjamin Graham, renowned value investor and mentor to Warren Buffet, explains that investors are partnered with &#34;Mr. Market,&#34; a mercurial fellow prone to fits of despair and jubilation. When he&#39;s overly excited, you should consider selling to him; when he&#39;s pessimistic, you should think about buying. Right now, Mr. Market is very downbeat on diversified international industrial giant 3M. One way to see this is that the company&#39;s dividend yield, at around 3.3%, is near the top end of its historical range.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/35404c30dd22bffd6cc4a1450aa485c9\" tg-width=\"720\" tg-height=\"433\" width=\"100%\" height=\"auto\"/><span>MMM Dividend Yield data by YCharts</span></p><p>Graham had some other advice when it came to actually selecting stocks. Specifically, he argued that most investors would be wise sticking to large, financially strong companies, with strong dividend histories. 3M stacks up well on these measures. It has a market cap of $100 billion, which makes it a mega-cap stock. Its balance sheet is investment-grade rated by the major credit agencies, so it&#39;s financially strong. And it has increased its dividend annually for over 60 years, making it a very elite Dividend King.</p><p>So why is Mr. Market pessimistic? The answer is a mixture of slowing growth and some product and environmental lawsuits. These are notable problems, but they&#39;re not insurmountable. On the business front, the industrial giant&#39;s operations wax and wane over time just like any other company. Given its history and focus on innovation, it should eventually get back on a better track. As for the lawsuits, they could be costly, but it&#39;s likely that 3M will be able to handle the hit. In the end, this is an attractively priced name with a great history that is dealing with issues that seem transitory.</p><h2>A proven value creator</h2><p><b>Matt DiLallo (Brookfield Asset Management):</b> I like to invest. Because of that, I routinely purchase a variety of stocks. However, if I could only buy one in the coming year, Brookfield Asset Management would be my top choice.</p><p>For starters, I love the company&#39;s management. CEO Bruce Flatt is a personal favorite of mine. He&#39;s right up there with Warren Buffett in my book as one of the best value investors around. I enjoy reading his quarterly letter to shareholders, which Flatt fills with investing and economic insight. He&#39;s also a proven value creator. Since becoming CEO in 2002, he&#39;s helped Brookfield deliver a 15.7% total annualized return, pulverizing the <b>S&amp;P 500</b>&#39;s 10.6% total return during that time frame. </p><p>I also like the company&#39;s business model. Brookfield is a leading global alternative asset manager focused on real estate, infrastructure, and renewable energy -- three of my favorite investing themes. An investment in Brookfield provides broad exposure to those three asset classes and many more. Brookfield invests directly across those themes and manages private equity funds focused on those sectors.</p><p>Finally, Brookfield has enormous upside potential. It expects to double its fee-bearing assets under management over the next five years. Combine that with performance-based earnings on its funds and the compounding value of its balance sheet investments, and it has the potential of generating up to 25% annualized total returns over the next five years. That upside, along with all the other positives, is why I&#39;d buy Brookfield if it were the only stock I could purchase this year. </p><h2>Investors are overlooking the growth potential here</h2><p><b>Neha Chamaria</b> <b>(Brookfield Renewable)</b>: 2021 is turning out to be a record-setting year for global renewable electricity addition, but this could just be the beginning. Yet shares of one of the largest pure-play renewables companies that&#39;s growing at a steady pace have languished this year, which is why Brookfield Renewable would be at the top of my shopping list of stocks to buy in 2022.</p><p>Brookfield Renewable, in fact, generated record funds from operations (FFO) in its third quarter and believes it could grow FFO by nearly 20% per year through 2026 through a combination of organic and inorganic growth. 2021 was also a solid year in terms of growth initiatives, with Brookfield Renewable expanding its U.S. distributed-generation business by nearly five times, signing agreements to acquire multiple late-stage solar development projects in the U.S. and even making meaningful headway in the high-potential green hydrogen space.</p><p>Brookfield Renewable&#39;s current development pipeline is larger than ever, and the company is committed to growing dividends annually by 5% to 9%. That shouldn&#39;t be tough given the solid pace of growth in its FFO. That dividend growth, its dividend yield of 3.4%, and the humongous growth potential in renewable energy are the biggest reasons why I consider Brookfield Renewable a top stock for 2022.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>If I Could Buy Only 1 Stock in 2022, This Would Be It</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIf I Could Buy Only 1 Stock in 2022, This Would Be It\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-02 13:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/01/if-i-could-buy-only-1-stock-in-2022-this-would-be/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>We're firm believers in the benefit of owning a diversified portfolio of stocks. However, we all have our favorite stocks.We asked some of our Fool.com contributors to whittle their favorites down to ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/01/if-i-could-buy-only-1-stock-in-2022-this-would-be/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BAM":"布鲁克菲尔德资产管理","BK4133":"新能源发电业者","MMM":"3M","BK4534":"瑞士信贷持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4512":"苹果概念","BEP":"Brookfield Renewable Partners LP","BK4135":"资产管理与托管银行","BEPC":"Brookfield Renewable Corp.","BK4206":"工业集团企业"},"source_url":"https://www.fool.com/investing/2022/01/01/if-i-could-buy-only-1-stock-in-2022-this-would-be/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2200444738","content_text":"We're firm believers in the benefit of owning a diversified portfolio of stocks. However, we all have our favorite stocks.We asked some of our Fool.com contributors to whittle their favorites down to their top choice to buy in 2022 if they could only pick one. Here's why 3M (NYSE:MMM), Brookfield Asset Management (NYSE:BAM), and Brookfield Renewable (NYSE:BEP)(NYSE:BEPC) topped their lists as the one stock they'd buy this year. Image source: Getty Images.A diversified giant that's still on saleReuben Gregg Brewer (3M): Benjamin Graham, renowned value investor and mentor to Warren Buffet, explains that investors are partnered with \"Mr. Market,\" a mercurial fellow prone to fits of despair and jubilation. When he's overly excited, you should consider selling to him; when he's pessimistic, you should think about buying. Right now, Mr. Market is very downbeat on diversified international industrial giant 3M. One way to see this is that the company's dividend yield, at around 3.3%, is near the top end of its historical range.MMM Dividend Yield data by YChartsGraham had some other advice when it came to actually selecting stocks. Specifically, he argued that most investors would be wise sticking to large, financially strong companies, with strong dividend histories. 3M stacks up well on these measures. It has a market cap of $100 billion, which makes it a mega-cap stock. Its balance sheet is investment-grade rated by the major credit agencies, so it's financially strong. And it has increased its dividend annually for over 60 years, making it a very elite Dividend King.So why is Mr. Market pessimistic? The answer is a mixture of slowing growth and some product and environmental lawsuits. These are notable problems, but they're not insurmountable. On the business front, the industrial giant's operations wax and wane over time just like any other company. Given its history and focus on innovation, it should eventually get back on a better track. As for the lawsuits, they could be costly, but it's likely that 3M will be able to handle the hit. In the end, this is an attractively priced name with a great history that is dealing with issues that seem transitory.A proven value creatorMatt DiLallo (Brookfield Asset Management): I like to invest. Because of that, I routinely purchase a variety of stocks. However, if I could only buy one in the coming year, Brookfield Asset Management would be my top choice.For starters, I love the company's management. CEO Bruce Flatt is a personal favorite of mine. He's right up there with Warren Buffett in my book as one of the best value investors around. I enjoy reading his quarterly letter to shareholders, which Flatt fills with investing and economic insight. He's also a proven value creator. Since becoming CEO in 2002, he's helped Brookfield deliver a 15.7% total annualized return, pulverizing the S&P 500's 10.6% total return during that time frame. I also like the company's business model. Brookfield is a leading global alternative asset manager focused on real estate, infrastructure, and renewable energy -- three of my favorite investing themes. An investment in Brookfield provides broad exposure to those three asset classes and many more. Brookfield invests directly across those themes and manages private equity funds focused on those sectors.Finally, Brookfield has enormous upside potential. It expects to double its fee-bearing assets under management over the next five years. Combine that with performance-based earnings on its funds and the compounding value of its balance sheet investments, and it has the potential of generating up to 25% annualized total returns over the next five years. That upside, along with all the other positives, is why I'd buy Brookfield if it were the only stock I could purchase this year. Investors are overlooking the growth potential hereNeha Chamaria (Brookfield Renewable): 2021 is turning out to be a record-setting year for global renewable electricity addition, but this could just be the beginning. Yet shares of one of the largest pure-play renewables companies that's growing at a steady pace have languished this year, which is why Brookfield Renewable would be at the top of my shopping list of stocks to buy in 2022.Brookfield Renewable, in fact, generated record funds from operations (FFO) in its third quarter and believes it could grow FFO by nearly 20% per year through 2026 through a combination of organic and inorganic growth. 2021 was also a solid year in terms of growth initiatives, with Brookfield Renewable expanding its U.S. distributed-generation business by nearly five times, signing agreements to acquire multiple late-stage solar development projects in the U.S. and even making meaningful headway in the high-potential green hydrogen space.Brookfield Renewable's current development pipeline is larger than ever, and the company is committed to growing dividends annually by 5% to 9%. That shouldn't be tough given the solid pace of growth in its FFO. That dividend growth, its dividend yield of 3.4%, and the humongous growth potential in renewable energy are the biggest reasons why I consider Brookfield Renewable a top stock for 2022.","news_type":1},"isVote":1,"tweetType":1,"viewCount":843,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":692329526,"gmtCreate":1640854341920,"gmtModify":1640854342261,"author":{"id":"3554895157968981","authorId":"3554895157968981","name":"canoboi","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like and&nbsp; comment..thanks","listText":"Like and&nbsp; comment..thanks","text":"Like and comment..thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/692329526","repostId":"1125407253","repostType":4,"isVote":1,"tweetType":1,"viewCount":616,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":696298510,"gmtCreate":1640698607475,"gmtModify":1640698607769,"author":{"id":"3554895157968981","authorId":"3554895157968981","name":"canoboi","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like and comment thanks","listText":"Like and comment thanks","text":"Like and comment thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/696298510","repostId":"1182153918","repostType":4,"repost":{"id":"1182153918","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1640696271,"share":"https://www.laohu8.com/m/news/1182153918?lang=&edition=full","pubTime":"2021-12-28 20:57","market":"us","language":"en","title":"Toplines Before US Market Open on Tuesday","url":"https://stock-news.laohu8.com/highlight/detail?id=1182153918","media":"Tiger Newspress","summary":"The S&P 500 and Dow futures hit all-time highs on Tuesday, building on a record-setting rally amid t","content":"<p>The S&amp;P 500 and Dow futures hit all-time highs on Tuesday, building on a record-setting rally amid thin trading volumes, with investors trying to shrug off the impact from Omicron-driven travel disruptions and store closures.</p>\n<p>Apple Inc(AAPL.O) closed all of its 12 New York City stores to indoor shopping, the latest company to tighten protocols as cases surged across the United States and prompted thousands of flight cancellations for the fourth day on Monday.</p>\n<p>However, strong consumer demand trends reinstated confidence about the underlying economic strength and helped Wall Street climb for a fourth straight day on Monday. The S&amp;P 500 and Nasdaq posted their best four-day rally since November 2020.</p>\n<p>Data last week showing the Omicron variant being less deadly than feared, and new pills and more vaccines to fight COVID-19 also spurred risk appetite, putting the three main indexes on pace for monthly gains.</p>\n<p>At 8:00 a.m. ET, Dow e-minis were up 91 points, or 0.25%, S&amp;P 500 e-minis were up 11.75 points, or 0.25%, and Nasdaq 100 e-minis were up 77.75 points, or 0.47%.&nbsp;Some megacap companies have roared in the recent rally, with Apple Inc (AAPL.O) — up marginally in premarket trading — within spitting distance of becoming the first U.S. company to hit $3 trillion in market capitalization.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/2529d5fc75126a96cbbc5d6e8f3ec05a\" tg-width=\"667\" tg-height=\"211\" width=\"100%\" height=\"auto\"><span>*Source From Tiger Trade, EST 08:00</span></p>\n<p><b>Stocks making the biggest moves premarket: Apple, Vipshop, Coinbase and others</b></p>\n<p>Apple (AAPL) – The company is once again approaching a $3 trillion market value, needing to reach $182.86 per share to achieve that milestone. Separately, Apple is closing its 12 New York City stores to indoor traffic due to the spread of the Covid-19 omicron variant. Apple edged higher by 0.3% in premarket action.</p>\n<p>Tesla（TSLA）–&nbsp;Tesla has 30% upside in 2022 on China demand, Wedbush Says,&nbsp;and reiterates its outperform rating and $1,400 price target.&nbsp;Tesla&nbsp;stock&nbsp;added&nbsp;1.77%&nbsp;in&nbsp;premarket.</p>\n<p>Nvidia (NVDA) – The graphics chip maker’s shares added 1.2% in the premarket after rising for the past 4 days in a row and helping to lead the iShares Semiconductor ETF (SOXX) to a record high in Monday trading. Advanced Micro Devices (AMD) – also a big factor in driving the SOXX higher – added 1% in premarket trading. Chip stocks have been rising amid supply shortages and strong demand, leading to higher prices for chips.</p>\n<p>Coinbase (COIN) – The cryptocurrency exchange operator’s shares dropped 2.2% in the premarket as the price of bitcoin retreated, putting the stock in danger of breaking a four-day win streak that saw it gain 17.7% over that stretch.</p>\n<p>Vipshop Holdings (VIPS) – The China-based e-commerce company’s stock fell 2.4% in the premarket after cutting its current-quarter revenue guidance. Vipshop cited its “latest view on the market and operational conditions” without being specific, but a Jefferies report said warmer weather and an increase in Covid-19 cases likely dented consumer demand.</p>\n<p></p>\n<p>R.R. Donnelley (RRD) – R.R. Donnelley slid 1.6% in premarket trading after the business communications and marketing services company disclosed an intrusion into its technical systems. Donnelley said it is investigating and is not aware of any client data being compromised.</p>\n<p></p>\n<p>Extreme Networks (EXTR) – The cloud computing company’s stock jumped 3.6% in premarket action after Needham raised its price target on the stock to $18.50 per share from $16. The stock had closed Monday at $16.03.</p>\n<p></p>\n<p>Howard Hughes (HHC) – The real estate firm has reportedly agreed to sell a controlling interest in the Bank of America Tower in Chicago to private equity firm Oak Hill Advisors for more than $1 billion, according to a Dow Jones report quoting sources familiar with the deal.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Toplines Before US Market Open on Tuesday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nToplines Before US Market Open on Tuesday\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-28 20:57</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>The S&amp;P 500 and Dow futures hit all-time highs on Tuesday, building on a record-setting rally amid thin trading volumes, with investors trying to shrug off the impact from Omicron-driven travel disruptions and store closures.</p>\n<p>Apple Inc(AAPL.O) closed all of its 12 New York City stores to indoor shopping, the latest company to tighten protocols as cases surged across the United States and prompted thousands of flight cancellations for the fourth day on Monday.</p>\n<p>However, strong consumer demand trends reinstated confidence about the underlying economic strength and helped Wall Street climb for a fourth straight day on Monday. The S&amp;P 500 and Nasdaq posted their best four-day rally since November 2020.</p>\n<p>Data last week showing the Omicron variant being less deadly than feared, and new pills and more vaccines to fight COVID-19 also spurred risk appetite, putting the three main indexes on pace for monthly gains.</p>\n<p>At 8:00 a.m. ET, Dow e-minis were up 91 points, or 0.25%, S&amp;P 500 e-minis were up 11.75 points, or 0.25%, and Nasdaq 100 e-minis were up 77.75 points, or 0.47%.&nbsp;Some megacap companies have roared in the recent rally, with Apple Inc (AAPL.O) — up marginally in premarket trading — within spitting distance of becoming the first U.S. company to hit $3 trillion in market capitalization.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/2529d5fc75126a96cbbc5d6e8f3ec05a\" tg-width=\"667\" tg-height=\"211\" width=\"100%\" height=\"auto\"><span>*Source From Tiger Trade, EST 08:00</span></p>\n<p><b>Stocks making the biggest moves premarket: Apple, Vipshop, Coinbase and others</b></p>\n<p>Apple (AAPL) – The company is once again approaching a $3 trillion market value, needing to reach $182.86 per share to achieve that milestone. Separately, Apple is closing its 12 New York City stores to indoor traffic due to the spread of the Covid-19 omicron variant. Apple edged higher by 0.3% in premarket action.</p>\n<p>Tesla（TSLA）–&nbsp;Tesla has 30% upside in 2022 on China demand, Wedbush Says,&nbsp;and reiterates its outperform rating and $1,400 price target.&nbsp;Tesla&nbsp;stock&nbsp;added&nbsp;1.77%&nbsp;in&nbsp;premarket.</p>\n<p>Nvidia (NVDA) – The graphics chip maker’s shares added 1.2% in the premarket after rising for the past 4 days in a row and helping to lead the iShares Semiconductor ETF (SOXX) to a record high in Monday trading. Advanced Micro Devices (AMD) – also a big factor in driving the SOXX higher – added 1% in premarket trading. Chip stocks have been rising amid supply shortages and strong demand, leading to higher prices for chips.</p>\n<p>Coinbase (COIN) – The cryptocurrency exchange operator’s shares dropped 2.2% in the premarket as the price of bitcoin retreated, putting the stock in danger of breaking a four-day win streak that saw it gain 17.7% over that stretch.</p>\n<p>Vipshop Holdings (VIPS) – The China-based e-commerce company’s stock fell 2.4% in the premarket after cutting its current-quarter revenue guidance. Vipshop cited its “latest view on the market and operational conditions” without being specific, but a Jefferies report said warmer weather and an increase in Covid-19 cases likely dented consumer demand.</p>\n<p></p>\n<p>R.R. Donnelley (RRD) – R.R. Donnelley slid 1.6% in premarket trading after the business communications and marketing services company disclosed an intrusion into its technical systems. Donnelley said it is investigating and is not aware of any client data being compromised.</p>\n<p></p>\n<p>Extreme Networks (EXTR) – The cloud computing company’s stock jumped 3.6% in premarket action after Needham raised its price target on the stock to $18.50 per share from $16. The stock had closed Monday at $16.03.</p>\n<p></p>\n<p>Howard Hughes (HHC) – The real estate firm has reportedly agreed to sell a controlling interest in the Bank of America Tower in Chicago to private equity firm Oak Hill Advisors for more than $1 billion, according to a Dow Jones report quoting sources familiar with the deal.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉",".SPX":"S&P 500 Index","AAPL":"苹果","COIN":"Coinbase Global, Inc.",".DJI":"道琼斯","AMD":"美国超微公司","NVDA":"英伟达",".IXIC":"NASDAQ Composite"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1182153918","content_text":"The S&P 500 and Dow futures hit all-time highs on Tuesday, building on a record-setting rally amid thin trading volumes, with investors trying to shrug off the impact from Omicron-driven travel disruptions and store closures.\nApple Inc(AAPL.O) closed all of its 12 New York City stores to indoor shopping, the latest company to tighten protocols as cases surged across the United States and prompted thousands of flight cancellations for the fourth day on Monday.\nHowever, strong consumer demand trends reinstated confidence about the underlying economic strength and helped Wall Street climb for a fourth straight day on Monday. The S&P 500 and Nasdaq posted their best four-day rally since November 2020.\nData last week showing the Omicron variant being less deadly than feared, and new pills and more vaccines to fight COVID-19 also spurred risk appetite, putting the three main indexes on pace for monthly gains.\nAt 8:00 a.m. ET, Dow e-minis were up 91 points, or 0.25%, S&P 500 e-minis were up 11.75 points, or 0.25%, and Nasdaq 100 e-minis were up 77.75 points, or 0.47%. Some megacap companies have roared in the recent rally, with Apple Inc (AAPL.O) — up marginally in premarket trading — within spitting distance of becoming the first U.S. company to hit $3 trillion in market capitalization.\n*Source From Tiger Trade, EST 08:00\nStocks making the biggest moves premarket: Apple, Vipshop, Coinbase and others\nApple (AAPL) – The company is once again approaching a $3 trillion market value, needing to reach $182.86 per share to achieve that milestone. Separately, Apple is closing its 12 New York City stores to indoor traffic due to the spread of the Covid-19 omicron variant. Apple edged higher by 0.3% in premarket action.\nTesla（TSLA）– Tesla has 30% upside in 2022 on China demand, Wedbush Says, and reiterates its outperform rating and $1,400 price target. Tesla stock added 1.77% in premarket.\nNvidia (NVDA) – The graphics chip maker’s shares added 1.2% in the premarket after rising for the past 4 days in a row and helping to lead the iShares Semiconductor ETF (SOXX) to a record high in Monday trading. Advanced Micro Devices (AMD) – also a big factor in driving the SOXX higher – added 1% in premarket trading. Chip stocks have been rising amid supply shortages and strong demand, leading to higher prices for chips.\nCoinbase (COIN) – The cryptocurrency exchange operator’s shares dropped 2.2% in the premarket as the price of bitcoin retreated, putting the stock in danger of breaking a four-day win streak that saw it gain 17.7% over that stretch.\nVipshop Holdings (VIPS) – The China-based e-commerce company’s stock fell 2.4% in the premarket after cutting its current-quarter revenue guidance. Vipshop cited its “latest view on the market and operational conditions” without being specific, but a Jefferies report said warmer weather and an increase in Covid-19 cases likely dented consumer demand.\n\nR.R. Donnelley (RRD) – R.R. Donnelley slid 1.6% in premarket trading after the business communications and marketing services company disclosed an intrusion into its technical systems. Donnelley said it is investigating and is not aware of any client data being compromised.\n\nExtreme Networks (EXTR) – The cloud computing company’s stock jumped 3.6% in premarket action after Needham raised its price target on the stock to $18.50 per share from $16. The stock had closed Monday at $16.03.\n\nHoward Hughes (HHC) – The real estate firm has reportedly agreed to sell a controlling interest in the Bank of America Tower in Chicago to private equity firm Oak Hill Advisors for more than $1 billion, according to a Dow Jones report quoting sources familiar with the deal.","news_type":1},"isVote":1,"tweetType":1,"viewCount":620,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":696931071,"gmtCreate":1640593493923,"gmtModify":1640593494254,"author":{"id":"3554895157968981","authorId":"3554895157968981","name":"canoboi","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like and comment thanks","listText":"Like and comment thanks","text":"Like and comment thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/696931071","repostId":"2194177239","repostType":4,"repost":{"id":"2194177239","pubTimestamp":1640559609,"share":"https://www.laohu8.com/m/news/2194177239?lang=&edition=full","pubTime":"2021-12-27 07:00","market":"us","language":"en","title":"Santa Claus Rally watch: What to know this week","url":"https://stock-news.laohu8.com/highlight/detail?id=2194177239","media":"Yahoo Finance","summary":"As traders return from the holiday-shortened week, the price action heading into the new year will be closely monitored — especially given the relatively light economic data and earnings calendar for the coming days.The S&P 500  is entering the period known for ushering in the so-called Santa Claus Rally, or seasonally strong timeframe for stocks at the end of each year.According to data from LPL Financial, the Santa Claus Rally period encapsulates the seven days most likely to be higher in any ","content":"<p>As traders return from the holiday-shortened week, the price action heading into the new year will be closely monitored — especially given the relatively light economic data and earnings calendar for the coming days.</p>\n<p>The S&amp;P 500 (^GSPC) is entering the period known for ushering in the so-called Santa Claus Rally, or seasonally strong timeframe for stocks at the end of each year.</p>\n<p>The term, coined by Stock Trader's Almanac in the 1970s, encompasses the final five trading days of the year and first two sessions of the new year. This year, that Santa Claus Rally window is set to start on Monday, Dec. 27 — or the latest a Santa Claus rally has started in 11 years, due to the timing of the holidays this year.</p>\n<p>According to data from LPL Financial, the Santa Claus Rally period encapsulates the seven days most likely to be higher in any given year. Since 1950, the Santa Claus Rally period has produced a positive return for the S&amp;P 500 78.9% of the time, with an average return of 1.33%.</p>\n<p>“Why are these seven days so strong?” wrote Ryan Detrick, LPL Financial chief market strategist, in a note. “Whether optimism over a coming new year, holiday spending, traders on vacation, institutions squaring up their books — or the holiday spirit — the bottom line is that bulls tend to believe in Santa.”</p>\n<p>And if history is any indication, the absence of a Santa Claus Rally has also typically served as a harbinger of lower near-term returns.</p>\n<p>\"Going back to the mid-1990s, there have been only six times Santa failed to show in December. January was lower five of those six times, and the full year had a solid gain only once (in 2016, but a mini-bear market early in the year),\" Detrick added.</p>\n<p>“Considering the bear markets of 2000 and 2008 both took place after <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the rare instances that Santa failed to show makes believers out of us,\" he said. A bear market typically refers to when stocks drop at least 20% from recent record highs. \"Should this seasonally strong period miss the mark, it could be a warning sign.\"</p>\n<p>And this year, investors do have considerable additional concerns to mull heading into the new year. Though stocks closed out Thursday's session at fresh record highs before the long holiday weekend, December still marked a volatile month to start, with renewed concerns over the Omicron variant and the potential for tighter monetary policy from the Federal Reserve weighing on risk assets. Plus, prospects for more near-term fiscal support via the Biden administration's Build Back Better bill have dwindled, and inflation concerns spiked further. Last week, the Bureau of Economic Analysis reported core personal consumption expenditures (PCE) — the Fed's preferred inflation gauge — rose at a 4.7% year-over-year clip, or the fastest since 1983.</p>\n<p>\"If the U.S. was not battling the Omicron variant, U.S. stocks would be dancing higher as the Santa Claus Rally would have kept the climb going into uncharted territory,\" Edward Moya, chief market strategist at OANDA, wrote in a note last week. \"It is too early to say for sure if we will get a Santa Claus Rally, but given all the short-term risks of Fed tightening, Chinese weakness, fiscal support uncertainty and COVID, Wall Street is not complaining.\"</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1279eeacff5d764e6ff5b3e8f7a24f49\" tg-width=\"4000\" tg-height=\"2667\" referrerpolicy=\"no-referrer\"><span>A man in a Santa Claus costume gestures on the floor at the closing bell of the Dow Industrial Average at the New York Stock Exchange on December 5, 2019 in New York. (Photo by Bryan R. Smith / AFP) (Photo by BRYAN R. SMITH/AFP via Getty Images)BRYAN R. SMITH via Getty Images</span></p>\n<h2>Economic calendar</h2>\n<ul>\n <li><p><b>Monday: </b>Dallas Federal Reserve Manufacturing Activity Index, Dec. (13.0 expected, 11.8 in November)</p></li>\n <li><p><b>Tuesday: </b>FHFA House Price Index, month-over-month, October (0.9% in September); S&amp;P <a href=\"https://laohu8.com/S/CLGX\">CoreLogic</a> Case-Shiller 20 City Composite Index, month-over-month, October (0.9% expected, 0.96% in September); S&amp;P CoreLogic Case-Shiller 20 City Composite Index, year-over-year, October (18.6%. expected, 19.05% in September); S&amp;P CoreLogic Case-Shiller Home Price Index, year-over-year, November (19.51% in October); Richmond Fed Manufacturing Index, December (11 expected,11 in November)</p></li>\n <li><p><b>Wednesday: </b>Wholesale Inventories, month-over-month, November preliminary (1.7% expected, 2.3% in October); Advance Goods Trade Balance, November (-$89.0 billion expected, -$82.9 billion in October); Retail Inventories, month-over-month, November (0.5% expected, 0.1% in October); Pending Home Sales, month-over-month, November (0.5% expected, 7.5% in October)</p></li>\n <li><p><b>Thursday: </b>Initial jobless claims, week ended Dec. 25. (205,000 during prior week); Continuing claims, week ended Dec. 18 (1.859 million during prior week); MNI Chicago PMI, December (62.2 expected, 61.8 in November)</p></li>\n <li><p><b>Friday: </b><i>No notable reports scheduled for release</i></p></li>\n</ul>\n<h2>Earnings calendar</h2>\n<ul>\n <li><p><b>Monday: </b><i>No notable reports scheduled for release</i></p></li>\n <li><p><b>Tuesday: </b><i>No notable reports scheduled for release</i></p></li>\n <li><p><b>Wednesday: </b>FuelCell Energy Inc. (FCEL) before market open</p></li>\n <li><p><b>Thursday: </b><i>No notable reports scheduled for release</i></p></li>\n <li><p><b>Friday: </b><i>No notable reports scheduled for release</i></p></li>\n</ul>","source":"yahoofinance_au","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Santa Claus Rally watch: What to know this week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSanta Claus Rally watch: What to know this week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-27 07:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/santa-claus-rally-watch-what-to-know-this-week-142909627.html><strong>Yahoo Finance</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>As traders return from the holiday-shortened week, the price action heading into the new year will be closely monitored — especially given the relatively light economic data and earnings calendar for ...</p>\n\n<a href=\"https://finance.yahoo.com/news/santa-claus-rally-watch-what-to-know-this-week-142909627.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4096":"电气部件与设备","BK4541":"氢能源","SPY.AU":"SPDR® S&P 500® ETF Trust","FCEL":"燃料电池能源"},"source_url":"https://finance.yahoo.com/news/santa-claus-rally-watch-what-to-know-this-week-142909627.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2194177239","content_text":"As traders return from the holiday-shortened week, the price action heading into the new year will be closely monitored — especially given the relatively light economic data and earnings calendar for the coming days.\nThe S&P 500 (^GSPC) is entering the period known for ushering in the so-called Santa Claus Rally, or seasonally strong timeframe for stocks at the end of each year.\nThe term, coined by Stock Trader's Almanac in the 1970s, encompasses the final five trading days of the year and first two sessions of the new year. This year, that Santa Claus Rally window is set to start on Monday, Dec. 27 — or the latest a Santa Claus rally has started in 11 years, due to the timing of the holidays this year.\nAccording to data from LPL Financial, the Santa Claus Rally period encapsulates the seven days most likely to be higher in any given year. Since 1950, the Santa Claus Rally period has produced a positive return for the S&P 500 78.9% of the time, with an average return of 1.33%.\n“Why are these seven days so strong?” wrote Ryan Detrick, LPL Financial chief market strategist, in a note. “Whether optimism over a coming new year, holiday spending, traders on vacation, institutions squaring up their books — or the holiday spirit — the bottom line is that bulls tend to believe in Santa.”\nAnd if history is any indication, the absence of a Santa Claus Rally has also typically served as a harbinger of lower near-term returns.\n\"Going back to the mid-1990s, there have been only six times Santa failed to show in December. January was lower five of those six times, and the full year had a solid gain only once (in 2016, but a mini-bear market early in the year),\" Detrick added.\n“Considering the bear markets of 2000 and 2008 both took place after one of the rare instances that Santa failed to show makes believers out of us,\" he said. A bear market typically refers to when stocks drop at least 20% from recent record highs. \"Should this seasonally strong period miss the mark, it could be a warning sign.\"\nAnd this year, investors do have considerable additional concerns to mull heading into the new year. Though stocks closed out Thursday's session at fresh record highs before the long holiday weekend, December still marked a volatile month to start, with renewed concerns over the Omicron variant and the potential for tighter monetary policy from the Federal Reserve weighing on risk assets. Plus, prospects for more near-term fiscal support via the Biden administration's Build Back Better bill have dwindled, and inflation concerns spiked further. Last week, the Bureau of Economic Analysis reported core personal consumption expenditures (PCE) — the Fed's preferred inflation gauge — rose at a 4.7% year-over-year clip, or the fastest since 1983.\n\"If the U.S. was not battling the Omicron variant, U.S. stocks would be dancing higher as the Santa Claus Rally would have kept the climb going into uncharted territory,\" Edward Moya, chief market strategist at OANDA, wrote in a note last week. \"It is too early to say for sure if we will get a Santa Claus Rally, but given all the short-term risks of Fed tightening, Chinese weakness, fiscal support uncertainty and COVID, Wall Street is not complaining.\"\nA man in a Santa Claus costume gestures on the floor at the closing bell of the Dow Industrial Average at the New York Stock Exchange on December 5, 2019 in New York. (Photo by Bryan R. Smith / AFP) (Photo by BRYAN R. SMITH/AFP via Getty Images)BRYAN R. SMITH via Getty Images\nEconomic calendar\n\nMonday: Dallas Federal Reserve Manufacturing Activity Index, Dec. (13.0 expected, 11.8 in November)\nTuesday: FHFA House Price Index, month-over-month, October (0.9% in September); S&P CoreLogic Case-Shiller 20 City Composite Index, month-over-month, October (0.9% expected, 0.96% in September); S&P CoreLogic Case-Shiller 20 City Composite Index, year-over-year, October (18.6%. expected, 19.05% in September); S&P CoreLogic Case-Shiller Home Price Index, year-over-year, November (19.51% in October); Richmond Fed Manufacturing Index, December (11 expected,11 in November)\nWednesday: Wholesale Inventories, month-over-month, November preliminary (1.7% expected, 2.3% in October); Advance Goods Trade Balance, November (-$89.0 billion expected, -$82.9 billion in October); Retail Inventories, month-over-month, November (0.5% expected, 0.1% in October); Pending Home Sales, month-over-month, November (0.5% expected, 7.5% in October)\nThursday: Initial jobless claims, week ended Dec. 25. (205,000 during prior week); Continuing claims, week ended Dec. 18 (1.859 million during prior week); MNI Chicago PMI, December (62.2 expected, 61.8 in November)\nFriday: No notable reports scheduled for release\n\nEarnings calendar\n\nMonday: No notable reports scheduled for release\nTuesday: No notable reports scheduled for release\nWednesday: FuelCell Energy Inc. (FCEL) before market open\nThursday: No notable reports scheduled for release\nFriday: No notable reports scheduled for release","news_type":1},"isVote":1,"tweetType":1,"viewCount":727,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698588186,"gmtCreate":1640448827048,"gmtModify":1640448827341,"author":{"id":"3554895157968981","authorId":"3554895157968981","name":"canoboi","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like and comment thanks","listText":"Like and comment thanks","text":"Like and comment thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/698588186","repostId":"2193317305","repostType":4,"repost":{"id":"2193317305","pubTimestamp":1640399660,"share":"https://www.laohu8.com/m/news/2193317305?lang=&edition=full","pubTime":"2021-12-25 10:34","market":"us","language":"en","title":"Can This Top Blue Chip Stock Handle Soaring Inflation?","url":"https://stock-news.laohu8.com/highlight/detail?id=2193317305","media":"Motley Fool","summary":"We are in strange times right now, so how companies navigate the current environment is vital to their success.","content":"<p>In the month of November, the Consumer Price Index, a widely used measure of inflation, jumped 6.8% from a year ago. Sparked by supply-chain disruptions and labor shortages across the economy, it was the highest increase in almost 40 years.&nbsp;</p>\n<p>For a company like&nbsp;<b>Home Depot</b>&nbsp;(NYSE:HD) that has done extremely well during the pandemic, the threat of rising costs is a real challenge heading into the new year, having possibly negative implications ahead of what is traditionally a busy spring and summer for the&nbsp;business.&nbsp;</p>\n<p>Continue reading to find out how this&nbsp;blue chip stock&nbsp;is dealing with the current situation.&nbsp;</p>\n<h2>Lumber prices are going back up&nbsp;</h2>\n<p>A major commodity that has a meaningful&nbsp;impact&nbsp;on Home Depot's&nbsp;business&nbsp;is lumber. From April 2020 to May 2021,&nbsp;lumber prices skyrocketed&nbsp;to nearly $1,700 per thousand board feet, an all-time record. Prices came down over the following few months, but they shot up again from mid-November to mid-December, settling at just over $1,000 per thousand board feet today. This is still extremely high from a historical perspective.&nbsp;</p>\n<p>\"Lumber is a driver of projects throughout the business, and that certainly carries on,\" Chief Executive Officer Craig Menear highlighted on the company's third-quarter earnings call. During Home Depot's fiscal second quarter that ended Aug. 1 (when lumber prices were sky-high), the company posted record quarterly sales of $41.1 billion. The gross margin of 33.2%, while down slightly from previous quarters, was still very healthy and in line with past results.&nbsp;</p>\n<p>This is a positive indicator of Home Depot's ability to handle the unpredictable price swings with a core commodity like lumber. As prices soared, unit sales fell. Even so, the business reported a historic quarter. Now, as lumber prices rise, especially ahead of the busy home-building and remodeling season in the spring and summer, don't be surprised if lumber unit sales start to drop again.&nbsp;</p>\n<p>Nonetheless, other product categories like outdoor garden, appliances, and kitchen and bath should be strong. And thanks to a robust housing market, characterized by low interest rates, consumers are increasingly looking to undertake renovation projects to boost the value of their existing homes. This underlying trend supports demand for the products and services Home Depot offers.&nbsp;</p>\n<p>\"We have effectively managed inflationary environments in the past, and we feel good about our ability to continue managing through the current environment,\" said President and Chief Operating Officer Ted Decker on the latest conference call with Wall Street analysts.</p>\n<h2>Home Depot's success is&nbsp;undeniable&nbsp;</h2>\n<p>One of Home Depot's overarching objectives is to be the low-cost provider in the home improvement industry. This means that the business wants to lag competitors when raising prices and lead when reducing prices. Obviously, this negatively impacts profitability in the near term as the company is hesitant to pass higher costs on to consumers.&nbsp;</p>\n<p>But if we look at Home Depot's historical performance, we see that this is definitely the right strategy to take. Over the past several years, while revenue has grown in the mid-single digits on a yearly basis, net income has soared as a result of expanding margins. In fiscal 2015, profit totaled $7 billion. Over the trailing-12-month period, it was almost $16 billion.&nbsp;</p>\n<p>And the business is popular among contractors and other professionals, who account for roughly 45% of sales. Instead of immediately passing on higher input costs, which could alienate these high-value customers and push them to competitors, Home Depot understands that building long-term relationships with them is crucial to the success of the company. Sacrificing margin in unusual times like today to keep customers loyal is the right move.&nbsp;</p>\n<p>The current economic environment is full of uncertainties with issues like the omicron coronavirus variant and tightening monetary policy receiving the bulk of investors' attention. When it comes to inflation in particular, I have no reason to believe that Home Depot won't be able to step up to whatever challenges 2022 brings. &nbsp;</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Can This Top Blue Chip Stock Handle Soaring Inflation?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCan This Top Blue Chip Stock Handle Soaring Inflation?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-25 10:34 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/24/can-top-blue-chip-stock-handle-soaring-inflation/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In the month of November, the Consumer Price Index, a widely used measure of inflation, jumped 6.8% from a year ago. Sparked by supply-chain disruptions and labor shortages across the economy, it was ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/24/can-top-blue-chip-stock-handle-soaring-inflation/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4566":"资本集团","BK4083":"家庭装潢零售","BK4567":"ESG概念","HD":"家得宝","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4534":"瑞士信贷持仓","BK4550":"红杉资本持仓","BK4504":"桥水持仓"},"source_url":"https://www.fool.com/investing/2021/12/24/can-top-blue-chip-stock-handle-soaring-inflation/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2193317305","content_text":"In the month of November, the Consumer Price Index, a widely used measure of inflation, jumped 6.8% from a year ago. Sparked by supply-chain disruptions and labor shortages across the economy, it was the highest increase in almost 40 years. \nFor a company like Home Depot (NYSE:HD) that has done extremely well during the pandemic, the threat of rising costs is a real challenge heading into the new year, having possibly negative implications ahead of what is traditionally a busy spring and summer for the business. \nContinue reading to find out how this blue chip stock is dealing with the current situation. \nLumber prices are going back up \nA major commodity that has a meaningful impact on Home Depot's business is lumber. From April 2020 to May 2021, lumber prices skyrocketed to nearly $1,700 per thousand board feet, an all-time record. Prices came down over the following few months, but they shot up again from mid-November to mid-December, settling at just over $1,000 per thousand board feet today. This is still extremely high from a historical perspective. \n\"Lumber is a driver of projects throughout the business, and that certainly carries on,\" Chief Executive Officer Craig Menear highlighted on the company's third-quarter earnings call. During Home Depot's fiscal second quarter that ended Aug. 1 (when lumber prices were sky-high), the company posted record quarterly sales of $41.1 billion. The gross margin of 33.2%, while down slightly from previous quarters, was still very healthy and in line with past results. \nThis is a positive indicator of Home Depot's ability to handle the unpredictable price swings with a core commodity like lumber. As prices soared, unit sales fell. Even so, the business reported a historic quarter. Now, as lumber prices rise, especially ahead of the busy home-building and remodeling season in the spring and summer, don't be surprised if lumber unit sales start to drop again. \nNonetheless, other product categories like outdoor garden, appliances, and kitchen and bath should be strong. And thanks to a robust housing market, characterized by low interest rates, consumers are increasingly looking to undertake renovation projects to boost the value of their existing homes. This underlying trend supports demand for the products and services Home Depot offers. \n\"We have effectively managed inflationary environments in the past, and we feel good about our ability to continue managing through the current environment,\" said President and Chief Operating Officer Ted Decker on the latest conference call with Wall Street analysts.\nHome Depot's success is undeniable \nOne of Home Depot's overarching objectives is to be the low-cost provider in the home improvement industry. This means that the business wants to lag competitors when raising prices and lead when reducing prices. Obviously, this negatively impacts profitability in the near term as the company is hesitant to pass higher costs on to consumers. \nBut if we look at Home Depot's historical performance, we see that this is definitely the right strategy to take. Over the past several years, while revenue has grown in the mid-single digits on a yearly basis, net income has soared as a result of expanding margins. In fiscal 2015, profit totaled $7 billion. Over the trailing-12-month period, it was almost $16 billion. \nAnd the business is popular among contractors and other professionals, who account for roughly 45% of sales. Instead of immediately passing on higher input costs, which could alienate these high-value customers and push them to competitors, Home Depot understands that building long-term relationships with them is crucial to the success of the company. Sacrificing margin in unusual times like today to keep customers loyal is the right move. \nThe current economic environment is full of uncertainties with issues like the omicron coronavirus variant and tightening monetary policy receiving the bulk of investors' attention. When it comes to inflation in particular, I have no reason to believe that Home Depot won't be able to step up to whatever challenges 2022 brings.","news_type":1},"isVote":1,"tweetType":1,"viewCount":619,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698057423,"gmtCreate":1640268416571,"gmtModify":1640268513740,"author":{"id":"3554895157968981","authorId":"3554895157968981","name":"canoboi","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like and comment thks","listText":"Like and comment thks","text":"Like and comment thks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/698057423","repostId":"1165632180","repostType":4,"repost":{"id":"1165632180","pubTimestamp":1640268327,"share":"https://www.laohu8.com/m/news/1165632180?lang=&edition=full","pubTime":"2021-12-23 22:05","market":"us","language":"en","title":"Allakos rebounds amid bearish views on trial setback","url":"https://stock-news.laohu8.com/highlight/detail?id=1165632180","media":"seekingalpha","summary":"After losing more than a quarter of its market cap on Wednesday, Allakos(NASDAQ:ALLK)shares have rec","content":"<p>After losing more than a quarter of its market cap on Wednesday, Allakos(NASDAQ:ALLK)shares have recovered in the pre-market&nbsp;with arise of ~10.9%on above-average volume. About 4.6M company shares have changed hands compared to the 65-day average volume of ~1.3M.</p>\n<p>According to sites tracking the mentions of ticker symbols on social media sites, Allakos (ALLK) has so far retained its lead as the most popular stock on Twitter in the pre-market.</p>\n<p>The return of investor interest in the mid-cap biotech comes despite its underwhelming data from two late-stage studies for lirentelimab (AK002), an experimental therapy for eosinophilic gastrointestinal diseases (EGID). Both ENIGMA 2 and KRYPTOS trials had not met the patient-reported symptomatic co-primary endpoints with statistical significance, the&nbsp;company said after the close on Tuesday.Amid the selloff, several Wall Street analysts issued bearish views on the stock.</p>\n<p>Double downgrading Allakos (ALLK) to Underperform from Buy, Bank of America argued that the lack of benefit shown in studies “likely spells the end of both programs with little chance of broad approval,” for lirentelimab. The price target cut to $12 from $155 per share implies a premium of ~40.4% to the last close.</p>\n<p>However, Morgan Stanley maintains the Equal Weight rating on the stock despite lowing the price target to $10 from $86 per share, a premium of ~17.0% to the last close. The analysts led by Michael E Ulz argue that despite a significant decline in eosinophils, a co-primary endpoint, there were no benefits seen for symptoms, a key co-primary endpoint for both studies.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Allakos rebounds amid bearish views on trial setback</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAllakos rebounds amid bearish views on trial setback\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-23 22:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3782996-alks-stock-rebounds-amid-bearish-views-on-trial-setback><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After losing more than a quarter of its market cap on Wednesday, Allakos(NASDAQ:ALLK)shares have recovered in the pre-market with arise of ~10.9%on above-average volume. About 4.6M company shares have...</p>\n\n<a href=\"https://seekingalpha.com/news/3782996-alks-stock-rebounds-amid-bearish-views-on-trial-setback\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ALLK":"Allakos Inc."},"source_url":"https://seekingalpha.com/news/3782996-alks-stock-rebounds-amid-bearish-views-on-trial-setback","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1165632180","content_text":"After losing more than a quarter of its market cap on Wednesday, Allakos(NASDAQ:ALLK)shares have recovered in the pre-market with arise of ~10.9%on above-average volume. About 4.6M company shares have changed hands compared to the 65-day average volume of ~1.3M.\nAccording to sites tracking the mentions of ticker symbols on social media sites, Allakos (ALLK) has so far retained its lead as the most popular stock on Twitter in the pre-market.\nThe return of investor interest in the mid-cap biotech comes despite its underwhelming data from two late-stage studies for lirentelimab (AK002), an experimental therapy for eosinophilic gastrointestinal diseases (EGID). Both ENIGMA 2 and KRYPTOS trials had not met the patient-reported symptomatic co-primary endpoints with statistical significance, the company said after the close on Tuesday.Amid the selloff, several Wall Street analysts issued bearish views on the stock.\nDouble downgrading Allakos (ALLK) to Underperform from Buy, Bank of America argued that the lack of benefit shown in studies “likely spells the end of both programs with little chance of broad approval,” for lirentelimab. The price target cut to $12 from $155 per share implies a premium of ~40.4% to the last close.\nHowever, Morgan Stanley maintains the Equal Weight rating on the stock despite lowing the price target to $10 from $86 per share, a premium of ~17.0% to the last close. The analysts led by Michael E Ulz argue that despite a significant decline in eosinophils, a co-primary endpoint, there were no benefits seen for symptoms, a key co-primary endpoint for both studies.","news_type":1},"isVote":1,"tweetType":1,"viewCount":678,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691843505,"gmtCreate":1640173699052,"gmtModify":1640173790397,"author":{"id":"3554895157968981","authorId":"3554895157968981","name":"canoboi","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like and comment thanks","listText":"Like and comment thanks","text":"Like and comment thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/691843505","repostId":"1130487812","repostType":4,"repost":{"id":"1130487812","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1640172109,"share":"https://www.laohu8.com/m/news/1130487812?lang=&edition=full","pubTime":"2021-12-22 19:21","market":"us","language":"en","title":"Read Why Loop Capital Slashed Twitter Price Target By 22%","url":"https://stock-news.laohu8.com/highlight/detail?id=1130487812","media":"Benzinga","summary":"Loop Capital analyst Alan Gould lowered the price target on Twitter Inc to $65 from $84, implying 46","content":"<ul>\n <li><b>Loop Capital</b>&nbsp;analyst Alan Gould&nbsp;lowered the price target&nbsp;on&nbsp;<b>Twitter Inc</b>&nbsp;to $65 from $84, implying 46.5% upside, and reiterated a Buy.</li>\n <li>Gould states that not many investors see the potential for the company to generate 25% topline growth, raising an \"unanswered question\" on margin outlook and overhang for the stock after Twitter indicated that expenses would grow beyond the 25% floor already in place with existing programs.</li>\n <li>Gould adds that achieving Twitter management's 315 million DUA target for 2023 seems \"aggressive,\" and the sell-side is already 7% below this goal.</li>\n <li><b>Price Action:</b>&nbsp;TWTR shares traded lower by 0.34% at $44.21 in the premarket session on the last check Wednesday.</li>\n</ul>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Read Why Loop Capital Slashed Twitter Price Target By 22%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRead Why Loop Capital Slashed Twitter Price Target By 22%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-12-22 19:21</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<ul>\n <li><b>Loop Capital</b>&nbsp;analyst Alan Gould&nbsp;lowered the price target&nbsp;on&nbsp;<b>Twitter Inc</b>&nbsp;to $65 from $84, implying 46.5% upside, and reiterated a Buy.</li>\n <li>Gould states that not many investors see the potential for the company to generate 25% topline growth, raising an \"unanswered question\" on margin outlook and overhang for the stock after Twitter indicated that expenses would grow beyond the 25% floor already in place with existing programs.</li>\n <li>Gould adds that achieving Twitter management's 315 million DUA target for 2023 seems \"aggressive,\" and the sell-side is already 7% below this goal.</li>\n <li><b>Price Action:</b>&nbsp;TWTR shares traded lower by 0.34% at $44.21 in the premarket session on the last check Wednesday.</li>\n</ul>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TWTR":"Twitter"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1130487812","content_text":"Loop Capital analyst Alan Gould lowered the price target on Twitter Inc to $65 from $84, implying 46.5% upside, and reiterated a Buy.\nGould states that not many investors see the potential for the company to generate 25% topline growth, raising an \"unanswered question\" on margin outlook and overhang for the stock after Twitter indicated that expenses would grow beyond the 25% floor already in place with existing programs.\nGould adds that achieving Twitter management's 315 million DUA target for 2023 seems \"aggressive,\" and the sell-side is already 7% below this goal.\nPrice Action: TWTR shares traded lower by 0.34% at $44.21 in the premarket session on the last check Wednesday.","news_type":1},"isVote":1,"tweetType":1,"viewCount":618,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":699478262,"gmtCreate":1639884539295,"gmtModify":1639884539582,"author":{"id":"3554895157968981","authorId":"3554895157968981","name":"canoboi","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like and comment thanks","listText":"Like and comment thanks","text":"Like and comment thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/699478262","repostId":"1122414343","repostType":4,"repost":{"id":"1122414343","pubTimestamp":1639884070,"share":"https://www.laohu8.com/m/news/1122414343?lang=&edition=full","pubTime":"2021-12-19 11:21","market":"us","language":"en","title":"Novavax, Vir among healthcare gainers, Pfizer posts best rally in a decade","url":"https://stock-news.laohu8.com/highlight/detail?id=1122414343","media":"Seeking Alpha","summary":"The healthcare stocks in the S&P 500 outperformed all other sectors in the broader index with a ~2.5","content":"<p>The healthcare stocks in the S&amp;P 500 outperformed all other sectors in the broader index with a ~2.5% gain thanks mainly to M&amp;A prospects. <a href=\"https://laohu8.com/S/HCSG\">Healthcare</a> technology, along with names battling the resurgence of COVID-19, led the gainers while the overall index fell ~1.9%.</p>\n<p>Among stocks with more than $2B market capitalization and 100K average daily volume over the past week, <a href=\"https://laohu8.com/S/ARNA\">Arena Pharmaceuticals </a> dominated with a ~83.8% rise after <a href=\"https://laohu8.com/S/PFE\">Pfizer </a> agreed to acquire it in a ~$6.7B deal with 100% premium for the biotech. <a href=\"https://laohu8.com/S/CERN\">Cerner </a> also joined the M&amp;A-driven rally to gain ~20.7% over the week amid reports of a potential ~$30B bid from <a href=\"https://laohu8.com/S/ORCL\">Oracle </a> for the electronic-medical-records company.</p>\n<p>Vaccine developer, <a href=\"https://laohu8.com/S/NVAX\">Novavax </a> jumped ~30.5% as investors welcomed the WHO clearance for the company’s COVID-19 shot. Further gains for the Maryland-based biotech are likely when an expert panel of the European regulators is set to review the marketing authorization for the vaccine next week.</p>\n<p><a href=\"https://laohu8.com/S/BHVN\">Biohaven Pharmaceutical </a> posted a ~25.2% weekly rise after the company announced the approval for NURTEC ODT (rimegepant) in Israel, making it the first regulatory win for the migraine drug outside the U.S. Meanwhile, Vir Biotechnology (NASDAQ:VIR) surged ~23.7% to stand among best gainers for the second week this month. More data emerged this week confirming the Omicron-neutralizing effect of the company’s COVID-19 therapy developed in partnership with GlaxoSmithKline (NYSE:GSK). Rounding out the top five gainers, <a href=\"https://laohu8.com/S/ROIV\">Roivant Sciences </a> added ~22.6%.</p>\n<p>Notable gainer: <a href=\"https://laohu8.com/S/PFE\">Pfizer</a> (PFE) made headlines throughout the week, raising its sales guidance for the COVID-19 vaccine once again as the rapidly spreading Omicron variant highlighted the need for booster shots. Despite an abrupt end to its six-day rally on Friday, the <a href=\"https://laohu8.com/S/NWY\">New York</a>-based pharma giant with a ~12.7% rise recorded its best weekly gain since March 2009.</p>\n<p>Among worst performers of the week, two newly IPO’ed biotechs, Instil Bio (NASDAQ:TIL) and Exscientia (NASDAQ:EXAI), stood out, falling 19.3% and ~13.5%, respectively, despite their favorable ratings on Wall Street. Meanwhile, GoodRx Holdings (NASDAQ:GDRX), an operator of a price comparison platform for prescription medicine slumped ~15.6%.</p>\n<p>Last week’s best performer, <a href=\"https://laohu8.com/S/BHG\">Bright Health Group</a>, crashed ~13.1%, hurt by the sole Sell rating issued by <a href=\"https://laohu8.com/S/GS\">Goldman Sachs</a> even as the investment bank kicked off its coverage on managed care with largely positive views.</p>\n<p>Allogene Therapeutics (NASDAQ:ALLO) dropped ~12.3% after the company’s ASH presentations on Phase 1 data for experimental allogeneic <a href=\"https://laohu8.com/S/00699\">CAR</a> T therapies failed to excite investors, including Cathie Wood’s Ark Investment Management, which sold ~1.6M shares of the biotech several days later.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax, Vir among healthcare gainers, Pfizer posts best rally in a decade</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax, Vir among healthcare gainers, Pfizer posts best rally in a decade\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-19 11:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3781487-novavax-vir-among-healthcare-gainers-pfizer-posts-best-rally-in-a-decade><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The healthcare stocks in the S&P 500 outperformed all other sectors in the broader index with a ~2.5% gain thanks mainly to M&A prospects. Healthcare technology, along with names battling the ...</p>\n\n<a href=\"https://seekingalpha.com/news/3781487-novavax-vir-among-healthcare-gainers-pfizer-posts-best-rally-in-a-decade\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ARNA":"阿里那","CERN":"美国塞纳","BK4534":"瑞士信贷持仓","PFE":"辉瑞","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4550":"红杉资本持仓","BK4568":"美国抗疫概念","ORCL":"甲骨文","BK4007":"制药"},"source_url":"https://seekingalpha.com/news/3781487-novavax-vir-among-healthcare-gainers-pfizer-posts-best-rally-in-a-decade","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1122414343","content_text":"The healthcare stocks in the S&P 500 outperformed all other sectors in the broader index with a ~2.5% gain thanks mainly to M&A prospects. Healthcare technology, along with names battling the resurgence of COVID-19, led the gainers while the overall index fell ~1.9%.\nAmong stocks with more than $2B market capitalization and 100K average daily volume over the past week, Arena Pharmaceuticals  dominated with a ~83.8% rise after Pfizer  agreed to acquire it in a ~$6.7B deal with 100% premium for the biotech. Cerner  also joined the M&A-driven rally to gain ~20.7% over the week amid reports of a potential ~$30B bid from Oracle  for the electronic-medical-records company.\nVaccine developer, Novavax  jumped ~30.5% as investors welcomed the WHO clearance for the company’s COVID-19 shot. Further gains for the Maryland-based biotech are likely when an expert panel of the European regulators is set to review the marketing authorization for the vaccine next week.\nBiohaven Pharmaceutical  posted a ~25.2% weekly rise after the company announced the approval for NURTEC ODT (rimegepant) in Israel, making it the first regulatory win for the migraine drug outside the U.S. Meanwhile, Vir Biotechnology (NASDAQ:VIR) surged ~23.7% to stand among best gainers for the second week this month. More data emerged this week confirming the Omicron-neutralizing effect of the company’s COVID-19 therapy developed in partnership with GlaxoSmithKline (NYSE:GSK). Rounding out the top five gainers, Roivant Sciences  added ~22.6%.\nNotable gainer: Pfizer (PFE) made headlines throughout the week, raising its sales guidance for the COVID-19 vaccine once again as the rapidly spreading Omicron variant highlighted the need for booster shots. Despite an abrupt end to its six-day rally on Friday, the New York-based pharma giant with a ~12.7% rise recorded its best weekly gain since March 2009.\nAmong worst performers of the week, two newly IPO’ed biotechs, Instil Bio (NASDAQ:TIL) and Exscientia (NASDAQ:EXAI), stood out, falling 19.3% and ~13.5%, respectively, despite their favorable ratings on Wall Street. Meanwhile, GoodRx Holdings (NASDAQ:GDRX), an operator of a price comparison platform for prescription medicine slumped ~15.6%.\nLast week’s best performer, Bright Health Group, crashed ~13.1%, hurt by the sole Sell rating issued by Goldman Sachs even as the investment bank kicked off its coverage on managed care with largely positive views.\nAllogene Therapeutics (NASDAQ:ALLO) dropped ~12.3% after the company’s ASH presentations on Phase 1 data for experimental allogeneic CAR T therapies failed to excite investors, including Cathie Wood’s Ark Investment Management, which sold ~1.6M shares of the biotech several days later.","news_type":1},"isVote":1,"tweetType":1,"viewCount":672,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":699279794,"gmtCreate":1639824888317,"gmtModify":1639824888635,"author":{"id":"3554895157968981","authorId":"3554895157968981","name":"canoboi","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like n comment. Thks","listText":"Like n comment. Thks","text":"Like n comment. Thks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/699279794","repostId":"1116106959","repostType":4,"repost":{"id":"1116106959","pubTimestamp":1639785552,"share":"https://www.laohu8.com/m/news/1116106959?lang=&edition=full","pubTime":"2021-12-18 07:59","market":"us","language":"en","title":"Wall Street ends down after mostly negative week","url":"https://stock-news.laohu8.com/highlight/detail?id=1116106959","media":"Reuters","summary":" - Wall Street finished lower on Friday, weighed down by Big Tech as investors worried about the Omicron coronavirus variant and digested the Federal Reserve's decision to end its pandemic-era stimulus faster.All three main U.S. stock indexes ended with a decline for the week after the Fed on Wednesday signaled three quarter-percentage-point interest rate hikes by the end of 2022 to combat surging inflation.Nvidia dropped 2.1% and Alphabet lost 1.9%, both weighing on the S&P 500 and Nasdaq.The S","content":"<p>(Reuters) - Wall Street finished lower on Friday, weighed down by Big Tech as investors worried about the Omicron coronavirus variant and digested the Federal Reserve's decision to end its pandemic-era stimulus faster.</p>\n<p>All three main U.S. stock indexes ended with a decline for the week after the Fed on Wednesday signaled three quarter-percentage-point interest rate hikes by the end of 2022 to combat surging inflation.</p>\n<p>Nvidia dropped 2.1% and Alphabet lost 1.9%, both weighing on the S&amp;P 500 and Nasdaq.</p>\n<p>The S&amp;P 500 growth index lost 0.7% and the value index declined 1.4%.</p>\n<p>All of the 11 major S&amp;P 500 sector indexes fell, with financials leading the way down with a 2.3% drop. Energy lost 2.2%.</p>\n<p>Adding to uncertainty, Pfizer said on Friday the pandemic could extend through next year. European countries geared up for further travel and social restrictions and a study warned that the rapidly spreading Omicron coronavirus variant was five times more likely to reinfect people than its predecessor, Delta.</p>\n<p>Traders also pointed to year-end tax selling and the simultaneous expiration of stock options, stock index futures and index options contracts - known as triple witching - as potential causes for volatility.</p>\n<p>\"It's a big options expiration day,\" said Joe Saluzzi, co-manager of trading at Themis Trading in Chatham, New Jersey. \"And now you draw on top of that some Omicron, and you've got volatility, and I think it creates a lot of uncertainty amongst investors. Where are you going to position for the end of the year?\"</p>\n<p>Heavyweight growth stocks including Nvidia and Microsoft have outperformed the broader market in 2021, while the Philadelphia SE Semiconductor index has surged about 35%. The benchmark S&amp;P 500 index gained around 23% in the same period.</p>\n<p>In Friday's session, the Dow Jones Industrial Average fell 1.48% to end at 35,365.44 points, while the S&amp;P 500 lost 1.03% to 4,620.64.</p>\n<p>The Nasdaq Composite dropped 0.07% to 15,169.68.</p>\n<p>On a positive note, the small-cap Russell 2000 index rallied 1% after having fallen more than 10% from a record high in early November.</p>\n<p>With options expiring, volume on U.S. exchanges jumped to 16.6 billion shares, far above the 11.9 billion average over the last 20 trading days.</p>\n<p>For the week, the S&amp;P 500 fell 1.9%, the Dow lost 1.7% and the Nasdaq declined 2.9%.</p>\n<p>In Friday's session, Oracle tumbled 6.4% after the Wall Street Journal reported the enterprise software maker is in talks to buy electronic medical records company Cerner in a deal that could be valued at $30 billion. Shares of Cerner surged 12.9%.</p>\n<p>FedEx Corp rose almost 5% after the delivery firm reinstated its original fiscal 2022 forecast on Thursday, even as persistent labor woes chipped away profits.</p>\n<p>Declining issues outnumbered advancing ones on the NYSE by a 1.50-to-1 ratio; on Nasdaq, a 1.16-to-1 ratio favored advancers.</p>\n<p>The S&amp;P 500 posted 22 new 52-week highs and seven new lows; the Nasdaq Composite recorded 28 new highs and 341 new lows.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wall Street ends down after mostly negative week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWall Street ends down after mostly negative week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-18 07:59 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/us-stocks-wall-street-ends-212015460.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Reuters) - Wall Street finished lower on Friday, weighed down by Big Tech as investors worried about the Omicron coronavirus variant and digested the Federal Reserve's decision to end its pandemic-...</p>\n\n<a href=\"https://finance.yahoo.com/news/us-stocks-wall-street-ends-212015460.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite",".SPX":"S&P 500 Index",".DJI":"道琼斯"},"source_url":"https://finance.yahoo.com/news/us-stocks-wall-street-ends-212015460.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1116106959","content_text":"(Reuters) - Wall Street finished lower on Friday, weighed down by Big Tech as investors worried about the Omicron coronavirus variant and digested the Federal Reserve's decision to end its pandemic-era stimulus faster.\nAll three main U.S. stock indexes ended with a decline for the week after the Fed on Wednesday signaled three quarter-percentage-point interest rate hikes by the end of 2022 to combat surging inflation.\nNvidia dropped 2.1% and Alphabet lost 1.9%, both weighing on the S&P 500 and Nasdaq.\nThe S&P 500 growth index lost 0.7% and the value index declined 1.4%.\nAll of the 11 major S&P 500 sector indexes fell, with financials leading the way down with a 2.3% drop. Energy lost 2.2%.\nAdding to uncertainty, Pfizer said on Friday the pandemic could extend through next year. European countries geared up for further travel and social restrictions and a study warned that the rapidly spreading Omicron coronavirus variant was five times more likely to reinfect people than its predecessor, Delta.\nTraders also pointed to year-end tax selling and the simultaneous expiration of stock options, stock index futures and index options contracts - known as triple witching - as potential causes for volatility.\n\"It's a big options expiration day,\" said Joe Saluzzi, co-manager of trading at Themis Trading in Chatham, New Jersey. \"And now you draw on top of that some Omicron, and you've got volatility, and I think it creates a lot of uncertainty amongst investors. Where are you going to position for the end of the year?\"\nHeavyweight growth stocks including Nvidia and Microsoft have outperformed the broader market in 2021, while the Philadelphia SE Semiconductor index has surged about 35%. The benchmark S&P 500 index gained around 23% in the same period.\nIn Friday's session, the Dow Jones Industrial Average fell 1.48% to end at 35,365.44 points, while the S&P 500 lost 1.03% to 4,620.64.\nThe Nasdaq Composite dropped 0.07% to 15,169.68.\nOn a positive note, the small-cap Russell 2000 index rallied 1% after having fallen more than 10% from a record high in early November.\nWith options expiring, volume on U.S. exchanges jumped to 16.6 billion shares, far above the 11.9 billion average over the last 20 trading days.\nFor the week, the S&P 500 fell 1.9%, the Dow lost 1.7% and the Nasdaq declined 2.9%.\nIn Friday's session, Oracle tumbled 6.4% after the Wall Street Journal reported the enterprise software maker is in talks to buy electronic medical records company Cerner in a deal that could be valued at $30 billion. Shares of Cerner surged 12.9%.\nFedEx Corp rose almost 5% after the delivery firm reinstated its original fiscal 2022 forecast on Thursday, even as persistent labor woes chipped away profits.\nDeclining issues outnumbered advancing ones on the NYSE by a 1.50-to-1 ratio; on Nasdaq, a 1.16-to-1 ratio favored advancers.\nThe S&P 500 posted 22 new 52-week highs and seven new lows; the Nasdaq Composite recorded 28 new highs and 341 new lows.","news_type":1},"isVote":1,"tweetType":1,"viewCount":473,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":605893068,"gmtCreate":1639140384143,"gmtModify":1639140384427,"author":{"id":"3554895157968981","authorId":"3554895157968981","name":"canoboi","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like and comment. Thanks","listText":"Like and comment. Thanks","text":"Like and comment. Thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/605893068","repostId":"1160479644","repostType":4,"repost":{"id":"1160479644","pubTimestamp":1639130522,"share":"https://www.laohu8.com/m/news/1160479644?lang=&edition=full","pubTime":"2021-12-10 18:02","market":"sg","language":"en","title":"STI down as investors weigh faster Fed taper","url":"https://stock-news.laohu8.com/highlight/detail?id=1160479644","media":"businesstimes","summary":"SINGAPORE shares ended the week in negative territory ahead of key inflation data from the United St","content":"<div>\n<p>SINGAPORE shares ended the week in negative territory ahead of key inflation data from the United States and amid the China property debt crisis.\nThe Singapore Straits Times Index (STI) ended Friday (...</p>\n\n<a href=\"https://www.businesstimes.com.sg/stocks/sti-down-as-investors-weigh-faster-fed-taper-china-property-woes\">Web Link</a>\n\n</div>\n","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>STI down as investors weigh faster Fed taper</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSTI down as investors weigh faster Fed taper\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-10 18:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.businesstimes.com.sg/stocks/sti-down-as-investors-weigh-faster-fed-taper-china-property-woes><strong>businesstimes</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>SINGAPORE shares ended the week in negative territory ahead of key inflation data from the United States and amid the China property debt crisis.\nThe Singapore Straits Times Index (STI) ended Friday (...</p>\n\n<a href=\"https://www.businesstimes.com.sg/stocks/sti-down-as-investors-weigh-faster-fed-taper-china-property-woes\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"STI.SI":"富时新加坡海峡指数"},"source_url":"https://www.businesstimes.com.sg/stocks/sti-down-as-investors-weigh-faster-fed-taper-china-property-woes","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1160479644","content_text":"SINGAPORE shares ended the week in negative territory ahead of key inflation data from the United States and amid the China property debt crisis.\nThe Singapore Straits Times Index (STI) ended Friday (Dec 10) 0.22 per cent or 6.84 points lower at 3,135.61.\nSaid IG market strategist Yeap Jun Rong: \"The tapering of asset purchases from the Fed has taken greater focus lately, with the hawkish change in stance among Fed officials suggesting that it may come sooner rather than later, and the consumer price inflation data may potentially prompt an accelerated pace.\"\nAlso keeping investors on their toes is China's real estate woes.\nWith the exception of Indonesia's Jakarta Composite Index which gained 0.14 per cent, most key benchmark indices in the region ended the day in the red.\nJapan's Nikkei 225 was down 1 per cent; Hong Kong's Hang Seng Index slipped 1.07 per cent; South Korea's Kospi slipped 0.64 per cent and the Malaysia's Kuala Lumpur Composite Index shed 0.86 per cent.\nAcross the local market, decliners outpaced advancers 258 to 199 with about 1.86 billion shares worth S$863.8 million changing hands.\nCapitaLand Investment was the best-performing among the STI constituents with shares gaining 0.9 per cent or S$0.03 to S$3.47.\nSingapore Airlines was at the bottom of the table with shares slipping 2.4 per cent or S$0.12 to S$4.95.\nThai Beverage was the most heavily traded on the blue-chip index with 24.1 million shares changing hands. It shares were down 1.5 per cent or S$0.01 to S$0.665.","news_type":1},"isVote":1,"tweetType":1,"viewCount":621,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":602554024,"gmtCreate":1639046354491,"gmtModify":1639046354731,"author":{"id":"3554895157968981","authorId":"3554895157968981","name":"canoboi","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like and comment. Thanks","listText":"Like and comment. Thanks","text":"Like and comment. Thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/602554024","repostId":"1154556769","repostType":4,"repost":{"id":"1154556769","pubTimestamp":1639043123,"share":"https://www.laohu8.com/m/news/1154556769?lang=&edition=full","pubTime":"2021-12-09 17:45","market":"us","language":"en","title":"Is Roku Too Good To Pass Up at This Price?","url":"https://stock-news.laohu8.com/highlight/detail?id=1154556769","media":"InvestorPlace","summary":"ROKU stock has taken a beating, but shares are bouncing back on news of a YouTube deal","content":"<p><b>Roku</b>(NASDAQ:<b><u>ROKU</u></b>) seems to be in an enviable position. It operates the most popular streaming service in the United States. But as the world began to return to some semblance of normalcy, investors sold shares of this and other pandemic plays. Since hitting an all-time high of $490.76 in late July, ROKU stock is down nearly 50%. And that includes today’s 18% pop in shares.</p>\n<p>Today’s big run-up came on the news Roku&nbsp;reached a multi-year extension deal&nbsp;with&nbsp;<b>Google</b>(NASDAQ:<b><u>GOOGL</u></b>) for YouTube and YouTube TV, ending a months-long battle between the two companies.</p>\n<p>The question now is whether investors will continue piling into shares at a discount or return to selling ROKU stock.</p>\n<p><b>Roku: From Set-top Boxes to a Streaming Giant</b></p>\n<p>Roku has been around since well before cord-cutting came into vogue. In fact, the company was founded all the way back in 2002.</p>\n<p>The first set-top boxes were developed in conjunction with&nbsp;<b>Netflix</b>(NASDAQ:<b><u>NFLX</u></b>), which was looking for ways to evolve from a company that simply shipped DVDs by mail. Netflix decided to&nbsp;spin off the Roku business&nbsp;into its own company in 2008 so Roku could enter into third-party agreements with other streaming services.</p>\n<p>Obviously, this worked out well for both companies. Netflix is the king of streaming content, while Roku is the top streaming service in both the U.S. and Mexico.</p>\n<p>Roku is also starting to get in on the content game. Roku Originals launched on the Roku Channel in May, featuring original scripted and unscripted series, as well as documentaries. And Roku just released its first original movie, “Zoey’s Extraordinary Christmas.” Over the next two years, the Roku Channel is expected to launch 50 new original programs.</p>\n<p><b>Cord-Cutting, COVID-19 Make Roku a Star</b></p>\n<p>Two major trends converged roughly a year and a half ago to make ROKU stock a breakout star: cord-cutting and the coronavirus pandemic.</p>\n<p>As we all experienced first-hand, the coronavirus pandemic and resulting stay-at-home orders made home entertainment more popular than ever. From its March 2020 bottom to its early 2021 high, ROKU stock skyrocketed from around $58 per share to nearly $487, gaining 736% in 11 months.</p>\n<p>In addition to the pandemic, the company is benefitting from the cord-cutting trend in which consumers are canceling or forgoing traditional cable TV in favor of the myriad streaming options available.</p>\n<p>According to eMarketer, 35.5 million U.S. households, or around 27%, will have canceled their pay-TV subscriptions by the end of this year. The researcher predicts that number will jump to 46.6 million households, or more than 35%, by the end of 2024.</p>\n<p>Of course, those are just the people who are canceling their cable or satellite TV subscriptions. There is an ever-growing cohort who has never had a traditional TV subscription and don’t plan to.</p>\n<p>According to Pew Research, more than 60% of people age 18 to 29 who don’t have a traditional TV subscription say they have never had one. And more than 70% of all age groups polled who do not pay for a traditional TV service say it’s because it’s not necessary. All the content they want to watch can be accessed online.</p>\n<p>Continuing to capture a large share of this population should not be hard for Roku. Its hardware, now in its 10th generation, gives streaming content providers like&nbsp;<b>Disney</b>&nbsp;(NYSE:<b><u>DIS</u></b>), HBO Max, Netflix, Paramount,<b>Apple</b>(NASDAQ:<b><u>AAPL</u></b>) TV and&nbsp;<b>Amazon</b>(NASDAQ:<b><u>AMZN</u></b>) Prime Video convenient access to all those new customers. Roku provides the funnel for its customers to access all those channels and more.</p>\n<p>But the hardware only makes up a fraction of Roku’s revenue. The company actually gets much more from advertising, which will continue to be an important revenue source as companies follow consumers and look for ways to get their ads in front of streaming viewers.</p>\n<p><b>Roku’s Q3 Report Disappoints Investors</b></p>\n<p>For the third quarter,reported in mid-November, Roku said player revenue fell 26% year over year to $97.4 million. However, platform revenue, which includes advertising, jumped by 82% from a year ago to hit $582.5 million.</p>\n<p>Meanwhile, total net revenue for the third quarter jumped by 51% from a year ago to $680 million. Average revenue per user (ARPU) reached $40 for the first time in the company’s history and was up 49% from a year ago. And the number of active accounts grew by 1.3 million from Q2 to 56.4 million.</p>\n<p>The companybeat analysts’ estimateson earnings per share, coming in at 48 cents, or 8 cents better than expected. However, it missed on revenue and the number of active accounts. Fourth-quarter revenue guidance of $885 million to $900 million also came in below expectations.</p>\n<p>Roku blamed its slower-than-expected growth on supply chain disruptions that are affecting manufacturers around the world. The company also noted that while unit sales were down on a year-over-year basis, the Q3 2020 numbers were artificially high because of massive demand for Roku devices during the pandemic.</p>\n<p>Those are fair complaints. As I’ve noted in many previous stories, 2020 was a crazy year and threw a lot of metrics out of whack. So, I’m not concerned at all that Roku didn’t improve on the massive growth it saw during an unprecedented pandemic.</p>\n<p><b>The Bottom Line on ROKU Stock</b></p>\n<p>ROKU stock sold off sharply following the Q3 report and remained in a free-fall until this week’s bounce. The YouTube deal is certainly a plus for the company and removed a headwind for the stock.</p>\n<p>Interestingly, one of the biggest Roku bulls is Cathie Wood of&nbsp;<b>ARK Invest</b>. Early last month, it was announced that two of the exchange-traded funds she runs&nbsp;took big positions in ROKU stock.</p>\n<p>The<b>Ark Innovation ETF</b>(NYSE:<b><u>ARKK</u></b>) and&nbsp;<b>ARK Next Generation ETF</b>(NYSE:<b><u>ARKW</u></b>) bought over 200,000 shares of Roku combined. ROKU is now the&nbsp;No. 3 holding in ARKK, with a position worth nearly $949 million. And it’s the&nbsp;No. 7 holding in ARKW, with $205 million in shares.</p>\n<p>Obviously, Wood is expecting big things from Roku in the coming months. Considering how far Roku has fallen in the past six months, ROKU stock certainly has plenty of room to run.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Roku Too Good To Pass Up at This Price?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Roku Too Good To Pass Up at This Price?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-09 17:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/12/roku-stock-too-good-to-pass-up-at-this-price/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Roku(NASDAQ:ROKU) seems to be in an enviable position. It operates the most popular streaming service in the United States. But as the world began to return to some semblance of normalcy, investors ...</p>\n\n<a href=\"https://investorplace.com/2021/12/roku-stock-too-good-to-pass-up-at-this-price/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ROKU":"Roku Inc"},"source_url":"https://investorplace.com/2021/12/roku-stock-too-good-to-pass-up-at-this-price/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1154556769","content_text":"Roku(NASDAQ:ROKU) seems to be in an enviable position. It operates the most popular streaming service in the United States. But as the world began to return to some semblance of normalcy, investors sold shares of this and other pandemic plays. Since hitting an all-time high of $490.76 in late July, ROKU stock is down nearly 50%. And that includes today’s 18% pop in shares.\nToday’s big run-up came on the news Roku reached a multi-year extension deal with Google(NASDAQ:GOOGL) for YouTube and YouTube TV, ending a months-long battle between the two companies.\nThe question now is whether investors will continue piling into shares at a discount or return to selling ROKU stock.\nRoku: From Set-top Boxes to a Streaming Giant\nRoku has been around since well before cord-cutting came into vogue. In fact, the company was founded all the way back in 2002.\nThe first set-top boxes were developed in conjunction with Netflix(NASDAQ:NFLX), which was looking for ways to evolve from a company that simply shipped DVDs by mail. Netflix decided to spin off the Roku business into its own company in 2008 so Roku could enter into third-party agreements with other streaming services.\nObviously, this worked out well for both companies. Netflix is the king of streaming content, while Roku is the top streaming service in both the U.S. and Mexico.\nRoku is also starting to get in on the content game. Roku Originals launched on the Roku Channel in May, featuring original scripted and unscripted series, as well as documentaries. And Roku just released its first original movie, “Zoey’s Extraordinary Christmas.” Over the next two years, the Roku Channel is expected to launch 50 new original programs.\nCord-Cutting, COVID-19 Make Roku a Star\nTwo major trends converged roughly a year and a half ago to make ROKU stock a breakout star: cord-cutting and the coronavirus pandemic.\nAs we all experienced first-hand, the coronavirus pandemic and resulting stay-at-home orders made home entertainment more popular than ever. From its March 2020 bottom to its early 2021 high, ROKU stock skyrocketed from around $58 per share to nearly $487, gaining 736% in 11 months.\nIn addition to the pandemic, the company is benefitting from the cord-cutting trend in which consumers are canceling or forgoing traditional cable TV in favor of the myriad streaming options available.\nAccording to eMarketer, 35.5 million U.S. households, or around 27%, will have canceled their pay-TV subscriptions by the end of this year. The researcher predicts that number will jump to 46.6 million households, or more than 35%, by the end of 2024.\nOf course, those are just the people who are canceling their cable or satellite TV subscriptions. There is an ever-growing cohort who has never had a traditional TV subscription and don’t plan to.\nAccording to Pew Research, more than 60% of people age 18 to 29 who don’t have a traditional TV subscription say they have never had one. And more than 70% of all age groups polled who do not pay for a traditional TV service say it’s because it’s not necessary. All the content they want to watch can be accessed online.\nContinuing to capture a large share of this population should not be hard for Roku. Its hardware, now in its 10th generation, gives streaming content providers like Disney (NYSE:DIS), HBO Max, Netflix, Paramount,Apple(NASDAQ:AAPL) TV and Amazon(NASDAQ:AMZN) Prime Video convenient access to all those new customers. Roku provides the funnel for its customers to access all those channels and more.\nBut the hardware only makes up a fraction of Roku’s revenue. The company actually gets much more from advertising, which will continue to be an important revenue source as companies follow consumers and look for ways to get their ads in front of streaming viewers.\nRoku’s Q3 Report Disappoints Investors\nFor the third quarter,reported in mid-November, Roku said player revenue fell 26% year over year to $97.4 million. However, platform revenue, which includes advertising, jumped by 82% from a year ago to hit $582.5 million.\nMeanwhile, total net revenue for the third quarter jumped by 51% from a year ago to $680 million. Average revenue per user (ARPU) reached $40 for the first time in the company’s history and was up 49% from a year ago. And the number of active accounts grew by 1.3 million from Q2 to 56.4 million.\nThe companybeat analysts’ estimateson earnings per share, coming in at 48 cents, or 8 cents better than expected. However, it missed on revenue and the number of active accounts. Fourth-quarter revenue guidance of $885 million to $900 million also came in below expectations.\nRoku blamed its slower-than-expected growth on supply chain disruptions that are affecting manufacturers around the world. The company also noted that while unit sales were down on a year-over-year basis, the Q3 2020 numbers were artificially high because of massive demand for Roku devices during the pandemic.\nThose are fair complaints. As I’ve noted in many previous stories, 2020 was a crazy year and threw a lot of metrics out of whack. So, I’m not concerned at all that Roku didn’t improve on the massive growth it saw during an unprecedented pandemic.\nThe Bottom Line on ROKU Stock\nROKU stock sold off sharply following the Q3 report and remained in a free-fall until this week’s bounce. The YouTube deal is certainly a plus for the company and removed a headwind for the stock.\nInterestingly, one of the biggest Roku bulls is Cathie Wood of ARK Invest. Early last month, it was announced that two of the exchange-traded funds she runs took big positions in ROKU stock.\nTheArk Innovation ETF(NYSE:ARKK) and ARK Next Generation ETF(NYSE:ARKW) bought over 200,000 shares of Roku combined. ROKU is now the No. 3 holding in ARKK, with a position worth nearly $949 million. And it’s the No. 7 holding in ARKW, with $205 million in shares.\nObviously, Wood is expecting big things from Roku in the coming months. Considering how far Roku has fallen in the past six months, ROKU stock certainly has plenty of room to run.","news_type":1},"isVote":1,"tweetType":1,"viewCount":222,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":602355182,"gmtCreate":1638975620041,"gmtModify":1638975620314,"author":{"id":"3554895157968981","authorId":"3554895157968981","name":"canoboi","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like and comment. Thks","listText":"Like and comment. Thks","text":"Like and comment. Thks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/602355182","repostId":"1100353648","repostType":4,"repost":{"id":"1100353648","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638975407,"share":"https://www.laohu8.com/m/news/1100353648?lang=&edition=full","pubTime":"2021-12-08 22:56","market":"us","language":"en","title":"Airlines and cruise line stocks jumped in morning trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1100353648","media":"Tiger Newspress","summary":"Airlines and cruise line stocks jumped in morning trading.","content":"<p>Airlines and cruise line stocks jumped in morning trading.</p>\n<p><img src=\"https://static.tigerbbs.com/994b55083be6d042bbbfb1c0599d47cd\" tg-width=\"407\" tg-height=\"483\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/0947f84e60588e489e2e964fe5a018dc\" tg-width=\"405\" tg-height=\"189\" referrerpolicy=\"no-referrer\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Airlines and cruise line stocks jumped in morning trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAirlines and cruise line stocks jumped in morning trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-08 22:56</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Airlines and cruise line stocks jumped in morning trading.</p>\n<p><img src=\"https://static.tigerbbs.com/994b55083be6d042bbbfb1c0599d47cd\" tg-width=\"407\" tg-height=\"483\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/0947f84e60588e489e2e964fe5a018dc\" tg-width=\"405\" tg-height=\"189\" referrerpolicy=\"no-referrer\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CCL":"嘉年华邮轮","LUV":"西南航空","JBLU":"捷蓝航空","UAL":"联合大陆航空","SAVE":"Spirit Airlines","DAL":"达美航空","RCL":"皇家加勒比邮轮","NCLH":"挪威邮轮","AAL":"美国航空","BA":"波音"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1100353648","content_text":"Airlines and cruise line stocks jumped in morning trading.","news_type":1},"isVote":1,"tweetType":1,"viewCount":186,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":601549809,"gmtCreate":1638543940804,"gmtModify":1638543940956,"author":{"id":"3554895157968981","authorId":"3554895157968981","name":"canoboi","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like n comment thanks","listText":"Like n comment thanks","text":"Like n comment thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/601549809","repostId":"2188528084","repostType":4,"repost":{"id":"2188528084","pubTimestamp":1638543717,"share":"https://www.laohu8.com/m/news/2188528084?lang=&edition=full","pubTime":"2021-12-03 23:01","market":"us","language":"en","title":"5 Warren Buffett Stocks Are Screaming Buys in December","url":"https://stock-news.laohu8.com/highlight/detail?id=2188528084","media":"Motley Fool","summary":"Riding the Oracle of Omaha's coattails is often a moneymaking proposition.","content":"<p>Making money for shareholders has been in Warren Buffett's blood since taking over as CEO of <b>Berkshire Hathaway</b> (NYSE:BRK.A)(NYSE:BRK.B) in 1965. Over that time, he's led Berkshire to an average annual gain of about 20%, which translates into aggregate gains, including the year-to-date performance of the Class A shares (BRK.A), of approximately 3,500,000%. Gains like this are why the investing world pays close attention to what the Oracle of Omaha is buying and selling.</p>\n<p>Based on the latest 13F filing with the Securities and Exchange Commission, Berkshire Hathaway has stakes in 45 securities. Among these 45 holdings, five Warren Buffett stocks stand out as screaming buys in December.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/e92116e97f06291ec28eda85974acb1b\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Berkshire Hathaway CEO Warren Buffett. Image source: The Motley Fool.</span></p>\n<h2>Amazon</h2>\n<p>While I'm well aware this isn't going to win any points for originality, e-commerce kingpin <b>Amazon</b> (NASDAQ:AMZN) remains a surefire stock to own in Buffett's portfolio.</p>\n<p>Most people are familiar with Amazon for its dominant online marketplace. According to an August report from eMarketer, Amazon is expected to handle 41.4% of all U.S. online sales in 2021. That's about 34 percentage points higher than the next-closest competitor. The key, though, is that the company has signed up 200 million people to a Prime membership worldwide. The annual fees collected from these members helps to buoy razor-thin retail margins and allows Amazon to consistently undercut brick-and-mortar retailers on price.</p>\n<p>However, the company's future rests with its considerably higher-margin segments, such as cloud infrastructure services. Amazon Web Services (AWS) accounted for only 13.4% of net sales in the third quarter, yet contributed 61.8% of the company's operating income. Even with online sales slowing as coronavirus vaccination rates tick higher and life returns to some semblance of normal, Amazon's critical highest-margin segments (AWS, subscriptions, and advertising) continue to grow rapidly.</p>\n<p>If Amazon were to simply hit the median price-to-operating cash flow it's been trading at for the past 11 years, we could be looking at a $10,000 a share company by mid-decade.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/b18b49b2b35da2fc49e0a83b883d1c22\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Bristol Myers Squibb</h2>\n<p>Another Warren Buffett stock that's quickly become a screaming buy is pharmaceutical company <b>Bristol Myers Squibb</b> (NYSE:BMY).</p>\n<p>Bristol Myers' success is dependent on organically developing and growing its brand-name pharmaceutical portfolio, as well as leaning on acquisitions to push the needle higher.</p>\n<p>From an internal development perspective, some of the company's biggest wins include cancer immunotherapy Opdivo and oral anticoagulant Eliquis -- the latter of which was developed with <b>Pfizer</b>. Eliquis should push for $10 billion in sales for Bristol Myers this year, while Opdivo hit $7 billion in revenue last year. Opdivo is particularly intriguing given that it's being examined in dozens of clinical trials and has already received approval for 10 indications in the U.S. Label expansion opportunities, pricing power, and improved cancer screening diagnostics all have the potential to make this a $10 billion a year therapy.</p>\n<p>Bristol Myers also made waves with its November 2019 acquisition of cancer and immunology drugmaker Celgene. Buying Celgene added a handful of blockbuster drugs to Bristol's portfolio, including multiple myeloma treatment Revlimid, which will potentially top $13 billion in 2021 sales. Revlimid is protected from an onslaught of generic competition for four more years, which means Bristol Myers will be generating bountiful cash flow in the meantime.</p>\n<p>At just 7 times consensus forward-year earnings per share, it's an absolute steal.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/a295212aa2b7c99c921b8afa2a4aa3a2\" tg-width=\"700\" tg-height=\"467\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2><a href=\"https://laohu8.com/S/V\">Visa</a></h2>\n<p>The recent sell-off in payment processing behemoth <b>Visa</b> (NYSE:V) makes it a screaming buy, too.</p>\n<p>Over the past couple of months, Wall Street and investors have raised concerns about payment facilitators like <b>Square</b>&nbsp;or cryptocurrencies eating into Visa's dominance. However, these concerns seem unfounded given Visa's utter dominance of the processing space. As of 2018, it held a 53% share of U.S. credit card network purchase volume, which was more than 30 percentage points higher than the next-closest competitor. I should also mention the U.S. is the leading market for consumption in the world.</p>\n<p>Visa's outperformance is also a function of its lending avoidance. By sticking to the processing side of the equation, the company avoids having to set aside capital to cover credit delinquencies during recessions. Not having to cover credit/loan losses is a big reason why Visa rebounds faster than other financial stocks and maintains a profit margin north of 50%.</p>\n<p>And have I mentioned that Visa is <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the smartest ways to play rapidly rising inflation? Since the company's fees are tied to the price of goods and services, its revenue and profits will grow as the price for goods and services rises.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1c5a0257bdd17a5ff3cf22a10de43ce0\" tg-width=\"700\" tg-height=\"467\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Teva Pharmaceutical Industries</h2>\n<p>The cheapest stock in Warren Buffett's portfolio, brand-name and generic-drug company <b>Teva Pharmaceutical Industries</b> (NYSE:TEVA), is begging to be bought as well. Teva can currently be purchased for a little more than 3 times Wall Street's consensus earnings per share in 2021 and 2022.</p>\n<p>Unlike Amazon, Bristol Myers, and Visa, Teva hasn't been firing on all cylinders. Since 2016, the company settled a bribery scandal, buried itself in debt after overpaying for generic-drugmaker Actavis, and has faced a mountain of litigation concerning its role in the opioid epidemic. But while there's reason to not give Teva a valuation premium, an earnings multiple of 3 is overly pessimistic given the steps being taken to right the ship.</p>\n<p>In late 2017, Kare Schultz took over as CEO. He's a turnaround specialist who's taken clear steps to improve the business. During his tenure, net debt has been reduced from over $34 billion to around $22 billion, and annual operating expenses have been cut by a double-digit percentage. Teva is leaner than it's been in years and is capable of maintaining annual operating cash flow of $2 billion (or higher).</p>\n<p>Furthermore, there's light at the end of the tunnel when it comes to opioid litigation. A trial in California recently went in favor of drugmakers, which could put some bargaining power back in Teva's court. If Schultz can negotiate a national settlement where free or reduced-cost medicine, not cash, is the lure, Teva could probably double very quickly.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/7343c3ce7330b86321a8ec9384d4baea\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Bank of America</h2>\n<p>The final Warren Buffett stock to buy hand over fist in December is banking juggernaut <b>Bank of America</b> (NYSE:BAC).</p>\n<p>Bank stocks like BofA are on the cusp of hitting their growth sweet spot. With inflation picking up, the Federal Reserve will more than likely need to act in 2022 or 2023 to raise interest rates. Boosting the federal funds target rate will lift the net interest income-earning potential of banks with outstanding variable-rate loans.</p>\n<p>Among money-center banks, none is more interest-sensitive than Bank of America. The company's third-quarter earnings presentation points out that a 100-basis-point parallel shift in the interest rate yield curve would generate an estimated $7.2 billion in added net interest income over 12 months. Although we're unlikely to see a 100-basis-point shift in 12 months, we are on the verge of seeing higher interest rates significantly bolster BofA's profit potential.</p>\n<p>The other impressive aspect of Warren Buffett's second-largest holding is its digitization efforts. Though you probably don't think of Bank of America as a tech-savvy business, the number of digital active users has grown to nearly 41 million, with 43% of all sales in the third quarter coming from online or mobile banking. This push to digitize has allowed the company to consolidate some of its branches in order to reduce costs.</p>\n<p>Bank of America should be a no-brainer buy as it enters the sweet spot of its growth cycle.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Warren Buffett Stocks Are Screaming Buys in December</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Warren Buffett Stocks Are Screaming Buys in December\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-03 23:01 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/03/5-warren-buffett-stocks-screaming-buys-in-december/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Making money for shareholders has been in Warren Buffett's blood since taking over as CEO of Berkshire Hathaway (NYSE:BRK.A)(NYSE:BRK.B) in 1965. Over that time, he's led Berkshire to an average ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/03/5-warren-buffett-stocks-screaming-buys-in-december/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BRK.B":"伯克希尔B","BAC":"美国银行","TEVA":"梯瓦制药","BK4532":"文艺复兴科技持仓","BK4550":"红杉资本持仓","BK4106":"数据处理与外包服务","BK4566":"资本集团","BK4507":"流媒体概念","V":"Visa","BK4538":"云计算","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4535":"淡马锡持仓","BK4176":"多领域控股","BK4207":"综合性银行","BK4559":"巴菲特持仓","BK4553":"喜马拉雅资本持仓","BK4504":"桥水持仓","BK4524":"宅经济概念","BK4554":"元宇宙及AR概念","AMZN":"亚马逊","BK4561":"索罗斯持仓","BK4557":"大麻股","BK4548":"巴美列捷福持仓","BK4527":"明星科技股","BK4551":"寇图资本持仓","BK4503":"景林资产持仓","BK4534":"瑞士信贷持仓","BK4122":"互联网与直销零售","BMY":"施贵宝","BRK.A":"伯克希尔","BK4007":"制药"},"source_url":"https://www.fool.com/investing/2021/12/03/5-warren-buffett-stocks-screaming-buys-in-december/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2188528084","content_text":"Making money for shareholders has been in Warren Buffett's blood since taking over as CEO of Berkshire Hathaway (NYSE:BRK.A)(NYSE:BRK.B) in 1965. Over that time, he's led Berkshire to an average annual gain of about 20%, which translates into aggregate gains, including the year-to-date performance of the Class A shares (BRK.A), of approximately 3,500,000%. Gains like this are why the investing world pays close attention to what the Oracle of Omaha is buying and selling.\nBased on the latest 13F filing with the Securities and Exchange Commission, Berkshire Hathaway has stakes in 45 securities. Among these 45 holdings, five Warren Buffett stocks stand out as screaming buys in December.\nBerkshire Hathaway CEO Warren Buffett. Image source: The Motley Fool.\nAmazon\nWhile I'm well aware this isn't going to win any points for originality, e-commerce kingpin Amazon (NASDAQ:AMZN) remains a surefire stock to own in Buffett's portfolio.\nMost people are familiar with Amazon for its dominant online marketplace. According to an August report from eMarketer, Amazon is expected to handle 41.4% of all U.S. online sales in 2021. That's about 34 percentage points higher than the next-closest competitor. The key, though, is that the company has signed up 200 million people to a Prime membership worldwide. The annual fees collected from these members helps to buoy razor-thin retail margins and allows Amazon to consistently undercut brick-and-mortar retailers on price.\nHowever, the company's future rests with its considerably higher-margin segments, such as cloud infrastructure services. Amazon Web Services (AWS) accounted for only 13.4% of net sales in the third quarter, yet contributed 61.8% of the company's operating income. Even with online sales slowing as coronavirus vaccination rates tick higher and life returns to some semblance of normal, Amazon's critical highest-margin segments (AWS, subscriptions, and advertising) continue to grow rapidly.\nIf Amazon were to simply hit the median price-to-operating cash flow it's been trading at for the past 11 years, we could be looking at a $10,000 a share company by mid-decade.\nImage source: Getty Images.\nBristol Myers Squibb\nAnother Warren Buffett stock that's quickly become a screaming buy is pharmaceutical company Bristol Myers Squibb (NYSE:BMY).\nBristol Myers' success is dependent on organically developing and growing its brand-name pharmaceutical portfolio, as well as leaning on acquisitions to push the needle higher.\nFrom an internal development perspective, some of the company's biggest wins include cancer immunotherapy Opdivo and oral anticoagulant Eliquis -- the latter of which was developed with Pfizer. Eliquis should push for $10 billion in sales for Bristol Myers this year, while Opdivo hit $7 billion in revenue last year. Opdivo is particularly intriguing given that it's being examined in dozens of clinical trials and has already received approval for 10 indications in the U.S. Label expansion opportunities, pricing power, and improved cancer screening diagnostics all have the potential to make this a $10 billion a year therapy.\nBristol Myers also made waves with its November 2019 acquisition of cancer and immunology drugmaker Celgene. Buying Celgene added a handful of blockbuster drugs to Bristol's portfolio, including multiple myeloma treatment Revlimid, which will potentially top $13 billion in 2021 sales. Revlimid is protected from an onslaught of generic competition for four more years, which means Bristol Myers will be generating bountiful cash flow in the meantime.\nAt just 7 times consensus forward-year earnings per share, it's an absolute steal.\nImage source: Getty Images.\nVisa\nThe recent sell-off in payment processing behemoth Visa (NYSE:V) makes it a screaming buy, too.\nOver the past couple of months, Wall Street and investors have raised concerns about payment facilitators like Square or cryptocurrencies eating into Visa's dominance. However, these concerns seem unfounded given Visa's utter dominance of the processing space. As of 2018, it held a 53% share of U.S. credit card network purchase volume, which was more than 30 percentage points higher than the next-closest competitor. I should also mention the U.S. is the leading market for consumption in the world.\nVisa's outperformance is also a function of its lending avoidance. By sticking to the processing side of the equation, the company avoids having to set aside capital to cover credit delinquencies during recessions. Not having to cover credit/loan losses is a big reason why Visa rebounds faster than other financial stocks and maintains a profit margin north of 50%.\nAnd have I mentioned that Visa is one of the smartest ways to play rapidly rising inflation? Since the company's fees are tied to the price of goods and services, its revenue and profits will grow as the price for goods and services rises.\nImage source: Getty Images.\nTeva Pharmaceutical Industries\nThe cheapest stock in Warren Buffett's portfolio, brand-name and generic-drug company Teva Pharmaceutical Industries (NYSE:TEVA), is begging to be bought as well. Teva can currently be purchased for a little more than 3 times Wall Street's consensus earnings per share in 2021 and 2022.\nUnlike Amazon, Bristol Myers, and Visa, Teva hasn't been firing on all cylinders. Since 2016, the company settled a bribery scandal, buried itself in debt after overpaying for generic-drugmaker Actavis, and has faced a mountain of litigation concerning its role in the opioid epidemic. But while there's reason to not give Teva a valuation premium, an earnings multiple of 3 is overly pessimistic given the steps being taken to right the ship.\nIn late 2017, Kare Schultz took over as CEO. He's a turnaround specialist who's taken clear steps to improve the business. During his tenure, net debt has been reduced from over $34 billion to around $22 billion, and annual operating expenses have been cut by a double-digit percentage. Teva is leaner than it's been in years and is capable of maintaining annual operating cash flow of $2 billion (or higher).\nFurthermore, there's light at the end of the tunnel when it comes to opioid litigation. A trial in California recently went in favor of drugmakers, which could put some bargaining power back in Teva's court. If Schultz can negotiate a national settlement where free or reduced-cost medicine, not cash, is the lure, Teva could probably double very quickly.\nImage source: Getty Images.\nBank of America\nThe final Warren Buffett stock to buy hand over fist in December is banking juggernaut Bank of America (NYSE:BAC).\nBank stocks like BofA are on the cusp of hitting their growth sweet spot. With inflation picking up, the Federal Reserve will more than likely need to act in 2022 or 2023 to raise interest rates. Boosting the federal funds target rate will lift the net interest income-earning potential of banks with outstanding variable-rate loans.\nAmong money-center banks, none is more interest-sensitive than Bank of America. The company's third-quarter earnings presentation points out that a 100-basis-point parallel shift in the interest rate yield curve would generate an estimated $7.2 billion in added net interest income over 12 months. Although we're unlikely to see a 100-basis-point shift in 12 months, we are on the verge of seeing higher interest rates significantly bolster BofA's profit potential.\nThe other impressive aspect of Warren Buffett's second-largest holding is its digitization efforts. Though you probably don't think of Bank of America as a tech-savvy business, the number of digital active users has grown to nearly 41 million, with 43% of all sales in the third quarter coming from online or mobile banking. This push to digitize has allowed the company to consolidate some of its branches in order to reduce costs.\nBank of America should be a no-brainer buy as it enters the sweet spot of its growth cycle.","news_type":1},"isVote":1,"tweetType":1,"viewCount":313,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":609871370,"gmtCreate":1638271641570,"gmtModify":1638271641727,"author":{"id":"3554895157968981","authorId":"3554895157968981","name":"canoboi","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like and comment thanks","listText":"Like and comment thanks","text":"Like and comment thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/609871370","repostId":"2187586148","repostType":4,"isVote":1,"tweetType":1,"viewCount":123,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":600472363,"gmtCreate":1638194690382,"gmtModify":1638194690766,"author":{"id":"3554895157968981","authorId":"3554895157968981","name":"canoboi","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like and comment. Thanks","listText":"Like and comment. Thanks","text":"Like and comment. Thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/600472363","repostId":"1115824573","repostType":4,"repost":{"id":"1115824573","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638191842,"share":"https://www.laohu8.com/m/news/1115824573?lang=&edition=full","pubTime":"2021-11-29 21:17","market":"us","language":"en","title":"Toplines Before US Market Open on Monday","url":"https://stock-news.laohu8.com/highlight/detail?id=1115824573","media":"Tiger Newspress","summary":"U.S. stock index futures jumped on Monday as investors rushed in to take advantage of steep virus-dr","content":"<p>U.S. stock index futures jumped on Monday as investors rushed in to take advantage of steep virus-driven losses while awaiting more details on the severity of the Omicron coronavirus variant.</p>\n<p>At 8:00 a.m. ET, Dow e-minis were up 226 points, or 0.65%. S&amp;P 500 e-minis were up 37 points, or 0.81% and Nasdaq 100 e-minis were up 148.75 points, or 0.93%.</p>\n<p><img src=\"https://static.tigerbbs.com/4e047384eb051a409672b8ce439d9f38\" tg-width=\"1080\" tg-height=\"392\" referrerpolicy=\"no-referrer\"></p>\n<p>Wall Street indexes had slumped between 2% and 3.5% on Friday after news of the variant triggered a global selloff, as countries introduced new travel curbs on fears it could resist vaccinations and upend a nascent economic reopening.</p>\n<p>President Joe Biden is due to update the public on the variant and the United States' response later in the day, the White House said.</p>\n<p><b>Stocks making the biggest moves premarket:</b></p>\n<p><b>Moderna</b>&nbsp;— Shares of the vaccine maker continued their rally, jumping more than 10% in early morning trading Monday after gaining 20% on Friday. On Sunday the company’s chief medical officer said Moderna&nbsp;could roll out a reformulated vaccine&nbsp;against the omicron variant of Covid early next year.</p>\n<p><b>Li Auto</b> —&nbsp;U.S.-listed shares of Li Auto rose 8.5%&nbsp;in premarket trading. Li Auto&nbsp;reported adjusted earnings of 3 cents a share from $1.21 billion in sales. Wall Street was looking for a 3-cent loss from $1.13 billion in sales. At this point, earnings are less important that sales for Li. The company is still growing rapidly. Sales in the third quarter rose more than 209% year over year.</p>\n<p><b>Tesla</b>&nbsp;—&nbsp;The German automotive news outlet Automobilwoche&nbsp;reported Monday that Tesla’s new manufacturing facility in that country will start production in December.Tesla&nbsp;shares&nbsp;rallied&nbsp;1.5%&nbsp;in premarket trading.</p>\n<p><b>Apple</b>&nbsp;—&nbsp;Apple&nbsp;rose 1.5% after HSBC raised its price target on the iPhone maker's stock.</p>\n<p><b>Airlines</b> — Major airlines ticked up as investors bought the dip following&nbsp;new travel suspensions in Asia and Europe, in response to the newly discovered omicron variant of Covid-19.United,Delta&nbsp;and&nbsp;American Airlines&nbsp;each gained about 1%, after losing about 7% Friday. Travel booking site&nbsp;Expedia&nbsp;also rose, about 2%.</p>\n<p><b>Cruise lines</b> —Carnival,Royal Caribbean Cruises&nbsp;and&nbsp;Norwegian Cruise Line Holdings&nbsp;each rose more than 3% amid the broader rebound in travel stocks from Friday’s omicron-driven sell-off.</p>\n<p><b>Allbirds</b>— Shares of the shoe manufacturer rose 2.5% after several analysts initiated coverage of the stock. Morgan Stanley and Bank of America both posted a price target of $23, implying 16% upside to Friday’s close.</p>\n<p><b>Coinbase</b>— The cryptocurrency exchange’s shares rose more than 2% as the price of bitcoin rebounded, after selling off with the broader equities market on Friday. Other crypto-related equities got a lift too, with&nbsp;Microstrategy&nbsp;rising 3.4%.Tesla&nbsp;and&nbsp;Square&nbsp;added more than 1%.</p>\n<p><b>Zoom Video</b>— Zoom shares fell almost 2%, moving in the opposite direction of travel stocks and following a 5.7% jump on Friday. Other stay-at-home stocks dipped slightly Monday morning too, including&nbsp;Peloton,Netflix&nbsp;and&nbsp;Teladoc.</p>\n<p><b>Merck</b>— The pharmaceutical company’s shares fell 1.8% after Citi downgraded its stock to neutral from buy, saying development struggles for the company’s HIV drug islatravir will hurt Merck’s long-term potential.</p>\n<p><b>Wynn Resorts,Las Vegas Sands</b>— The Macao gaming sector is lower after Alvin Chau, the head of Macau’s biggest casino junket operator, and 10 others were arrested over allegedly illegal gambling platforms targeting mainland Chinese, according to a report by the South China Morning Post.Wynn&nbsp;fell 1.9% and&nbsp;Las Vegas Sands&nbsp;fell 1.2%</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Toplines Before US Market Open on Monday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nToplines Before US Market Open on Monday\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-11-29 21:17</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>U.S. stock index futures jumped on Monday as investors rushed in to take advantage of steep virus-driven losses while awaiting more details on the severity of the Omicron coronavirus variant.</p>\n<p>At 8:00 a.m. ET, Dow e-minis were up 226 points, or 0.65%. S&amp;P 500 e-minis were up 37 points, or 0.81% and Nasdaq 100 e-minis were up 148.75 points, or 0.93%.</p>\n<p><img src=\"https://static.tigerbbs.com/4e047384eb051a409672b8ce439d9f38\" tg-width=\"1080\" tg-height=\"392\" referrerpolicy=\"no-referrer\"></p>\n<p>Wall Street indexes had slumped between 2% and 3.5% on Friday after news of the variant triggered a global selloff, as countries introduced new travel curbs on fears it could resist vaccinations and upend a nascent economic reopening.</p>\n<p>President Joe Biden is due to update the public on the variant and the United States' response later in the day, the White House said.</p>\n<p><b>Stocks making the biggest moves premarket:</b></p>\n<p><b>Moderna</b>&nbsp;— Shares of the vaccine maker continued their rally, jumping more than 10% in early morning trading Monday after gaining 20% on Friday. On Sunday the company’s chief medical officer said Moderna&nbsp;could roll out a reformulated vaccine&nbsp;against the omicron variant of Covid early next year.</p>\n<p><b>Li Auto</b> —&nbsp;U.S.-listed shares of Li Auto rose 8.5%&nbsp;in premarket trading. Li Auto&nbsp;reported adjusted earnings of 3 cents a share from $1.21 billion in sales. Wall Street was looking for a 3-cent loss from $1.13 billion in sales. At this point, earnings are less important that sales for Li. The company is still growing rapidly. Sales in the third quarter rose more than 209% year over year.</p>\n<p><b>Tesla</b>&nbsp;—&nbsp;The German automotive news outlet Automobilwoche&nbsp;reported Monday that Tesla’s new manufacturing facility in that country will start production in December.Tesla&nbsp;shares&nbsp;rallied&nbsp;1.5%&nbsp;in premarket trading.</p>\n<p><b>Apple</b>&nbsp;—&nbsp;Apple&nbsp;rose 1.5% after HSBC raised its price target on the iPhone maker's stock.</p>\n<p><b>Airlines</b> — Major airlines ticked up as investors bought the dip following&nbsp;new travel suspensions in Asia and Europe, in response to the newly discovered omicron variant of Covid-19.United,Delta&nbsp;and&nbsp;American Airlines&nbsp;each gained about 1%, after losing about 7% Friday. Travel booking site&nbsp;Expedia&nbsp;also rose, about 2%.</p>\n<p><b>Cruise lines</b> —Carnival,Royal Caribbean Cruises&nbsp;and&nbsp;Norwegian Cruise Line Holdings&nbsp;each rose more than 3% amid the broader rebound in travel stocks from Friday’s omicron-driven sell-off.</p>\n<p><b>Allbirds</b>— Shares of the shoe manufacturer rose 2.5% after several analysts initiated coverage of the stock. Morgan Stanley and Bank of America both posted a price target of $23, implying 16% upside to Friday’s close.</p>\n<p><b>Coinbase</b>— The cryptocurrency exchange’s shares rose more than 2% as the price of bitcoin rebounded, after selling off with the broader equities market on Friday. Other crypto-related equities got a lift too, with&nbsp;Microstrategy&nbsp;rising 3.4%.Tesla&nbsp;and&nbsp;Square&nbsp;added more than 1%.</p>\n<p><b>Zoom Video</b>— Zoom shares fell almost 2%, moving in the opposite direction of travel stocks and following a 5.7% jump on Friday. Other stay-at-home stocks dipped slightly Monday morning too, including&nbsp;Peloton,Netflix&nbsp;and&nbsp;Teladoc.</p>\n<p><b>Merck</b>— The pharmaceutical company’s shares fell 1.8% after Citi downgraded its stock to neutral from buy, saying development struggles for the company’s HIV drug islatravir will hurt Merck’s long-term potential.</p>\n<p><b>Wynn Resorts,Las Vegas Sands</b>— The Macao gaming sector is lower after Alvin Chau, the head of Macau’s biggest casino junket operator, and 10 others were arrested over allegedly illegal gambling platforms targeting mainland Chinese, according to a report by the South China Morning Post.Wynn&nbsp;fell 1.9% and&nbsp;Las Vegas Sands&nbsp;fell 1.2%</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NCLH":"挪威邮轮","DAL":"达美航空","RCL":"皇家加勒比邮轮","WYNN":"永利度假村","ZM":"Zoom","MRK":"默沙东","TSLA":"特斯拉","LI":"理想汽车","BIRD":"Allbirds, Inc.","LVS":"金沙集团",".DJI":"道琼斯","CCL":"嘉年华邮轮","AAPL":"苹果",".IXIC":"NASDAQ Composite","AAL":"美国航空","MRNA":"Moderna, Inc.","UAL":"联合大陆航空",".SPX":"S&P 500 Index","COIN":"Coinbase Global, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1115824573","content_text":"U.S. stock index futures jumped on Monday as investors rushed in to take advantage of steep virus-driven losses while awaiting more details on the severity of the Omicron coronavirus variant.\nAt 8:00 a.m. ET, Dow e-minis were up 226 points, or 0.65%. S&P 500 e-minis were up 37 points, or 0.81% and Nasdaq 100 e-minis were up 148.75 points, or 0.93%.\n\nWall Street indexes had slumped between 2% and 3.5% on Friday after news of the variant triggered a global selloff, as countries introduced new travel curbs on fears it could resist vaccinations and upend a nascent economic reopening.\nPresident Joe Biden is due to update the public on the variant and the United States' response later in the day, the White House said.\nStocks making the biggest moves premarket:\nModerna — Shares of the vaccine maker continued their rally, jumping more than 10% in early morning trading Monday after gaining 20% on Friday. On Sunday the company’s chief medical officer said Moderna could roll out a reformulated vaccine against the omicron variant of Covid early next year.\nLi Auto — U.S.-listed shares of Li Auto rose 8.5% in premarket trading. Li Auto reported adjusted earnings of 3 cents a share from $1.21 billion in sales. Wall Street was looking for a 3-cent loss from $1.13 billion in sales. At this point, earnings are less important that sales for Li. The company is still growing rapidly. Sales in the third quarter rose more than 209% year over year.\nTesla — The German automotive news outlet Automobilwoche reported Monday that Tesla’s new manufacturing facility in that country will start production in December.Tesla shares rallied 1.5% in premarket trading.\nApple — Apple rose 1.5% after HSBC raised its price target on the iPhone maker's stock.\nAirlines — Major airlines ticked up as investors bought the dip following new travel suspensions in Asia and Europe, in response to the newly discovered omicron variant of Covid-19.United,Delta and American Airlines each gained about 1%, after losing about 7% Friday. Travel booking site Expedia also rose, about 2%.\nCruise lines —Carnival,Royal Caribbean Cruises and Norwegian Cruise Line Holdings each rose more than 3% amid the broader rebound in travel stocks from Friday’s omicron-driven sell-off.\nAllbirds— Shares of the shoe manufacturer rose 2.5% after several analysts initiated coverage of the stock. Morgan Stanley and Bank of America both posted a price target of $23, implying 16% upside to Friday’s close.\nCoinbase— The cryptocurrency exchange’s shares rose more than 2% as the price of bitcoin rebounded, after selling off with the broader equities market on Friday. Other crypto-related equities got a lift too, with Microstrategy rising 3.4%.Tesla and Square added more than 1%.\nZoom Video— Zoom shares fell almost 2%, moving in the opposite direction of travel stocks and following a 5.7% jump on Friday. Other stay-at-home stocks dipped slightly Monday morning too, including Peloton,Netflix and Teladoc.\nMerck— The pharmaceutical company’s shares fell 1.8% after Citi downgraded its stock to neutral from buy, saying development struggles for the company’s HIV drug islatravir will hurt Merck’s long-term potential.\nWynn Resorts,Las Vegas Sands— The Macao gaming sector is lower after Alvin Chau, the head of Macau’s biggest casino junket operator, and 10 others were arrested over allegedly illegal gambling platforms targeting mainland Chinese, according to a report by the South China Morning Post.Wynn fell 1.9% and Las Vegas Sands fell 1.2%","news_type":1},"isVote":1,"tweetType":1,"viewCount":273,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":873934049,"gmtCreate":1636827206365,"gmtModify":1636827206466,"author":{"id":"3554895157968981","authorId":"3554895157968981","name":"canoboi","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/873934049","repostId":"1102251183","repostType":4,"repost":{"id":"1102251183","pubTimestamp":1636772424,"share":"https://www.laohu8.com/m/news/1102251183?lang=&edition=full","pubTime":"2021-11-13 11:00","market":"us","language":"en","title":"Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.","url":"https://stock-news.laohu8.com/highlight/detail?id=1102251183","media":"Barrons","summary":"Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Mo","content":"<p>Pfizer’s&nbsp;chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that its Covid-19 antiviral had cut the risk of hospitalization by 89% in high-risk adults.</p>\n<p>“It can’t be just a random thing, that you’re able to beat this type of world record and get a grand slam at the same time by chance,” Dolsten said, scrambling sports metaphors as he sought to illustrate the magnitude of Pfizer’s twin wins: the development of a stunningly effective Covid-19 vaccine in just 10 months, followed a year later by the development of a similarly stunning Covid-19 antiviral.</p>\n<p>Two years ago, Pfizer (ticker: PFE) CEO Albert Bourla asked investors to take a big gamble on the research-and-development operation that Dolsten has rebuilt over the course of more than a decade. That bet is looking smarter than ever.</p>\n<p>Bourla has gotten rid of Pfizer’s off-patent drugs division and the last of its consumer health products, leaving behind a pure-play biopharma company that will live or die on the strength of Dolsten’s science.</p>\n<p>In a cover story in November 2019, <i>Barron’s</i> argued that Bourla and Dolsten could pull it off.</p>\n<p>The new antiviral data reaffirms the case for Pfizer that <i>Barron’s</i> made two years ago. Continuing to profit off the pandemic, however, brings new risks, as criticism grows over the global inequity in vaccine distribution. Low-income nations account for less than 1% of the more than seven billion doses administered worldwide. If distribution of Pfizer’s antiviral continues to favor wealthy nations, the company’s stock could ultimately suffer.</p>\n<p>Pfizer’s shares surged 10.9% the day the data came out, their best daily showing in at least 20 years. Still, with the stock now changing hands at around $50, investors continue to undervalue the company. Investors are pricing Pfizer at 12 times next year’s expected earnings, cheaper than peers like&nbsp;Johnson &amp; Johnson&nbsp;(JNJ) and&nbsp;Eli Lilly&nbsp;(LLY).</p>\n<p>The Pfizer discount can be attributed to concerns over the patent cliff the drugmaker faces at the end of the decade. The company stands to lose exclusivity over a handful of drugs that bring in billions in annual revenue.</p>\n<p>The worries are legitimate, but Pfizer’s scientific coup should give investors confidence that the company’s science can carry it safely over that cliff. It may take time for the market to catch up, but for long-term investors, it’s a promising opportunity.</p>\n<p>The success of the antiviral is the best illustration yet of Pfizer’s scientific prowess.</p>\n<p>While Pfizer’s Covid-19 vaccine came out of the labs of the German biotech&nbsp;BioNTech&nbsp;(BNTX), the new Covid-19 antiviral was whipped up by what Dolsten called a “dream team” of scientists at Pfizer’s own labs across the Northeast U.S.</p>\n<p>In the earliest days of the pandemic, Pfizer split its efforts between its collaboration with BioNTech on the vaccine and its quest for a Covid-19 pill. The vaccine effort operated on a huge scale; Dolsten called it a “mega team” that spanned the Atlantic.</p>\n<p>The antiviral project was a much smaller operation—a group of Pfizer experts operating with resources left over from the vaccine push.</p>\n<p>“The small molecule was more like a nimble, laser-focused, high-end team, with rather moderate resources,” Dolsten said.</p>\n<p>Dolsten gathered some of Pfizer’s most experienced scientists to work on the antiviral project, including its head of medicine design, Charlotte Allerton. The scientists started with work Pfizer had done years ago on a type of antiviral called a protease inhibitor.</p>\n<p>“[Pfizer’s] pharmaceutical R&amp;D is better than people had thought.”</p>\n<p>The protease inhibitors in the Pfizer library, however, had been administered intravenously, and had not worked well when delivered orally. The team had to figure out how to adapt the drugs to oral administration, a substantial undertaking.</p>\n<p>“They had to really create a lot of new chemistry,” Dolsten said. The scientists created 600 compounds to nail down the right drug, a process that might normally take years, and which they accomplished in a matter of months. “Four years turned into four months here,” he said.</p>\n<p>Pfizer started testing the pill in humans in March. It is now running a number of Phase 2/3 trials of the drug, including one for patients who are high risk, one for patients not high risk, and one as a prophylaxis for patients who have been exposed to the virus but aren’t yet sick. In the first readout, the drug looked substantially more effective than the Covid treatment pill from&nbsp;Merck&nbsp;(MRK).</p>\n<p>“It definitely helps prove the point that [Pfizer’s] pharmaceutical R&amp;D is better than people had thought,” says Louise Chen, an analyst at Cantor Fitzgerald, who has an Overweight rating and a $61 price target on the stock.</p>\n<p>Chen says that she doesn’t expect investors to come around to her way of thinking until there is more clarity on the durability of Covid-19 vaccine and pill sales, and the rest of the pipeline gets proved out.</p>\n<p>“There is not one event that I think will trigger a re-rating of the stock at the next level,” she says. “Until those things play out, I don’t think that it necessarily will.”</p>\n<p>That makes a bet on Pfizer a long-term play. In the meantime, the experience of&nbsp;Moderna&nbsp;(MRNA) in recent weeks is highlighting the potential for the vaccine makers to come under scrutiny over unequal distribution of vaccines.</p>\n<p>Biden administration officials have been increasingly frustrated with Moderna, calling on the company to ramp up production so it can offer more doses at not-for-profit prices to low-income countries, with one top official calling on the company to “step up.”</p>\n<p>Moderna shares are down more than 40% over the past three months.</p>\n<p>As the pandemic persists, Pfizer risks eroding the enormous goodwill it earned roughly a year ago when it introduced its Covid-19 vaccine. Earlier this month, Pfizer CEO Bourla blamed low-income countries for unfair vaccine distribution, telling <i>Barron’s</i> that it was their fault for not placing orders. Pfizer has sold a billion vaccine doses to the U.S. at a not-for-profit price to donate to poor countries, and says that a total of at least two billion doses will be delivered to low- and middle-income nations by the end of next year.</p>\n<p>When it comes to antivirals, Pfizer has said only that it will offer tiered pricing for poorer nations, the same approach it has taken with its vaccine.</p>\n<p>That contrasts sharply with Merck’s plan to make its own Covid-19 pill available to poor countries. Merck has signed a deal with a United Nations-backed group that will allow its pill to be licensed globally, with no royalties paid to Merck.</p>\n<p>Dolsten said that Pfizer is looking into licensing its pill under a similar mechanism as Merck’s. “We will look at those options,” he said. “By no means have we said we would do something different. We just want to make sure whoever will be involved gets the advice and skill to do this.”</p>\n<p>Such a step couldn’t come soon enough. Late last month, activists protested outside Bourla’s home, calling on Pfizer to share its vaccine manufacturing technology and to fill orders from low-income countries ahead of those from wealthy countries.</p>\n<p>An aggressive plan to share its antiviral would help stave off such criticism, keeping Pfizer in the relative good graces of Washington and allowing its impressive science to continue to drive the stock higher.</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-13 11:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/buy-pfizer-stock-covid-19-51636674652?mod=hp_LEAD_1><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that...</p>\n\n<a href=\"https://www.barrons.com/articles/buy-pfizer-stock-covid-19-51636674652?mod=hp_LEAD_1\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.barrons.com/articles/buy-pfizer-stock-covid-19-51636674652?mod=hp_LEAD_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1102251183","content_text":"Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that its Covid-19 antiviral had cut the risk of hospitalization by 89% in high-risk adults.\n“It can’t be just a random thing, that you’re able to beat this type of world record and get a grand slam at the same time by chance,” Dolsten said, scrambling sports metaphors as he sought to illustrate the magnitude of Pfizer’s twin wins: the development of a stunningly effective Covid-19 vaccine in just 10 months, followed a year later by the development of a similarly stunning Covid-19 antiviral.\nTwo years ago, Pfizer (ticker: PFE) CEO Albert Bourla asked investors to take a big gamble on the research-and-development operation that Dolsten has rebuilt over the course of more than a decade. That bet is looking smarter than ever.\nBourla has gotten rid of Pfizer’s off-patent drugs division and the last of its consumer health products, leaving behind a pure-play biopharma company that will live or die on the strength of Dolsten’s science.\nIn a cover story in November 2019, Barron’s argued that Bourla and Dolsten could pull it off.\nThe new antiviral data reaffirms the case for Pfizer that Barron’s made two years ago. Continuing to profit off the pandemic, however, brings new risks, as criticism grows over the global inequity in vaccine distribution. Low-income nations account for less than 1% of the more than seven billion doses administered worldwide. If distribution of Pfizer’s antiviral continues to favor wealthy nations, the company’s stock could ultimately suffer.\nPfizer’s shares surged 10.9% the day the data came out, their best daily showing in at least 20 years. Still, with the stock now changing hands at around $50, investors continue to undervalue the company. Investors are pricing Pfizer at 12 times next year’s expected earnings, cheaper than peers like Johnson & Johnson (JNJ) and Eli Lilly (LLY).\nThe Pfizer discount can be attributed to concerns over the patent cliff the drugmaker faces at the end of the decade. The company stands to lose exclusivity over a handful of drugs that bring in billions in annual revenue.\nThe worries are legitimate, but Pfizer’s scientific coup should give investors confidence that the company’s science can carry it safely over that cliff. It may take time for the market to catch up, but for long-term investors, it’s a promising opportunity.\nThe success of the antiviral is the best illustration yet of Pfizer’s scientific prowess.\nWhile Pfizer’s Covid-19 vaccine came out of the labs of the German biotech BioNTech (BNTX), the new Covid-19 antiviral was whipped up by what Dolsten called a “dream team” of scientists at Pfizer’s own labs across the Northeast U.S.\nIn the earliest days of the pandemic, Pfizer split its efforts between its collaboration with BioNTech on the vaccine and its quest for a Covid-19 pill. The vaccine effort operated on a huge scale; Dolsten called it a “mega team” that spanned the Atlantic.\nThe antiviral project was a much smaller operation—a group of Pfizer experts operating with resources left over from the vaccine push.\n“The small molecule was more like a nimble, laser-focused, high-end team, with rather moderate resources,” Dolsten said.\nDolsten gathered some of Pfizer’s most experienced scientists to work on the antiviral project, including its head of medicine design, Charlotte Allerton. The scientists started with work Pfizer had done years ago on a type of antiviral called a protease inhibitor.\n“[Pfizer’s] pharmaceutical R&D is better than people had thought.”\nThe protease inhibitors in the Pfizer library, however, had been administered intravenously, and had not worked well when delivered orally. The team had to figure out how to adapt the drugs to oral administration, a substantial undertaking.\n“They had to really create a lot of new chemistry,” Dolsten said. The scientists created 600 compounds to nail down the right drug, a process that might normally take years, and which they accomplished in a matter of months. “Four years turned into four months here,” he said.\nPfizer started testing the pill in humans in March. It is now running a number of Phase 2/3 trials of the drug, including one for patients who are high risk, one for patients not high risk, and one as a prophylaxis for patients who have been exposed to the virus but aren’t yet sick. In the first readout, the drug looked substantially more effective than the Covid treatment pill from Merck (MRK).\n“It definitely helps prove the point that [Pfizer’s] pharmaceutical R&D is better than people had thought,” says Louise Chen, an analyst at Cantor Fitzgerald, who has an Overweight rating and a $61 price target on the stock.\nChen says that she doesn’t expect investors to come around to her way of thinking until there is more clarity on the durability of Covid-19 vaccine and pill sales, and the rest of the pipeline gets proved out.\n“There is not one event that I think will trigger a re-rating of the stock at the next level,” she says. “Until those things play out, I don’t think that it necessarily will.”\nThat makes a bet on Pfizer a long-term play. In the meantime, the experience of Moderna (MRNA) in recent weeks is highlighting the potential for the vaccine makers to come under scrutiny over unequal distribution of vaccines.\nBiden administration officials have been increasingly frustrated with Moderna, calling on the company to ramp up production so it can offer more doses at not-for-profit prices to low-income countries, with one top official calling on the company to “step up.”\nModerna shares are down more than 40% over the past three months.\nAs the pandemic persists, Pfizer risks eroding the enormous goodwill it earned roughly a year ago when it introduced its Covid-19 vaccine. Earlier this month, Pfizer CEO Bourla blamed low-income countries for unfair vaccine distribution, telling Barron’s that it was their fault for not placing orders. Pfizer has sold a billion vaccine doses to the U.S. at a not-for-profit price to donate to poor countries, and says that a total of at least two billion doses will be delivered to low- and middle-income nations by the end of next year.\nWhen it comes to antivirals, Pfizer has said only that it will offer tiered pricing for poorer nations, the same approach it has taken with its vaccine.\nThat contrasts sharply with Merck’s plan to make its own Covid-19 pill available to poor countries. Merck has signed a deal with a United Nations-backed group that will allow its pill to be licensed globally, with no royalties paid to Merck.\nDolsten said that Pfizer is looking into licensing its pill under a similar mechanism as Merck’s. “We will look at those options,” he said. “By no means have we said we would do something different. We just want to make sure whoever will be involved gets the advice and skill to do this.”\nSuch a step couldn’t come soon enough. Late last month, activists protested outside Bourla’s home, calling on Pfizer to share its vaccine manufacturing technology and to fill orders from low-income countries ahead of those from wealthy countries.\nAn aggressive plan to share its antiviral would help stave off such criticism, keeping Pfizer in the relative good graces of Washington and allowing its impressive science to continue to drive the stock higher.","news_type":1},"isVote":1,"tweetType":1,"viewCount":175,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":824347223,"gmtCreate":1634285305744,"gmtModify":1634285305860,"author":{"id":"3554895157968981","authorId":"3554895157968981","name":"canoboi","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like and comment.","listText":"Like and comment.","text":"Like and comment.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/824347223","repostId":"1126921416","repostType":4,"repost":{"id":"1126921416","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1634306113,"share":"https://www.laohu8.com/m/news/1126921416?lang=&edition=full","pubTime":"2021-10-15 21:55","market":"us","language":"en","title":"Crypto stocks jumped in morning trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1126921416","media":"Tiger Newspress","summary":"Crypto stocks jumped in morning trading after bitcoin hitting $60,000 as investors eye first U.S. ET","content":"<p>Crypto stocks jumped in morning trading&nbsp;after&nbsp;bitcoin hitting $60,000 as investors eye first U.S. ETFs.Bit Digital,Bit Mining,Marathon Digital,SoS Ltd,Riot Blockchain,Coinbase,The9 and Canaan climbed between 2% and 8%.</p>\n<p><img src=\"https://static.tigerbbs.com/11637edfa19a44b24ed7dcd77f7ba107\" tg-width=\"406\" tg-height=\"549\" referrerpolicy=\"no-referrer\"></p>\n<p>Bitcoin hit a six-month high on Friday, approaching the record hit in April, as traders became increasingly confident that U.S. regulators would approve the launch of an exchange-traded fund based on its futures contracts.</p>\n<p>The world’s biggest cryptocurrency rose more&nbsp;than&nbsp;4% to as high as $60000, its highest since mid-April. It has doubled in value this year and is near April’s record high of $64,895.</p>\n<p>The U.S. Securities and Exchange Commission (SEC) is poised to allow the first U.S. bitcoin futures ETF to begin trading next week, Bloomberg News reported on Thursday, citing people familiar with the matter.</p>\n<p>Ben Caselin, head of research and strategy at Asia-based cryptocurrency exchange AAX, said bitcoin’s spike above $59,000 wasn’t arbitrary and long-term investors had been accumulating it for a while.</p>\n<p>“It is widely expected that Q4 will see significant progress around a bitcoin ETF in the U.S.,” he said.</p>\n<p>Friday’s moves were also spurred by a tweet from the SEC’s investor education office, he said.</p>\n<p>\"Before investing in a fund that holds Bitcoin futures contracts, make sure you carefully weigh the potential risks and benefits,\" the SEC tweet&nbsp;here&nbsp;stated.</p>\n<p>Cryptocurrency investors have been waiting for news of approval of the country’s first bitcoin ETF, and some of bitcoin’s rally in recent months has been in anticipation of that move and how it could speed up its mainstream adoption and trading.</p>\n<p>Several fund managers, including the VanEck Bitcoin Trust, ProShares, Invesco, Valkyrie and Galaxy Digital Funds have applied to launch bitcoin ETFs in the United States. Cryptocurrency ETFs have been launched this year in Canada and Europe.</p>\n<p>SEC Chair Gary Gensler has previously said the crypto market involves many tokens which may be unregistered securities and leaves prices open to manipulation and millions of investors vulnerable to risks.</p>\n<p>The Bloomberg report said that the proposals by ProShares and Invesco are based on futures contracts and were filed under mutual fund rules that Gensler has said provide “significant investor protections”.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Crypto stocks jumped in morning trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCrypto stocks jumped in morning trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-10-15 21:55</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Crypto stocks jumped in morning trading&nbsp;after&nbsp;bitcoin hitting $60,000 as investors eye first U.S. ETFs.Bit Digital,Bit Mining,Marathon Digital,SoS Ltd,Riot Blockchain,Coinbase,The9 and Canaan climbed between 2% and 8%.</p>\n<p><img src=\"https://static.tigerbbs.com/11637edfa19a44b24ed7dcd77f7ba107\" tg-width=\"406\" tg-height=\"549\" referrerpolicy=\"no-referrer\"></p>\n<p>Bitcoin hit a six-month high on Friday, approaching the record hit in April, as traders became increasingly confident that U.S. regulators would approve the launch of an exchange-traded fund based on its futures contracts.</p>\n<p>The world’s biggest cryptocurrency rose more&nbsp;than&nbsp;4% to as high as $60000, its highest since mid-April. It has doubled in value this year and is near April’s record high of $64,895.</p>\n<p>The U.S. Securities and Exchange Commission (SEC) is poised to allow the first U.S. bitcoin futures ETF to begin trading next week, Bloomberg News reported on Thursday, citing people familiar with the matter.</p>\n<p>Ben Caselin, head of research and strategy at Asia-based cryptocurrency exchange AAX, said bitcoin’s spike above $59,000 wasn’t arbitrary and long-term investors had been accumulating it for a while.</p>\n<p>“It is widely expected that Q4 will see significant progress around a bitcoin ETF in the U.S.,” he said.</p>\n<p>Friday’s moves were also spurred by a tweet from the SEC’s investor education office, he said.</p>\n<p>\"Before investing in a fund that holds Bitcoin futures contracts, make sure you carefully weigh the potential risks and benefits,\" the SEC tweet&nbsp;here&nbsp;stated.</p>\n<p>Cryptocurrency investors have been waiting for news of approval of the country’s first bitcoin ETF, and some of bitcoin’s rally in recent months has been in anticipation of that move and how it could speed up its mainstream adoption and trading.</p>\n<p>Several fund managers, including the VanEck Bitcoin Trust, ProShares, Invesco, Valkyrie and Galaxy Digital Funds have applied to launch bitcoin ETFs in the United States. Cryptocurrency ETFs have been launched this year in Canada and Europe.</p>\n<p>SEC Chair Gary Gensler has previously said the crypto market involves many tokens which may be unregistered securities and leaves prices open to manipulation and millions of investors vulnerable to risks.</p>\n<p>The Bloomberg report said that the proposals by ProShares and Invesco are based on futures contracts and were filed under mutual fund rules that Gensler has said provide “significant investor protections”.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"COIN":"Coinbase Global, Inc.","SOS":"SOS Limited","RIOT":"Riot Platforms","BTCM":"BIT Mining","MARA":"Marathon Digital Holdings Inc","NCTY":"第九城市","BTBT":"Bit Digital, Inc.","CAN":"嘉楠科技"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1126921416","content_text":"Crypto stocks jumped in morning trading after bitcoin hitting $60,000 as investors eye first U.S. ETFs.Bit Digital,Bit Mining,Marathon Digital,SoS Ltd,Riot Blockchain,Coinbase,The9 and Canaan climbed between 2% and 8%.\n\nBitcoin hit a six-month high on Friday, approaching the record hit in April, as traders became increasingly confident that U.S. regulators would approve the launch of an exchange-traded fund based on its futures contracts.\nThe world’s biggest cryptocurrency rose more than 4% to as high as $60000, its highest since mid-April. It has doubled in value this year and is near April’s record high of $64,895.\nThe U.S. Securities and Exchange Commission (SEC) is poised to allow the first U.S. bitcoin futures ETF to begin trading next week, Bloomberg News reported on Thursday, citing people familiar with the matter.\nBen Caselin, head of research and strategy at Asia-based cryptocurrency exchange AAX, said bitcoin’s spike above $59,000 wasn’t arbitrary and long-term investors had been accumulating it for a while.\n“It is widely expected that Q4 will see significant progress around a bitcoin ETF in the U.S.,” he said.\nFriday’s moves were also spurred by a tweet from the SEC’s investor education office, he said.\n\"Before investing in a fund that holds Bitcoin futures contracts, make sure you carefully weigh the potential risks and benefits,\" the SEC tweet here stated.\nCryptocurrency investors have been waiting for news of approval of the country’s first bitcoin ETF, and some of bitcoin’s rally in recent months has been in anticipation of that move and how it could speed up its mainstream adoption and trading.\nSeveral fund managers, including the VanEck Bitcoin Trust, ProShares, Invesco, Valkyrie and Galaxy Digital Funds have applied to launch bitcoin ETFs in the United States. Cryptocurrency ETFs have been launched this year in Canada and Europe.\nSEC Chair Gary Gensler has previously said the crypto market involves many tokens which may be unregistered securities and leaves prices open to manipulation and millions of investors vulnerable to risks.\nThe Bloomberg report said that the proposals by ProShares and Invesco are based on futures contracts and were filed under mutual fund rules that Gensler has said provide “significant investor protections”.","news_type":1},"isVote":1,"tweetType":1,"viewCount":169,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":825369426,"gmtCreate":1634202190527,"gmtModify":1634202190677,"author":{"id":"3554895157968981","authorId":"3554895157968981","name":"canoboi","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like and comment thanks","listText":"Like and comment thanks","text":"Like and comment thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/825369426","repostId":"1131725095","repostType":4,"isVote":1,"tweetType":1,"viewCount":265,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":821792438,"gmtCreate":1633785788738,"gmtModify":1633785788837,"author":{"id":"3554895157968981","authorId":"3554895157968981","name":"canoboi","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like pls thks","listText":"Like pls thks","text":"Like pls thks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/821792438","repostId":"2174920514","repostType":4,"repost":{"id":"2174920514","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1633764600,"share":"https://www.laohu8.com/m/news/2174920514?lang=&edition=full","pubTime":"2021-10-09 15:30","market":"us","language":"en","title":"Is the stock market open on Columbus Day? Yes! But the bond market isn't--Here's why","url":"https://stock-news.laohu8.com/highlight/detail?id=2174920514","media":"Dow Jones","summary":"It's also Indigenous Peoples Day.\nIt's almost a perennial question on Wall Street. With Columbus Day","content":"<p>It's also Indigenous Peoples Day.</p>\n<p>It's almost a perennial question on Wall Street. With Columbus Day a federal holiday on Monday, investors are curious if the stock market will be opened.</p>\n<p>Here is the short answer: yes. But it isn't that simple.</p>\n<p>The bond market isn't. Bond traders are off as recommended by the Securities Industry and Financial Markets Association, known as Sifma.</p>\n<p>Columbus Day and Veterans Day are the two federal holidays when fixed-income markets are closed due to the federal holiday.</p>\n<p>As per usual, the Intercontinental Exchange<a href=\"https://laohu8.com/S/ICE\">$(ICE)$</a>-owned New York Stock Exchange and the Nasdaq Inc. <a href=\"https://laohu8.com/S/NDAQ\">$(NDAQ)$</a> will both be open regular hours. So, the Dow Jones Industrial Average , the S&amp;P 500 index and the Nasdaq Composite Index , to note the three main U.S. bourses, can figure out whether the weaker-than-expected jobs report released on Friday was bullish or bearish in the near term.</p>\n<p>Meanwhile, benchmark bonds can take a breather after the 10-year Treasury note yield, 30-year Treasury bond and 2-year Treasury note touched their highest yields in months (since March of 2020 in the case of the shorter-date debt).</p>\n<p>Now back to Columbus Day and the curious case of mixed up market closures.</p>\n<p>Here's perhaps why it is closed and equities trade on.</p>\n<p>Begun back in 1792 and declared a federal day off in 1937 by President Franklin D. Roosevelt, Columbus Day marks a state and federal holiday. Federal offices, including the U.S. Treasury Department, are closed. That means, Treasurys--a chunk of typical trading activity on regular days and a key benchmark--are also forced to take a holiday.</p>\n<p>Columbus Day isn't without its controversy as a holiday intended to celebrate Christopher Columbus for sailing the ocean blue in 1492. Firstly, not all states celebrate the Italian explorer's occasion on the same day. Tennessee tends to celebrate the holiday on Friday. Some states don't acknowledge the day at all, with Alaska, Vermont, Hawaii and South Dakota choosing not to observe it.</p>\n<p>Some regions choose to celebrate Indigenous Peoples Day, which honors Native Americans and challenges the concept that Columbus was the first to discover America. The holiday has been gaining support, as an alternative to Columbus Day.</p>\n<p>So, the next time that someone asks if the market is open on Columbus Day, you can tell them that it is complicated.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is the stock market open on Columbus Day? Yes! But the bond market isn't--Here's why</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs the stock market open on Columbus Day? Yes! But the bond market isn't--Here's why\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-10-09 15:30</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>It's also Indigenous Peoples Day.</p>\n<p>It's almost a perennial question on Wall Street. With Columbus Day a federal holiday on Monday, investors are curious if the stock market will be opened.</p>\n<p>Here is the short answer: yes. But it isn't that simple.</p>\n<p>The bond market isn't. Bond traders are off as recommended by the Securities Industry and Financial Markets Association, known as Sifma.</p>\n<p>Columbus Day and Veterans Day are the two federal holidays when fixed-income markets are closed due to the federal holiday.</p>\n<p>As per usual, the Intercontinental Exchange<a href=\"https://laohu8.com/S/ICE\">$(ICE)$</a>-owned New York Stock Exchange and the Nasdaq Inc. <a href=\"https://laohu8.com/S/NDAQ\">$(NDAQ)$</a> will both be open regular hours. So, the Dow Jones Industrial Average , the S&amp;P 500 index and the Nasdaq Composite Index , to note the three main U.S. bourses, can figure out whether the weaker-than-expected jobs report released on Friday was bullish or bearish in the near term.</p>\n<p>Meanwhile, benchmark bonds can take a breather after the 10-year Treasury note yield, 30-year Treasury bond and 2-year Treasury note touched their highest yields in months (since March of 2020 in the case of the shorter-date debt).</p>\n<p>Now back to Columbus Day and the curious case of mixed up market closures.</p>\n<p>Here's perhaps why it is closed and equities trade on.</p>\n<p>Begun back in 1792 and declared a federal day off in 1937 by President Franklin D. Roosevelt, Columbus Day marks a state and federal holiday. Federal offices, including the U.S. Treasury Department, are closed. That means, Treasurys--a chunk of typical trading activity on regular days and a key benchmark--are also forced to take a holiday.</p>\n<p>Columbus Day isn't without its controversy as a holiday intended to celebrate Christopher Columbus for sailing the ocean blue in 1492. Firstly, not all states celebrate the Italian explorer's occasion on the same day. Tennessee tends to celebrate the holiday on Friday. Some states don't acknowledge the day at all, with Alaska, Vermont, Hawaii and South Dakota choosing not to observe it.</p>\n<p>Some regions choose to celebrate Indigenous Peoples Day, which honors Native Americans and challenges the concept that Columbus was the first to discover America. The holiday has been gaining support, as an alternative to Columbus Day.</p>\n<p>So, the next time that someone asks if the market is open on Columbus Day, you can tell them that it is complicated.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite",".SPX":"S&P 500 Index","ICE":"洲际交易所",".DJI":"道琼斯","NDAQ":"纳斯达克OMX交易所"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2174920514","content_text":"It's also Indigenous Peoples Day.\nIt's almost a perennial question on Wall Street. With Columbus Day a federal holiday on Monday, investors are curious if the stock market will be opened.\nHere is the short answer: yes. But it isn't that simple.\nThe bond market isn't. Bond traders are off as recommended by the Securities Industry and Financial Markets Association, known as Sifma.\nColumbus Day and Veterans Day are the two federal holidays when fixed-income markets are closed due to the federal holiday.\nAs per usual, the Intercontinental Exchange$(ICE)$-owned New York Stock Exchange and the Nasdaq Inc. $(NDAQ)$ will both be open regular hours. So, the Dow Jones Industrial Average , the S&P 500 index and the Nasdaq Composite Index , to note the three main U.S. bourses, can figure out whether the weaker-than-expected jobs report released on Friday was bullish or bearish in the near term.\nMeanwhile, benchmark bonds can take a breather after the 10-year Treasury note yield, 30-year Treasury bond and 2-year Treasury note touched their highest yields in months (since March of 2020 in the case of the shorter-date debt).\nNow back to Columbus Day and the curious case of mixed up market closures.\nHere's perhaps why it is closed and equities trade on.\nBegun back in 1792 and declared a federal day off in 1937 by President Franklin D. Roosevelt, Columbus Day marks a state and federal holiday. Federal offices, including the U.S. Treasury Department, are closed. That means, Treasurys--a chunk of typical trading activity on regular days and a key benchmark--are also forced to take a holiday.\nColumbus Day isn't without its controversy as a holiday intended to celebrate Christopher Columbus for sailing the ocean blue in 1492. Firstly, not all states celebrate the Italian explorer's occasion on the same day. Tennessee tends to celebrate the holiday on Friday. Some states don't acknowledge the day at all, with Alaska, Vermont, Hawaii and South Dakota choosing not to observe it.\nSome regions choose to celebrate Indigenous Peoples Day, which honors Native Americans and challenges the concept that Columbus was the first to discover America. The holiday has been gaining support, as an alternative to Columbus Day.\nSo, the next time that someone asks if the market is open on Columbus Day, you can tell them that it is complicated.","news_type":1},"isVote":1,"tweetType":1,"viewCount":162,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":823280536,"gmtCreate":1633629291082,"gmtModify":1633629291510,"author":{"id":"3554895157968981","authorId":"3554895157968981","name":"canoboi","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like and comment. Thanks","listText":"Like and comment. Thanks","text":"Like and comment. Thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/823280536","repostId":"2173944807","repostType":4,"isVote":1,"tweetType":1,"viewCount":377,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":824347223,"gmtCreate":1634285305744,"gmtModify":1634285305860,"author":{"id":"3554895157968981","authorId":"3554895157968981","name":"canoboi","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like and comment.","listText":"Like and comment.","text":"Like and comment.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/824347223","repostId":"1126921416","repostType":4,"repost":{"id":"1126921416","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1634306113,"share":"https://www.laohu8.com/m/news/1126921416?lang=&edition=full","pubTime":"2021-10-15 21:55","market":"us","language":"en","title":"Crypto stocks jumped in morning trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1126921416","media":"Tiger Newspress","summary":"Crypto stocks jumped in morning trading after bitcoin hitting $60,000 as investors eye first U.S. ET","content":"<p>Crypto stocks jumped in morning trading&nbsp;after&nbsp;bitcoin hitting $60,000 as investors eye first U.S. ETFs.Bit Digital,Bit Mining,Marathon Digital,SoS Ltd,Riot Blockchain,Coinbase,The9 and Canaan climbed between 2% and 8%.</p>\n<p><img src=\"https://static.tigerbbs.com/11637edfa19a44b24ed7dcd77f7ba107\" tg-width=\"406\" tg-height=\"549\" referrerpolicy=\"no-referrer\"></p>\n<p>Bitcoin hit a six-month high on Friday, approaching the record hit in April, as traders became increasingly confident that U.S. regulators would approve the launch of an exchange-traded fund based on its futures contracts.</p>\n<p>The world’s biggest cryptocurrency rose more&nbsp;than&nbsp;4% to as high as $60000, its highest since mid-April. It has doubled in value this year and is near April’s record high of $64,895.</p>\n<p>The U.S. Securities and Exchange Commission (SEC) is poised to allow the first U.S. bitcoin futures ETF to begin trading next week, Bloomberg News reported on Thursday, citing people familiar with the matter.</p>\n<p>Ben Caselin, head of research and strategy at Asia-based cryptocurrency exchange AAX, said bitcoin’s spike above $59,000 wasn’t arbitrary and long-term investors had been accumulating it for a while.</p>\n<p>“It is widely expected that Q4 will see significant progress around a bitcoin ETF in the U.S.,” he said.</p>\n<p>Friday’s moves were also spurred by a tweet from the SEC’s investor education office, he said.</p>\n<p>\"Before investing in a fund that holds Bitcoin futures contracts, make sure you carefully weigh the potential risks and benefits,\" the SEC tweet&nbsp;here&nbsp;stated.</p>\n<p>Cryptocurrency investors have been waiting for news of approval of the country’s first bitcoin ETF, and some of bitcoin’s rally in recent months has been in anticipation of that move and how it could speed up its mainstream adoption and trading.</p>\n<p>Several fund managers, including the VanEck Bitcoin Trust, ProShares, Invesco, Valkyrie and Galaxy Digital Funds have applied to launch bitcoin ETFs in the United States. Cryptocurrency ETFs have been launched this year in Canada and Europe.</p>\n<p>SEC Chair Gary Gensler has previously said the crypto market involves many tokens which may be unregistered securities and leaves prices open to manipulation and millions of investors vulnerable to risks.</p>\n<p>The Bloomberg report said that the proposals by ProShares and Invesco are based on futures contracts and were filed under mutual fund rules that Gensler has said provide “significant investor protections”.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Crypto stocks jumped in morning trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCrypto stocks jumped in morning trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-10-15 21:55</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Crypto stocks jumped in morning trading&nbsp;after&nbsp;bitcoin hitting $60,000 as investors eye first U.S. ETFs.Bit Digital,Bit Mining,Marathon Digital,SoS Ltd,Riot Blockchain,Coinbase,The9 and Canaan climbed between 2% and 8%.</p>\n<p><img src=\"https://static.tigerbbs.com/11637edfa19a44b24ed7dcd77f7ba107\" tg-width=\"406\" tg-height=\"549\" referrerpolicy=\"no-referrer\"></p>\n<p>Bitcoin hit a six-month high on Friday, approaching the record hit in April, as traders became increasingly confident that U.S. regulators would approve the launch of an exchange-traded fund based on its futures contracts.</p>\n<p>The world’s biggest cryptocurrency rose more&nbsp;than&nbsp;4% to as high as $60000, its highest since mid-April. It has doubled in value this year and is near April’s record high of $64,895.</p>\n<p>The U.S. Securities and Exchange Commission (SEC) is poised to allow the first U.S. bitcoin futures ETF to begin trading next week, Bloomberg News reported on Thursday, citing people familiar with the matter.</p>\n<p>Ben Caselin, head of research and strategy at Asia-based cryptocurrency exchange AAX, said bitcoin’s spike above $59,000 wasn’t arbitrary and long-term investors had been accumulating it for a while.</p>\n<p>“It is widely expected that Q4 will see significant progress around a bitcoin ETF in the U.S.,” he said.</p>\n<p>Friday’s moves were also spurred by a tweet from the SEC’s investor education office, he said.</p>\n<p>\"Before investing in a fund that holds Bitcoin futures contracts, make sure you carefully weigh the potential risks and benefits,\" the SEC tweet&nbsp;here&nbsp;stated.</p>\n<p>Cryptocurrency investors have been waiting for news of approval of the country’s first bitcoin ETF, and some of bitcoin’s rally in recent months has been in anticipation of that move and how it could speed up its mainstream adoption and trading.</p>\n<p>Several fund managers, including the VanEck Bitcoin Trust, ProShares, Invesco, Valkyrie and Galaxy Digital Funds have applied to launch bitcoin ETFs in the United States. Cryptocurrency ETFs have been launched this year in Canada and Europe.</p>\n<p>SEC Chair Gary Gensler has previously said the crypto market involves many tokens which may be unregistered securities and leaves prices open to manipulation and millions of investors vulnerable to risks.</p>\n<p>The Bloomberg report said that the proposals by ProShares and Invesco are based on futures contracts and were filed under mutual fund rules that Gensler has said provide “significant investor protections”.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"COIN":"Coinbase Global, Inc.","SOS":"SOS Limited","RIOT":"Riot Platforms","BTCM":"BIT Mining","MARA":"Marathon Digital Holdings Inc","NCTY":"第九城市","BTBT":"Bit Digital, Inc.","CAN":"嘉楠科技"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1126921416","content_text":"Crypto stocks jumped in morning trading after bitcoin hitting $60,000 as investors eye first U.S. ETFs.Bit Digital,Bit Mining,Marathon Digital,SoS Ltd,Riot Blockchain,Coinbase,The9 and Canaan climbed between 2% and 8%.\n\nBitcoin hit a six-month high on Friday, approaching the record hit in April, as traders became increasingly confident that U.S. regulators would approve the launch of an exchange-traded fund based on its futures contracts.\nThe world’s biggest cryptocurrency rose more than 4% to as high as $60000, its highest since mid-April. It has doubled in value this year and is near April’s record high of $64,895.\nThe U.S. Securities and Exchange Commission (SEC) is poised to allow the first U.S. bitcoin futures ETF to begin trading next week, Bloomberg News reported on Thursday, citing people familiar with the matter.\nBen Caselin, head of research and strategy at Asia-based cryptocurrency exchange AAX, said bitcoin’s spike above $59,000 wasn’t arbitrary and long-term investors had been accumulating it for a while.\n“It is widely expected that Q4 will see significant progress around a bitcoin ETF in the U.S.,” he said.\nFriday’s moves were also spurred by a tweet from the SEC’s investor education office, he said.\n\"Before investing in a fund that holds Bitcoin futures contracts, make sure you carefully weigh the potential risks and benefits,\" the SEC tweet here stated.\nCryptocurrency investors have been waiting for news of approval of the country’s first bitcoin ETF, and some of bitcoin’s rally in recent months has been in anticipation of that move and how it could speed up its mainstream adoption and trading.\nSeveral fund managers, including the VanEck Bitcoin Trust, ProShares, Invesco, Valkyrie and Galaxy Digital Funds have applied to launch bitcoin ETFs in the United States. Cryptocurrency ETFs have been launched this year in Canada and Europe.\nSEC Chair Gary Gensler has previously said the crypto market involves many tokens which may be unregistered securities and leaves prices open to manipulation and millions of investors vulnerable to risks.\nThe Bloomberg report said that the proposals by ProShares and Invesco are based on futures contracts and were filed under mutual fund rules that Gensler has said provide “significant investor protections”.","news_type":1},"isVote":1,"tweetType":1,"viewCount":169,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698057423,"gmtCreate":1640268416571,"gmtModify":1640268513740,"author":{"id":"3554895157968981","authorId":"3554895157968981","name":"canoboi","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like and comment thks","listText":"Like and comment thks","text":"Like and comment thks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/698057423","repostId":"1165632180","repostType":4,"isVote":1,"tweetType":1,"viewCount":678,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":600472363,"gmtCreate":1638194690382,"gmtModify":1638194690766,"author":{"id":"3554895157968981","authorId":"3554895157968981","name":"canoboi","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like and comment. Thanks","listText":"Like and comment. Thanks","text":"Like and comment. Thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/600472363","repostId":"1115824573","repostType":4,"repost":{"id":"1115824573","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638191842,"share":"https://www.laohu8.com/m/news/1115824573?lang=&edition=full","pubTime":"2021-11-29 21:17","market":"us","language":"en","title":"Toplines Before US Market Open on Monday","url":"https://stock-news.laohu8.com/highlight/detail?id=1115824573","media":"Tiger Newspress","summary":"U.S. stock index futures jumped on Monday as investors rushed in to take advantage of steep virus-dr","content":"<p>U.S. stock index futures jumped on Monday as investors rushed in to take advantage of steep virus-driven losses while awaiting more details on the severity of the Omicron coronavirus variant.</p>\n<p>At 8:00 a.m. ET, Dow e-minis were up 226 points, or 0.65%. S&amp;P 500 e-minis were up 37 points, or 0.81% and Nasdaq 100 e-minis were up 148.75 points, or 0.93%.</p>\n<p><img src=\"https://static.tigerbbs.com/4e047384eb051a409672b8ce439d9f38\" tg-width=\"1080\" tg-height=\"392\" referrerpolicy=\"no-referrer\"></p>\n<p>Wall Street indexes had slumped between 2% and 3.5% on Friday after news of the variant triggered a global selloff, as countries introduced new travel curbs on fears it could resist vaccinations and upend a nascent economic reopening.</p>\n<p>President Joe Biden is due to update the public on the variant and the United States' response later in the day, the White House said.</p>\n<p><b>Stocks making the biggest moves premarket:</b></p>\n<p><b>Moderna</b>&nbsp;— Shares of the vaccine maker continued their rally, jumping more than 10% in early morning trading Monday after gaining 20% on Friday. On Sunday the company’s chief medical officer said Moderna&nbsp;could roll out a reformulated vaccine&nbsp;against the omicron variant of Covid early next year.</p>\n<p><b>Li Auto</b> —&nbsp;U.S.-listed shares of Li Auto rose 8.5%&nbsp;in premarket trading. Li Auto&nbsp;reported adjusted earnings of 3 cents a share from $1.21 billion in sales. Wall Street was looking for a 3-cent loss from $1.13 billion in sales. At this point, earnings are less important that sales for Li. The company is still growing rapidly. Sales in the third quarter rose more than 209% year over year.</p>\n<p><b>Tesla</b>&nbsp;—&nbsp;The German automotive news outlet Automobilwoche&nbsp;reported Monday that Tesla’s new manufacturing facility in that country will start production in December.Tesla&nbsp;shares&nbsp;rallied&nbsp;1.5%&nbsp;in premarket trading.</p>\n<p><b>Apple</b>&nbsp;—&nbsp;Apple&nbsp;rose 1.5% after HSBC raised its price target on the iPhone maker's stock.</p>\n<p><b>Airlines</b> — Major airlines ticked up as investors bought the dip following&nbsp;new travel suspensions in Asia and Europe, in response to the newly discovered omicron variant of Covid-19.United,Delta&nbsp;and&nbsp;American Airlines&nbsp;each gained about 1%, after losing about 7% Friday. Travel booking site&nbsp;Expedia&nbsp;also rose, about 2%.</p>\n<p><b>Cruise lines</b> —Carnival,Royal Caribbean Cruises&nbsp;and&nbsp;Norwegian Cruise Line Holdings&nbsp;each rose more than 3% amid the broader rebound in travel stocks from Friday’s omicron-driven sell-off.</p>\n<p><b>Allbirds</b>— Shares of the shoe manufacturer rose 2.5% after several analysts initiated coverage of the stock. Morgan Stanley and Bank of America both posted a price target of $23, implying 16% upside to Friday’s close.</p>\n<p><b>Coinbase</b>— The cryptocurrency exchange’s shares rose more than 2% as the price of bitcoin rebounded, after selling off with the broader equities market on Friday. Other crypto-related equities got a lift too, with&nbsp;Microstrategy&nbsp;rising 3.4%.Tesla&nbsp;and&nbsp;Square&nbsp;added more than 1%.</p>\n<p><b>Zoom Video</b>— Zoom shares fell almost 2%, moving in the opposite direction of travel stocks and following a 5.7% jump on Friday. Other stay-at-home stocks dipped slightly Monday morning too, including&nbsp;Peloton,Netflix&nbsp;and&nbsp;Teladoc.</p>\n<p><b>Merck</b>— The pharmaceutical company’s shares fell 1.8% after Citi downgraded its stock to neutral from buy, saying development struggles for the company’s HIV drug islatravir will hurt Merck’s long-term potential.</p>\n<p><b>Wynn Resorts,Las Vegas Sands</b>— The Macao gaming sector is lower after Alvin Chau, the head of Macau’s biggest casino junket operator, and 10 others were arrested over allegedly illegal gambling platforms targeting mainland Chinese, according to a report by the South China Morning Post.Wynn&nbsp;fell 1.9% and&nbsp;Las Vegas Sands&nbsp;fell 1.2%</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Toplines Before US Market Open on Monday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nToplines Before US Market Open on Monday\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-11-29 21:17</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>U.S. stock index futures jumped on Monday as investors rushed in to take advantage of steep virus-driven losses while awaiting more details on the severity of the Omicron coronavirus variant.</p>\n<p>At 8:00 a.m. ET, Dow e-minis were up 226 points, or 0.65%. S&amp;P 500 e-minis were up 37 points, or 0.81% and Nasdaq 100 e-minis were up 148.75 points, or 0.93%.</p>\n<p><img src=\"https://static.tigerbbs.com/4e047384eb051a409672b8ce439d9f38\" tg-width=\"1080\" tg-height=\"392\" referrerpolicy=\"no-referrer\"></p>\n<p>Wall Street indexes had slumped between 2% and 3.5% on Friday after news of the variant triggered a global selloff, as countries introduced new travel curbs on fears it could resist vaccinations and upend a nascent economic reopening.</p>\n<p>President Joe Biden is due to update the public on the variant and the United States' response later in the day, the White House said.</p>\n<p><b>Stocks making the biggest moves premarket:</b></p>\n<p><b>Moderna</b>&nbsp;— Shares of the vaccine maker continued their rally, jumping more than 10% in early morning trading Monday after gaining 20% on Friday. On Sunday the company’s chief medical officer said Moderna&nbsp;could roll out a reformulated vaccine&nbsp;against the omicron variant of Covid early next year.</p>\n<p><b>Li Auto</b> —&nbsp;U.S.-listed shares of Li Auto rose 8.5%&nbsp;in premarket trading. Li Auto&nbsp;reported adjusted earnings of 3 cents a share from $1.21 billion in sales. Wall Street was looking for a 3-cent loss from $1.13 billion in sales. At this point, earnings are less important that sales for Li. The company is still growing rapidly. Sales in the third quarter rose more than 209% year over year.</p>\n<p><b>Tesla</b>&nbsp;—&nbsp;The German automotive news outlet Automobilwoche&nbsp;reported Monday that Tesla’s new manufacturing facility in that country will start production in December.Tesla&nbsp;shares&nbsp;rallied&nbsp;1.5%&nbsp;in premarket trading.</p>\n<p><b>Apple</b>&nbsp;—&nbsp;Apple&nbsp;rose 1.5% after HSBC raised its price target on the iPhone maker's stock.</p>\n<p><b>Airlines</b> — Major airlines ticked up as investors bought the dip following&nbsp;new travel suspensions in Asia and Europe, in response to the newly discovered omicron variant of Covid-19.United,Delta&nbsp;and&nbsp;American Airlines&nbsp;each gained about 1%, after losing about 7% Friday. Travel booking site&nbsp;Expedia&nbsp;also rose, about 2%.</p>\n<p><b>Cruise lines</b> —Carnival,Royal Caribbean Cruises&nbsp;and&nbsp;Norwegian Cruise Line Holdings&nbsp;each rose more than 3% amid the broader rebound in travel stocks from Friday’s omicron-driven sell-off.</p>\n<p><b>Allbirds</b>— Shares of the shoe manufacturer rose 2.5% after several analysts initiated coverage of the stock. Morgan Stanley and Bank of America both posted a price target of $23, implying 16% upside to Friday’s close.</p>\n<p><b>Coinbase</b>— The cryptocurrency exchange’s shares rose more than 2% as the price of bitcoin rebounded, after selling off with the broader equities market on Friday. Other crypto-related equities got a lift too, with&nbsp;Microstrategy&nbsp;rising 3.4%.Tesla&nbsp;and&nbsp;Square&nbsp;added more than 1%.</p>\n<p><b>Zoom Video</b>— Zoom shares fell almost 2%, moving in the opposite direction of travel stocks and following a 5.7% jump on Friday. Other stay-at-home stocks dipped slightly Monday morning too, including&nbsp;Peloton,Netflix&nbsp;and&nbsp;Teladoc.</p>\n<p><b>Merck</b>— The pharmaceutical company’s shares fell 1.8% after Citi downgraded its stock to neutral from buy, saying development struggles for the company’s HIV drug islatravir will hurt Merck’s long-term potential.</p>\n<p><b>Wynn Resorts,Las Vegas Sands</b>— The Macao gaming sector is lower after Alvin Chau, the head of Macau’s biggest casino junket operator, and 10 others were arrested over allegedly illegal gambling platforms targeting mainland Chinese, according to a report by the South China Morning Post.Wynn&nbsp;fell 1.9% and&nbsp;Las Vegas Sands&nbsp;fell 1.2%</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NCLH":"挪威邮轮","DAL":"达美航空","RCL":"皇家加勒比邮轮","WYNN":"永利度假村","ZM":"Zoom","MRK":"默沙东","TSLA":"特斯拉","LI":"理想汽车","BIRD":"Allbirds, Inc.","LVS":"金沙集团",".DJI":"道琼斯","CCL":"嘉年华邮轮","AAPL":"苹果",".IXIC":"NASDAQ Composite","AAL":"美国航空","MRNA":"Moderna, Inc.","UAL":"联合大陆航空",".SPX":"S&P 500 Index","COIN":"Coinbase Global, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1115824573","content_text":"U.S. stock index futures jumped on Monday as investors rushed in to take advantage of steep virus-driven losses while awaiting more details on the severity of the Omicron coronavirus variant.\nAt 8:00 a.m. ET, Dow e-minis were up 226 points, or 0.65%. S&P 500 e-minis were up 37 points, or 0.81% and Nasdaq 100 e-minis were up 148.75 points, or 0.93%.\n\nWall Street indexes had slumped between 2% and 3.5% on Friday after news of the variant triggered a global selloff, as countries introduced new travel curbs on fears it could resist vaccinations and upend a nascent economic reopening.\nPresident Joe Biden is due to update the public on the variant and the United States' response later in the day, the White House said.\nStocks making the biggest moves premarket:\nModerna — Shares of the vaccine maker continued their rally, jumping more than 10% in early morning trading Monday after gaining 20% on Friday. On Sunday the company’s chief medical officer said Moderna could roll out a reformulated vaccine against the omicron variant of Covid early next year.\nLi Auto — U.S.-listed shares of Li Auto rose 8.5% in premarket trading. Li Auto reported adjusted earnings of 3 cents a share from $1.21 billion in sales. Wall Street was looking for a 3-cent loss from $1.13 billion in sales. At this point, earnings are less important that sales for Li. The company is still growing rapidly. Sales in the third quarter rose more than 209% year over year.\nTesla — The German automotive news outlet Automobilwoche reported Monday that Tesla’s new manufacturing facility in that country will start production in December.Tesla shares rallied 1.5% in premarket trading.\nApple — Apple rose 1.5% after HSBC raised its price target on the iPhone maker's stock.\nAirlines — Major airlines ticked up as investors bought the dip following new travel suspensions in Asia and Europe, in response to the newly discovered omicron variant of Covid-19.United,Delta and American Airlines each gained about 1%, after losing about 7% Friday. Travel booking site Expedia also rose, about 2%.\nCruise lines —Carnival,Royal Caribbean Cruises and Norwegian Cruise Line Holdings each rose more than 3% amid the broader rebound in travel stocks from Friday’s omicron-driven sell-off.\nAllbirds— Shares of the shoe manufacturer rose 2.5% after several analysts initiated coverage of the stock. Morgan Stanley and Bank of America both posted a price target of $23, implying 16% upside to Friday’s close.\nCoinbase— The cryptocurrency exchange’s shares rose more than 2% as the price of bitcoin rebounded, after selling off with the broader equities market on Friday. Other crypto-related equities got a lift too, with Microstrategy rising 3.4%.Tesla and Square added more than 1%.\nZoom Video— Zoom shares fell almost 2%, moving in the opposite direction of travel stocks and following a 5.7% jump on Friday. Other stay-at-home stocks dipped slightly Monday morning too, including Peloton,Netflix and Teladoc.\nMerck— The pharmaceutical company’s shares fell 1.8% after Citi downgraded its stock to neutral from buy, saying development struggles for the company’s HIV drug islatravir will hurt Merck’s long-term potential.\nWynn Resorts,Las Vegas Sands— The Macao gaming sector is lower after Alvin Chau, the head of Macau’s biggest casino junket operator, and 10 others were arrested over allegedly illegal gambling platforms targeting mainland Chinese, according to a report by the South China Morning Post.Wynn fell 1.9% and Las Vegas Sands fell 1.2%","news_type":1},"isVote":1,"tweetType":1,"viewCount":273,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":602355182,"gmtCreate":1638975620041,"gmtModify":1638975620314,"author":{"id":"3554895157968981","authorId":"3554895157968981","name":"canoboi","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like and comment. Thks","listText":"Like and comment. Thks","text":"Like and comment. Thks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/602355182","repostId":"1100353648","repostType":4,"repost":{"id":"1100353648","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638975407,"share":"https://www.laohu8.com/m/news/1100353648?lang=&edition=full","pubTime":"2021-12-08 22:56","market":"us","language":"en","title":"Airlines and cruise line stocks jumped in morning trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1100353648","media":"Tiger Newspress","summary":"Airlines and cruise line stocks jumped in morning trading.","content":"<p>Airlines and cruise line stocks jumped in morning trading.</p>\n<p><img src=\"https://static.tigerbbs.com/994b55083be6d042bbbfb1c0599d47cd\" tg-width=\"407\" tg-height=\"483\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/0947f84e60588e489e2e964fe5a018dc\" tg-width=\"405\" tg-height=\"189\" referrerpolicy=\"no-referrer\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Airlines and cruise line stocks jumped in morning trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAirlines and cruise line stocks jumped in morning trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-08 22:56</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Airlines and cruise line stocks jumped in morning trading.</p>\n<p><img src=\"https://static.tigerbbs.com/994b55083be6d042bbbfb1c0599d47cd\" tg-width=\"407\" tg-height=\"483\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/0947f84e60588e489e2e964fe5a018dc\" tg-width=\"405\" tg-height=\"189\" referrerpolicy=\"no-referrer\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CCL":"嘉年华邮轮","LUV":"西南航空","JBLU":"捷蓝航空","UAL":"联合大陆航空","SAVE":"Spirit Airlines","DAL":"达美航空","RCL":"皇家加勒比邮轮","NCLH":"挪威邮轮","AAL":"美国航空","BA":"波音"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1100353648","content_text":"Airlines and cruise line stocks jumped in morning trading.","news_type":1},"isVote":1,"tweetType":1,"viewCount":186,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":609871370,"gmtCreate":1638271641570,"gmtModify":1638271641727,"author":{"id":"3554895157968981","authorId":"3554895157968981","name":"canoboi","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like and comment thanks","listText":"Like and comment thanks","text":"Like and comment thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/609871370","repostId":"2187586148","repostType":4,"repost":{"id":"2187586148","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1638264468,"share":"https://www.laohu8.com/m/news/2187586148?lang=&edition=full","pubTime":"2021-11-30 17:27","market":"us","language":"en","title":"5 Stocks To Watch For November 30, 2021","url":"https://stock-news.laohu8.com/highlight/detail?id=2187586148","media":"Benzinga","summary":"Some of the stocks that may grab investor focus today are:\n","content":"<p>Some of the stocks that may grab investor focus today are:</p>\n<ul>\n <li>Wall Street expects <b>Hewlett Packard Enterprise Company</b>&nbsp;(NYSE:HPE) to report quarterly earnings at $0.48 per share on revenue of $7.38 billion after the closing bell. Hewlett Packard Enterprise shares fell 1.2% to $14.43 in premarket trading&nbsp;Tuesday.</li>\n <li><b>UnitedHealth Group Inc</b> (NYSE:UNH) said it sees FY21 adjusted earnings of $18.75 to $18.90 per share on revenue of approximately $287 billion. The company also expects FY22 adjusted EPS of $21.10-$21.60 and revenue of $317 billion to $320 billion. UnitedHealth shares fell 1% to $447.7 in premarket trading&nbsp;Tuesday.</li>\n <li>Analysts are expecting <b>salesforce.com, inc.</b>&nbsp;(NYSE:CRM) to have earned $0.92 per share on revenue of $6.80 billion for the latest quarter. The company will release earnings after the markets close. salesforce.com shares dropped 0.6% to $294.98 in premarket tradingTuesday.</li>\n</ul>\n<ul>\n <li>Chatham Asset Management offered to acquire <b>R. R. Donnelley &amp; Sons Company</b> (NYSE:RRD) for $10.25 per share in cash. R. R. Donnelley shares gained 0.5% to $10.27 in after-hours trading, following a 10% surge in regular trading Monday.</li>\n <li>Analysts expect <b>NetApp, Inc.</b>&nbsp;(NASDAQ:NTAP) to post quarterly earnings at $1.21 per share on revenue of $1.55 billion after the closing bell. NetApp shares rose 0.3% to $91.80 in after-hours trading&nbsp;Monday.</li>\n</ul>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Stocks To Watch For November 30, 2021</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Stocks To Watch For November 30, 2021\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-11-30 17:27</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Some of the stocks that may grab investor focus today are:</p>\n<ul>\n <li>Wall Street expects <b>Hewlett Packard Enterprise Company</b>&nbsp;(NYSE:HPE) to report quarterly earnings at $0.48 per share on revenue of $7.38 billion after the closing bell. Hewlett Packard Enterprise shares fell 1.2% to $14.43 in premarket trading&nbsp;Tuesday.</li>\n <li><b>UnitedHealth Group Inc</b> (NYSE:UNH) said it sees FY21 adjusted earnings of $18.75 to $18.90 per share on revenue of approximately $287 billion. The company also expects FY22 adjusted EPS of $21.10-$21.60 and revenue of $317 billion to $320 billion. UnitedHealth shares fell 1% to $447.7 in premarket trading&nbsp;Tuesday.</li>\n <li>Analysts are expecting <b>salesforce.com, inc.</b>&nbsp;(NYSE:CRM) to have earned $0.92 per share on revenue of $6.80 billion for the latest quarter. The company will release earnings after the markets close. salesforce.com shares dropped 0.6% to $294.98 in premarket tradingTuesday.</li>\n</ul>\n<ul>\n <li>Chatham Asset Management offered to acquire <b>R. R. Donnelley &amp; Sons Company</b> (NYSE:RRD) for $10.25 per share in cash. R. R. Donnelley shares gained 0.5% to $10.27 in after-hours trading, following a 10% surge in regular trading Monday.</li>\n <li>Analysts expect <b>NetApp, Inc.</b>&nbsp;(NASDAQ:NTAP) to post quarterly earnings at $1.21 per share on revenue of $1.55 billion after the closing bell. NetApp shares rose 0.3% to $91.80 in after-hours trading&nbsp;Monday.</li>\n</ul>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4170":"电脑硬件、储存设备及电脑周边","BK4535":"淡马锡持仓","BK4548":"巴美列捷福持仓","BK4087":"商业印刷","RRD":"当纳利","BK4567":"ESG概念","BK4505":"高瓴资本持仓","BK4538":"云计算","BK4527":"明星科技股","CRM":"赛富时","HPE":"慧与科技","UNH":"联合健康","BK4528":"SaaS概念","NTAP":"美国网存","BK4154":"管理型保健护理","BK4566":"资本集团","BK4515":"5G概念"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2187586148","content_text":"Some of the stocks that may grab investor focus today are:\n\nWall Street expects Hewlett Packard Enterprise Company (NYSE:HPE) to report quarterly earnings at $0.48 per share on revenue of $7.38 billion after the closing bell. Hewlett Packard Enterprise shares fell 1.2% to $14.43 in premarket trading Tuesday.\nUnitedHealth Group Inc (NYSE:UNH) said it sees FY21 adjusted earnings of $18.75 to $18.90 per share on revenue of approximately $287 billion. The company also expects FY22 adjusted EPS of $21.10-$21.60 and revenue of $317 billion to $320 billion. UnitedHealth shares fell 1% to $447.7 in premarket trading Tuesday.\nAnalysts are expecting salesforce.com, inc. (NYSE:CRM) to have earned $0.92 per share on revenue of $6.80 billion for the latest quarter. The company will release earnings after the markets close. salesforce.com shares dropped 0.6% to $294.98 in premarket tradingTuesday.\n\n\nChatham Asset Management offered to acquire R. R. Donnelley & Sons Company (NYSE:RRD) for $10.25 per share in cash. R. R. Donnelley shares gained 0.5% to $10.27 in after-hours trading, following a 10% surge in regular trading Monday.\nAnalysts expect NetApp, Inc. (NASDAQ:NTAP) to post quarterly earnings at $1.21 per share on revenue of $1.55 billion after the closing bell. NetApp shares rose 0.3% to $91.80 in after-hours trading Monday.","news_type":1},"isVote":1,"tweetType":1,"viewCount":123,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":692329526,"gmtCreate":1640854341920,"gmtModify":1640854342261,"author":{"id":"3554895157968981","authorId":"3554895157968981","name":"canoboi","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like and&nbsp; comment..thanks","listText":"Like and&nbsp; comment..thanks","text":"Like and comment..thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/692329526","repostId":"1125407253","repostType":4,"repost":{"id":"1125407253","pubTimestamp":1640853615,"share":"https://www.laohu8.com/m/news/1125407253?lang=&edition=full","pubTime":"2021-12-30 16:40","market":"us","language":"en","title":"The S&P 500 could have 16% upside through the end of 2022, Fundstrat's Tom Lee says","url":"https://stock-news.laohu8.com/highlight/detail?id=1125407253","media":"Markets insider","summary":"The S&P 500 could surge 16% in 2022 to 5,600, according to a note from Fundstrat's Tom Lee.He pointe","content":"<html><head></head><body><ul><li><b>The S&amp;P 500 could surge 16% in 2022 to 5,600, according to a note from Fundstrat&#39;s Tom Lee.</b></li><li><b>He pointed out that since 1938, returns have been strong for stocks in the year after a 27% gain.</b></li><li><b>&#34;Our S&amp;P 500 5,100 by year-end 2022 target looks conservative, but we also expect plenty of turbulence,&#34; Lee said.</b></li></ul><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/5675d806b794ec8372558219eb7863b4\" tg-width=\"790\" tg-height=\"395\" width=\"100%\" height=\"auto\"/><span>Spencer Platt/Getty Images</span></p><p>Strength in the stock market after a solid 2021 is likely to continue into next year, as momentum continues to drive equities higher, according to Fundstrat&#39;s Tom lee.</p><p>He has already set a S&amp;P 500 price target of 5,100 by the end of 2022,representing potential upside of about 7% from Tuesday&#39;s close. But that estimate could be too conservative, according to a Wednesday note from Fundstrat.</p><p>With the S&amp;P 500 up nearly 30% in 2021, a historical analysis of past market returns suggests gains could extend higher into next year. Since 1938, the stock market has generated an average and median annual gain of 12% and 16%, respectively, in the year following a rise of at least 27%, according to Lee.</p><p>Those potential gains would send the S&amp;P 500 to between 5,400 and 5,600. &#34;Most years post +27% gains are actually very good...thus, we believe our base case of S&amp;P 500 5,100 is conservative,&#34; he said.</p><p>The rise in stocks isn&#39;t just being driven by momentum. It&#39;s also being buoyed by a strong economic backdrop and rising corporate profits. &#34;The rise in equities, in our view, has been justified by the substantial economic resilience coupled with tremendous operating leverage of businesses,&#34; Lee explained.</p><p>Still, despite the bright outlook, the Fundstrat team is expecting significant turbulence in 2022, especially in the first half of the year. That&#39;s because COVID cases could remain elevated, supply-chain glitches may persist, mid-term elections could contribute to uncertainty, and the Fed is on the verge of raising interest rates.</p><p>The question to Lee remains that if those risks are obvious, have they already been discounted by investors?</p><p>Whether they have or not, a 2022 gain of &#34;+12% to +16% probably more appropriate,&#34; Lee said.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The S&P 500 could have 16% upside through the end of 2022, Fundstrat's Tom Lee says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe S&P 500 could have 16% upside through the end of 2022, Fundstrat's Tom Lee says\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-30 16:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://markets.businessinsider.com/news/stocks/stock-market-outlook-sp500-strong-year-signals-more-upside-2022-2021-12><strong>Markets insider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The S&P 500 could surge 16% in 2022 to 5,600, according to a note from Fundstrat's Tom Lee.He pointed out that since 1938, returns have been strong for stocks in the year after a 27% gain.\"Our S&P 500...</p>\n\n<a href=\"https://markets.businessinsider.com/news/stocks/stock-market-outlook-sp500-strong-year-signals-more-upside-2022-2021-12\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".DJI":"道琼斯",".SPX":"S&P 500 Index",".IXIC":"NASDAQ Composite"},"source_url":"https://markets.businessinsider.com/news/stocks/stock-market-outlook-sp500-strong-year-signals-more-upside-2022-2021-12","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1125407253","content_text":"The S&P 500 could surge 16% in 2022 to 5,600, according to a note from Fundstrat's Tom Lee.He pointed out that since 1938, returns have been strong for stocks in the year after a 27% gain.\"Our S&P 500 5,100 by year-end 2022 target looks conservative, but we also expect plenty of turbulence,\" Lee said.Spencer Platt/Getty ImagesStrength in the stock market after a solid 2021 is likely to continue into next year, as momentum continues to drive equities higher, according to Fundstrat's Tom lee.He has already set a S&P 500 price target of 5,100 by the end of 2022,representing potential upside of about 7% from Tuesday's close. But that estimate could be too conservative, according to a Wednesday note from Fundstrat.With the S&P 500 up nearly 30% in 2021, a historical analysis of past market returns suggests gains could extend higher into next year. Since 1938, the stock market has generated an average and median annual gain of 12% and 16%, respectively, in the year following a rise of at least 27%, according to Lee.Those potential gains would send the S&P 500 to between 5,400 and 5,600. \"Most years post +27% gains are actually very good...thus, we believe our base case of S&P 500 5,100 is conservative,\" he said.The rise in stocks isn't just being driven by momentum. It's also being buoyed by a strong economic backdrop and rising corporate profits. \"The rise in equities, in our view, has been justified by the substantial economic resilience coupled with tremendous operating leverage of businesses,\" Lee explained.Still, despite the bright outlook, the Fundstrat team is expecting significant turbulence in 2022, especially in the first half of the year. That's because COVID cases could remain elevated, supply-chain glitches may persist, mid-term elections could contribute to uncertainty, and the Fed is on the verge of raising interest rates.The question to Lee remains that if those risks are obvious, have they already been discounted by investors?Whether they have or not, a 2022 gain of \"+12% to +16% probably more appropriate,\" Lee said.","news_type":1},"isVote":1,"tweetType":1,"viewCount":616,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":601549809,"gmtCreate":1638543940804,"gmtModify":1638543940956,"author":{"id":"3554895157968981","authorId":"3554895157968981","name":"canoboi","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like n comment thanks","listText":"Like n comment thanks","text":"Like n comment thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/601549809","repostId":"2188528084","repostType":4,"repost":{"id":"2188528084","pubTimestamp":1638543717,"share":"https://www.laohu8.com/m/news/2188528084?lang=&edition=full","pubTime":"2021-12-03 23:01","market":"us","language":"en","title":"5 Warren Buffett Stocks Are Screaming Buys in December","url":"https://stock-news.laohu8.com/highlight/detail?id=2188528084","media":"Motley Fool","summary":"Riding the Oracle of Omaha's coattails is often a moneymaking proposition.","content":"<p>Making money for shareholders has been in Warren Buffett's blood since taking over as CEO of <b>Berkshire Hathaway</b> (NYSE:BRK.A)(NYSE:BRK.B) in 1965. Over that time, he's led Berkshire to an average annual gain of about 20%, which translates into aggregate gains, including the year-to-date performance of the Class A shares (BRK.A), of approximately 3,500,000%. Gains like this are why the investing world pays close attention to what the Oracle of Omaha is buying and selling.</p>\n<p>Based on the latest 13F filing with the Securities and Exchange Commission, Berkshire Hathaway has stakes in 45 securities. Among these 45 holdings, five Warren Buffett stocks stand out as screaming buys in December.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/e92116e97f06291ec28eda85974acb1b\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Berkshire Hathaway CEO Warren Buffett. Image source: The Motley Fool.</span></p>\n<h2>Amazon</h2>\n<p>While I'm well aware this isn't going to win any points for originality, e-commerce kingpin <b>Amazon</b> (NASDAQ:AMZN) remains a surefire stock to own in Buffett's portfolio.</p>\n<p>Most people are familiar with Amazon for its dominant online marketplace. According to an August report from eMarketer, Amazon is expected to handle 41.4% of all U.S. online sales in 2021. That's about 34 percentage points higher than the next-closest competitor. The key, though, is that the company has signed up 200 million people to a Prime membership worldwide. The annual fees collected from these members helps to buoy razor-thin retail margins and allows Amazon to consistently undercut brick-and-mortar retailers on price.</p>\n<p>However, the company's future rests with its considerably higher-margin segments, such as cloud infrastructure services. Amazon Web Services (AWS) accounted for only 13.4% of net sales in the third quarter, yet contributed 61.8% of the company's operating income. Even with online sales slowing as coronavirus vaccination rates tick higher and life returns to some semblance of normal, Amazon's critical highest-margin segments (AWS, subscriptions, and advertising) continue to grow rapidly.</p>\n<p>If Amazon were to simply hit the median price-to-operating cash flow it's been trading at for the past 11 years, we could be looking at a $10,000 a share company by mid-decade.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/b18b49b2b35da2fc49e0a83b883d1c22\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Bristol Myers Squibb</h2>\n<p>Another Warren Buffett stock that's quickly become a screaming buy is pharmaceutical company <b>Bristol Myers Squibb</b> (NYSE:BMY).</p>\n<p>Bristol Myers' success is dependent on organically developing and growing its brand-name pharmaceutical portfolio, as well as leaning on acquisitions to push the needle higher.</p>\n<p>From an internal development perspective, some of the company's biggest wins include cancer immunotherapy Opdivo and oral anticoagulant Eliquis -- the latter of which was developed with <b>Pfizer</b>. Eliquis should push for $10 billion in sales for Bristol Myers this year, while Opdivo hit $7 billion in revenue last year. Opdivo is particularly intriguing given that it's being examined in dozens of clinical trials and has already received approval for 10 indications in the U.S. Label expansion opportunities, pricing power, and improved cancer screening diagnostics all have the potential to make this a $10 billion a year therapy.</p>\n<p>Bristol Myers also made waves with its November 2019 acquisition of cancer and immunology drugmaker Celgene. Buying Celgene added a handful of blockbuster drugs to Bristol's portfolio, including multiple myeloma treatment Revlimid, which will potentially top $13 billion in 2021 sales. Revlimid is protected from an onslaught of generic competition for four more years, which means Bristol Myers will be generating bountiful cash flow in the meantime.</p>\n<p>At just 7 times consensus forward-year earnings per share, it's an absolute steal.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/a295212aa2b7c99c921b8afa2a4aa3a2\" tg-width=\"700\" tg-height=\"467\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2><a href=\"https://laohu8.com/S/V\">Visa</a></h2>\n<p>The recent sell-off in payment processing behemoth <b>Visa</b> (NYSE:V) makes it a screaming buy, too.</p>\n<p>Over the past couple of months, Wall Street and investors have raised concerns about payment facilitators like <b>Square</b>&nbsp;or cryptocurrencies eating into Visa's dominance. However, these concerns seem unfounded given Visa's utter dominance of the processing space. As of 2018, it held a 53% share of U.S. credit card network purchase volume, which was more than 30 percentage points higher than the next-closest competitor. I should also mention the U.S. is the leading market for consumption in the world.</p>\n<p>Visa's outperformance is also a function of its lending avoidance. By sticking to the processing side of the equation, the company avoids having to set aside capital to cover credit delinquencies during recessions. Not having to cover credit/loan losses is a big reason why Visa rebounds faster than other financial stocks and maintains a profit margin north of 50%.</p>\n<p>And have I mentioned that Visa is <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the smartest ways to play rapidly rising inflation? Since the company's fees are tied to the price of goods and services, its revenue and profits will grow as the price for goods and services rises.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1c5a0257bdd17a5ff3cf22a10de43ce0\" tg-width=\"700\" tg-height=\"467\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Teva Pharmaceutical Industries</h2>\n<p>The cheapest stock in Warren Buffett's portfolio, brand-name and generic-drug company <b>Teva Pharmaceutical Industries</b> (NYSE:TEVA), is begging to be bought as well. Teva can currently be purchased for a little more than 3 times Wall Street's consensus earnings per share in 2021 and 2022.</p>\n<p>Unlike Amazon, Bristol Myers, and Visa, Teva hasn't been firing on all cylinders. Since 2016, the company settled a bribery scandal, buried itself in debt after overpaying for generic-drugmaker Actavis, and has faced a mountain of litigation concerning its role in the opioid epidemic. But while there's reason to not give Teva a valuation premium, an earnings multiple of 3 is overly pessimistic given the steps being taken to right the ship.</p>\n<p>In late 2017, Kare Schultz took over as CEO. He's a turnaround specialist who's taken clear steps to improve the business. During his tenure, net debt has been reduced from over $34 billion to around $22 billion, and annual operating expenses have been cut by a double-digit percentage. Teva is leaner than it's been in years and is capable of maintaining annual operating cash flow of $2 billion (or higher).</p>\n<p>Furthermore, there's light at the end of the tunnel when it comes to opioid litigation. A trial in California recently went in favor of drugmakers, which could put some bargaining power back in Teva's court. If Schultz can negotiate a national settlement where free or reduced-cost medicine, not cash, is the lure, Teva could probably double very quickly.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/7343c3ce7330b86321a8ec9384d4baea\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Bank of America</h2>\n<p>The final Warren Buffett stock to buy hand over fist in December is banking juggernaut <b>Bank of America</b> (NYSE:BAC).</p>\n<p>Bank stocks like BofA are on the cusp of hitting their growth sweet spot. With inflation picking up, the Federal Reserve will more than likely need to act in 2022 or 2023 to raise interest rates. Boosting the federal funds target rate will lift the net interest income-earning potential of banks with outstanding variable-rate loans.</p>\n<p>Among money-center banks, none is more interest-sensitive than Bank of America. The company's third-quarter earnings presentation points out that a 100-basis-point parallel shift in the interest rate yield curve would generate an estimated $7.2 billion in added net interest income over 12 months. Although we're unlikely to see a 100-basis-point shift in 12 months, we are on the verge of seeing higher interest rates significantly bolster BofA's profit potential.</p>\n<p>The other impressive aspect of Warren Buffett's second-largest holding is its digitization efforts. Though you probably don't think of Bank of America as a tech-savvy business, the number of digital active users has grown to nearly 41 million, with 43% of all sales in the third quarter coming from online or mobile banking. This push to digitize has allowed the company to consolidate some of its branches in order to reduce costs.</p>\n<p>Bank of America should be a no-brainer buy as it enters the sweet spot of its growth cycle.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Warren Buffett Stocks Are Screaming Buys in December</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Warren Buffett Stocks Are Screaming Buys in December\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-03 23:01 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/03/5-warren-buffett-stocks-screaming-buys-in-december/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Making money for shareholders has been in Warren Buffett's blood since taking over as CEO of Berkshire Hathaway (NYSE:BRK.A)(NYSE:BRK.B) in 1965. Over that time, he's led Berkshire to an average ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/03/5-warren-buffett-stocks-screaming-buys-in-december/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BRK.B":"伯克希尔B","BAC":"美国银行","TEVA":"梯瓦制药","BK4532":"文艺复兴科技持仓","BK4550":"红杉资本持仓","BK4106":"数据处理与外包服务","BK4566":"资本集团","BK4507":"流媒体概念","V":"Visa","BK4538":"云计算","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4535":"淡马锡持仓","BK4176":"多领域控股","BK4207":"综合性银行","BK4559":"巴菲特持仓","BK4553":"喜马拉雅资本持仓","BK4504":"桥水持仓","BK4524":"宅经济概念","BK4554":"元宇宙及AR概念","AMZN":"亚马逊","BK4561":"索罗斯持仓","BK4557":"大麻股","BK4548":"巴美列捷福持仓","BK4527":"明星科技股","BK4551":"寇图资本持仓","BK4503":"景林资产持仓","BK4534":"瑞士信贷持仓","BK4122":"互联网与直销零售","BMY":"施贵宝","BRK.A":"伯克希尔","BK4007":"制药"},"source_url":"https://www.fool.com/investing/2021/12/03/5-warren-buffett-stocks-screaming-buys-in-december/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2188528084","content_text":"Making money for shareholders has been in Warren Buffett's blood since taking over as CEO of Berkshire Hathaway (NYSE:BRK.A)(NYSE:BRK.B) in 1965. Over that time, he's led Berkshire to an average annual gain of about 20%, which translates into aggregate gains, including the year-to-date performance of the Class A shares (BRK.A), of approximately 3,500,000%. Gains like this are why the investing world pays close attention to what the Oracle of Omaha is buying and selling.\nBased on the latest 13F filing with the Securities and Exchange Commission, Berkshire Hathaway has stakes in 45 securities. Among these 45 holdings, five Warren Buffett stocks stand out as screaming buys in December.\nBerkshire Hathaway CEO Warren Buffett. Image source: The Motley Fool.\nAmazon\nWhile I'm well aware this isn't going to win any points for originality, e-commerce kingpin Amazon (NASDAQ:AMZN) remains a surefire stock to own in Buffett's portfolio.\nMost people are familiar with Amazon for its dominant online marketplace. According to an August report from eMarketer, Amazon is expected to handle 41.4% of all U.S. online sales in 2021. That's about 34 percentage points higher than the next-closest competitor. The key, though, is that the company has signed up 200 million people to a Prime membership worldwide. The annual fees collected from these members helps to buoy razor-thin retail margins and allows Amazon to consistently undercut brick-and-mortar retailers on price.\nHowever, the company's future rests with its considerably higher-margin segments, such as cloud infrastructure services. Amazon Web Services (AWS) accounted for only 13.4% of net sales in the third quarter, yet contributed 61.8% of the company's operating income. Even with online sales slowing as coronavirus vaccination rates tick higher and life returns to some semblance of normal, Amazon's critical highest-margin segments (AWS, subscriptions, and advertising) continue to grow rapidly.\nIf Amazon were to simply hit the median price-to-operating cash flow it's been trading at for the past 11 years, we could be looking at a $10,000 a share company by mid-decade.\nImage source: Getty Images.\nBristol Myers Squibb\nAnother Warren Buffett stock that's quickly become a screaming buy is pharmaceutical company Bristol Myers Squibb (NYSE:BMY).\nBristol Myers' success is dependent on organically developing and growing its brand-name pharmaceutical portfolio, as well as leaning on acquisitions to push the needle higher.\nFrom an internal development perspective, some of the company's biggest wins include cancer immunotherapy Opdivo and oral anticoagulant Eliquis -- the latter of which was developed with Pfizer. Eliquis should push for $10 billion in sales for Bristol Myers this year, while Opdivo hit $7 billion in revenue last year. Opdivo is particularly intriguing given that it's being examined in dozens of clinical trials and has already received approval for 10 indications in the U.S. Label expansion opportunities, pricing power, and improved cancer screening diagnostics all have the potential to make this a $10 billion a year therapy.\nBristol Myers also made waves with its November 2019 acquisition of cancer and immunology drugmaker Celgene. Buying Celgene added a handful of blockbuster drugs to Bristol's portfolio, including multiple myeloma treatment Revlimid, which will potentially top $13 billion in 2021 sales. Revlimid is protected from an onslaught of generic competition for four more years, which means Bristol Myers will be generating bountiful cash flow in the meantime.\nAt just 7 times consensus forward-year earnings per share, it's an absolute steal.\nImage source: Getty Images.\nVisa\nThe recent sell-off in payment processing behemoth Visa (NYSE:V) makes it a screaming buy, too.\nOver the past couple of months, Wall Street and investors have raised concerns about payment facilitators like Square or cryptocurrencies eating into Visa's dominance. However, these concerns seem unfounded given Visa's utter dominance of the processing space. As of 2018, it held a 53% share of U.S. credit card network purchase volume, which was more than 30 percentage points higher than the next-closest competitor. I should also mention the U.S. is the leading market for consumption in the world.\nVisa's outperformance is also a function of its lending avoidance. By sticking to the processing side of the equation, the company avoids having to set aside capital to cover credit delinquencies during recessions. Not having to cover credit/loan losses is a big reason why Visa rebounds faster than other financial stocks and maintains a profit margin north of 50%.\nAnd have I mentioned that Visa is one of the smartest ways to play rapidly rising inflation? Since the company's fees are tied to the price of goods and services, its revenue and profits will grow as the price for goods and services rises.\nImage source: Getty Images.\nTeva Pharmaceutical Industries\nThe cheapest stock in Warren Buffett's portfolio, brand-name and generic-drug company Teva Pharmaceutical Industries (NYSE:TEVA), is begging to be bought as well. Teva can currently be purchased for a little more than 3 times Wall Street's consensus earnings per share in 2021 and 2022.\nUnlike Amazon, Bristol Myers, and Visa, Teva hasn't been firing on all cylinders. Since 2016, the company settled a bribery scandal, buried itself in debt after overpaying for generic-drugmaker Actavis, and has faced a mountain of litigation concerning its role in the opioid epidemic. But while there's reason to not give Teva a valuation premium, an earnings multiple of 3 is overly pessimistic given the steps being taken to right the ship.\nIn late 2017, Kare Schultz took over as CEO. He's a turnaround specialist who's taken clear steps to improve the business. During his tenure, net debt has been reduced from over $34 billion to around $22 billion, and annual operating expenses have been cut by a double-digit percentage. Teva is leaner than it's been in years and is capable of maintaining annual operating cash flow of $2 billion (or higher).\nFurthermore, there's light at the end of the tunnel when it comes to opioid litigation. A trial in California recently went in favor of drugmakers, which could put some bargaining power back in Teva's court. If Schultz can negotiate a national settlement where free or reduced-cost medicine, not cash, is the lure, Teva could probably double very quickly.\nImage source: Getty Images.\nBank of America\nThe final Warren Buffett stock to buy hand over fist in December is banking juggernaut Bank of America (NYSE:BAC).\nBank stocks like BofA are on the cusp of hitting their growth sweet spot. With inflation picking up, the Federal Reserve will more than likely need to act in 2022 or 2023 to raise interest rates. Boosting the federal funds target rate will lift the net interest income-earning potential of banks with outstanding variable-rate loans.\nAmong money-center banks, none is more interest-sensitive than Bank of America. The company's third-quarter earnings presentation points out that a 100-basis-point parallel shift in the interest rate yield curve would generate an estimated $7.2 billion in added net interest income over 12 months. Although we're unlikely to see a 100-basis-point shift in 12 months, we are on the verge of seeing higher interest rates significantly bolster BofA's profit potential.\nThe other impressive aspect of Warren Buffett's second-largest holding is its digitization efforts. Though you probably don't think of Bank of America as a tech-savvy business, the number of digital active users has grown to nearly 41 million, with 43% of all sales in the third quarter coming from online or mobile banking. This push to digitize has allowed the company to consolidate some of its branches in order to reduce costs.\nBank of America should be a no-brainer buy as it enters the sweet spot of its growth cycle.","news_type":1},"isVote":1,"tweetType":1,"viewCount":313,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":865564361,"gmtCreate":1633003517041,"gmtModify":1633003517413,"author":{"id":"3554895157968981","authorId":"3554895157968981","name":"canoboi","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like and comment. Thanks","listText":"Like and comment. Thanks","text":"Like and comment. Thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/865564361","repostId":"1104172212","repostType":4,"repost":{"id":"1104172212","pubTimestamp":1632965278,"share":"https://www.laohu8.com/m/news/1104172212?lang=&edition=full","pubTime":"2021-09-30 09:27","market":"us","language":"en","title":"2021 Global Market Outlook - Q4 Update: Growing Pains","url":"https://stock-news.laohu8.com/highlight/detail?id=1104172212","media":"seekingalpha","summary":"Summary\n\nThe post-lockdown recovery has been powerful, and most developed economies have seen double","content":"<p><b>Summary</b></p>\n<ul>\n <li>The post-lockdown recovery has been powerful, and most developed economies have seen double-digit gross domestic product (GDP) rebounds from 2020 lows.</li>\n <li>The reopening trade should resume in coming months. The cyclical stocks that comprise the value factor are reporting stronger earnings upgrades than technology-heavy growth stocks, and the value factor is cheap compared to the growth factor.</li>\n <li>The key risk is that the delta variant or similar proves resilient to vaccination or that infection rates escalate during the Northern Hemisphere winter.</li>\n</ul>\n<p>The COVID-19 delta variant, inflation and central bank tapering are unnerving investors. <b>We expect the pandemic-recovery trade to resume as inflation subsides, infection rates decline and tapering turns out to not equal tightening. Amid this backdrop, our outlook favors equities over bonds, the value factor over the growth factor and non-U.S. stocks over U.S. stocks.</b></p>\n<p><b>Introduction</b></p>\n<p>The post-lockdown recovery has transitioned from energetic youthfulness to awkward adolescence. It’s still growing, although at a slower pace, and there are worries about what happens next, particularly about monetary policy and the outlook for inflation. Theinflation spikehas been larger than expected, but we still think it istransitory, caused by base effects from when the U.S. consumer price index (CPI) fell during the lockdown last year and by temporary supply bottlenecks. Inflation may remain high over the remainder of 2021 but should decline in early 2022. This means that even though the U.S. Federal Reserve (Fed) is likely to begin tapering back on asset purchases before the end of the year, rate hikes are unlikely before the second half of 2023.</p>\n<p>Another worry is thehighly contagious COVID-19 delta variant. The evidence so far is that vaccines are effective in preventing serious COVID-19 infections. Vaccination rates are accelerating globally, and emerging economies are catching up with developed markets. Infection rates appear to have peaked globally in early September. This means the reopening of economies should continue over the remainder of 2021. The onset of winter in the northern hemisphere will be a test, but the rollout of booster vaccination shots should help prevent widescale renewed lockdowns.</p>\n<p>The conclusions from our cycle, value and sentiment (CVS) investment decision-making process are broadly unchanged from our previous quarterly report. Global equities remain expensive, with the very expensive U.S. market offsetting better value elsewhere. Sentiment is slightly overbought, but not close to dangerous levels of euphoria. The strong cycle delivers a preference for equities over bonds for at least the next 12 months, despite expensive valuations. It also reinforces our preference for thevalue equity factor over the growth factorand for non-U.S. equities to outperform the U.S. market.</p>\n<p><b>Cycle still in recovery phase</b></p>\n<p>The post-lockdown recovery has been powerful, and most developed economies have seen double-digit gross domestic product (GDP) rebounds from 2020 lows. Even so, we think the cycle is still in the recovery phase, although it is maturing. Despite strong growth, there is plenty of spare capacity. This can be seen in the employment-to-population ratio for prime-age workers in the United States. The chart below shows the ratio has recovered from the pandemic lows, but only to levels reached during the relatively mild recessions in the early 1990s and 2000s. We expect theU.S. labor-market recoveryshould still resemble a typical post-recession recovery over the next few quarters.</p>\n<p><b>U.S. EMPLOYMENT-POPULATION RATIO FOR PRIME-AGE WORKERS</b></p>\n<p><img src=\"https://static.tigerbbs.com/28a91fe2991463e2285879c32cb1b8c7\" tg-width=\"1280\" tg-height=\"982\" referrerpolicy=\"no-referrer\"></p>\n<p>The U.S. recovery, however, is more advanced than that of other developed economies. The following chart shows how far GDP has recovered, relative to the pre-COVID-19 peak in 2019. GDP is 0.8% higher in the U.S., although this level is still short relative to the pre-COVID-19 trend. GDP is 2.5% below 2019 levels in the euro area and 4.5% below in the United Kingdom. We expect more cyclical upside for economic growth outside the U.S., and this should allow market leadership to rotate toward the rest of the world.</p>\n<p><b>GDP IN Q2 2021 RELATIVE TO PRE-COVID-19 PEAK IN 2019</b></p>\n<p><img src=\"https://static.tigerbbs.com/577d1b96aef08b71c9bdb6665a21b2ac\" tg-width=\"1280\" tg-height=\"982\" referrerpolicy=\"no-referrer\"></p>\n<p><b>Two key indicators</b></p>\n<p>Last quarter, we listed two indicators that should offer a guide to the Fed’s expected reaction to the inflation spike.</p>\n<p>The first is five-year/five-year breakeven inflation expectations, based on the pricing of Treasury Inflation Protected Securities (TIPS). This is the market’s forecast for average inflation over five years in five years’ time. It tells us that investors expect inflation will average 2.17% in the five years from late 2026 to late 2031. The TIPS yields are based on the CPI, while the Fed targets inflation as measured by the personal consumption expenditure (PCE) deflator. The two move together over time, but CPI inflation is generally around 0.25% higher than PCE inflation. A breakeven rate of 2.75% would suggest the market sees PCE inflation above 2.5% in five years’ time. Market inflation expectations are currently comfortably below the Fed’s worry point.</p>\n<p><b>WATCHPOINT INDICATOR #1: U.S. 5-YEAR/5-YEAR BREAKEVEN INFLATION RATE</b></p>\n<p><img src=\"https://static.tigerbbs.com/13f3cf57b58f600fe6681e9015779e85\" tg-width=\"1280\" tg-height=\"982\" referrerpolicy=\"no-referrer\"></p>\n<p>The second indicator is the Atlanta Fed’s Wage Growth Tracker, and this has a less-comforting message about inflation risks. It reached 3.9% in August, which isclose to the 4% thresholdwhere we judge that the Fed will become concerned about the inflationary impact on the growth of wages. A breakdown shows that the spike has been mostly driven by wages for low-skilled, young people in the leisure and hospitality industry. This suggests the surge has been caused by temporary labor supply shortages and that wage pressures should subside as economic activity normalizes. This indicator, however, will be an important watchpoint over the next few months.</p>\n<p><b>WATCHPOINT INDICATOR #2: ATLANTA FED WAGE GROWTH TRACKER</b></p>\n<p><img src=\"https://static.tigerbbs.com/a1d3ff1ca26f6d29a28f919c65531c9a\" tg-width=\"1280\" tg-height=\"982\" referrerpolicy=\"no-referrer\"></p>\n<p><b>Reopening trade still makes sense</b></p>\n<p>The reopening trade, which lifts long-term interest rates and favors cyclical and value stocks over technology and growth stocks, worked well for several months following the vaccine announcement last November. Value outperformed growth and yield curves steepened. The trade has reversed in recent months, however, amid fears that the delta variant might derail the economic recovery. The impact has been magnified by short covering in bond markets as investors, who have been short or underweight, have been forced by the rally to buy back into the market, pushing bond yields even lower.</p>\n<p>The reopening trade should resume in coming months. The cyclical stocks that comprise the value factor are reporting stronger earnings upgrades than technology-heavy growth stocks, and the value factor is cheap compared to the growth factor. Financial stocks comprise the largest sector in the MSCI World Value Index, and they should benefit from further yield-curve steepening, which boosts the profitability of banks. Long-term interest rates should rise as global growth remains above trend, delta-variant fears fade, the short squeeze unwinds and central banks begin tapering back on bond purchases.</p>\n<p>The rotation in economic growth leadership away from the United States should also help the reopening trade. The rest of the world is overweight cyclical value stocks relative to the U.S., which has a higher weight to technology stocks.</p>\n<p>Emerging market (EM) equities have been poor performers since the vaccine announcement, but there are some encouraging signs. Initially, they were held back by the exposure to technology stocks in the MSCI Emerging Markets Index and the slow rollout of COVID-19 vaccines. More recently, they have come under pressure from the slowdown in the Chinese economy and theregulatory crackdown on Chinese tech companies. The vaccine rollout across emerging markets has accelerated and policy easing in China should soon improve the growth outlook. The path of Chinese regulation is harder to predict, but it is now largely priced in, with Chinese technology companies underperforming their global peers by nearly 50% from February 2021 through mid-September.</p>\n<p>The resumption of the reopening trade should also result in U.S. dollar weakness. The U.S. Dollar Index (DXY) has traded sideways since the vaccine announcement. It should weaken once investors have confidence that delta-variant risks are subsiding and realize that the Fed is likely to remain dovish as inflation risks decline. The dollar typically gains during global downturns and declines in the recovery phase. Dollar weakness should support the performance of non-U.S. markets, particularly emerging markets.</p>\n<p><b>Risks: variants, inflation, China weakness</b></p>\n<p>The key risk is that the delta variant or similar proves resilient to vaccination or that infection rates escalate during the Northern Hemisphere winter. The evidence so far is that vaccinations are highly effective in preventing serious illness. In Israel, booster shots appear to have slowed the rate of new cases.</p>\n<p>Another watchpoint is inflation and the response of central banks. Our expectation is that this year’s inflation spike is mostly transitory and that the major central banks, led by the Fed, are still two years from raising interest rates.</p>\n<p>Finally, there is the risk of a sharper-than-expected slowdown in China.Credit growth has slowed this yearand the purchasing managers’ indexes (PMI) have trended lower. Monetary and fiscal policy have been eased, however, and senior officials have signaled that more stimulus is on the way. China policy direction and credit trends will be an important watchpoint over coming months.</p>\n<p><b>Regional snapshotsUnited States</b></p>\n<p>The U.S. economy is likely to sustain above-trend growth into 2022. However, the easiest gains appear in the rear-view mirror at the end of the third quarter as the recovery phase of the business cycle matures. This is most visible for corporate earnings, where S&amp;P 500® Index earnings-per-share already sit 20% above their previous cyclical high.</p>\n<p>Strong fundamentals have helped power the stock market to new highs. Early evidence that the delta-variant wave may be fading and the potential for greater vaccine access for children are positives for a more complete recovery in the quarters ahead. The Fedlooks poised to start tapering its asset purchasesaround the end of 2021. The timing of the first rate hike will then hinge on what happens to inflation next year. Our models suggest that inflation is likely to drop back below the Fed’s 2% target in 2022. If that is correct, the Fed is likely to remain on hold into the second half of 2023.</p>\n<p>Wage inflation is a key risk to this view. It is running unusually strong for this stage of the cycle, and record hiring intentions from businesses could exhaust spare capacity in the year ahead. We expect the 10-year U.S. Treasury yield to rise moderately from 1.37% in mid-September to 1.75% in coming months.</p>\n<p>Fiscal stimulus negotiations continue to grab headlines in Washington, D.C. Thetax provisions in these billsare likely to be the most impactful for financial markets. We estimate thathigher corporate taxescould subtract about four percentage points from S&amp;P 500 earnings growth in 2022. This could create volatility and opportunity in markets. Given our strong cyclical outlook, our bias continues to be a<i>risk-on</i>preference for equities over bonds for the medium-term.</p>\n<p><b>Eurozone</b></p>\n<p>Euro area growthslowed through the third quarter but looks on track for a return to above-trend growth over the fourth quarter and into 2022. Vaccination rates are high, and the euro area has more catch-up potential than other major economies, particularly the United States. The euro area is also set to receive more fiscal support than other regions, with the European Union’s pandemic recovery fund only just starting to disburse stimulus, which will provide significant support in southern Europe. Polls in advance of Germany’s federal election on Sept. 26 suggested the electorate was moving toward the political left, which means the new government is likely to support expansionary fiscal policy and a continued dovish stance by the European Central Bank (ECB).</p>\n<p>The MSCI EMU Index, which reflects the European Economic and Monetary Union, has performed broadly in line with the S&amp;P 500 so far in 2021. We think it has potential to outperform in coming quarters. Europe’s exposure to financials and cyclically sensitive sectors such as industrials, materials and energy, and its relatively small exposure to technology, gives it the potential to outperform as delta-variant fears subside, economic activity picks up and yield curves in Europe steepen.</p>\n<p><b>United Kingdom</b></p>\n<p>As of mid-year, UK GDP was still nearly 4.5% below its pre-pandemic peak. We see plenty of scope for strong catch-up growth as borders are fully reopened and activity normalizes. Supply bottlenecks and labor shortages have triggered a sharp rise in underlying inflation and created concerns that the Bank of England (BoE) may start rate hikes in the first half of 2022. We think the BoE is unlikely to be that aggressive. We expect inflation to decline in early 2022 as supply constraints ease, which should convince the BoE to delay rate hikes.</p>\n<p>The FTSE 100 Index is the cheapest of the major developed equity markets in late 2021, and this should help it reflect higher returns than other markets over the next decade. Around 70% of UK corporate earnings come from offshore, so one near-term risk is that further strengthening of British sterling dampens earnings growth. The other risks are mostly around policy missteps, for example, early tightening by the Bank of England.</p>\n<p><b>Japan</b></p>\n<p>The Japanese economy is expected to get a shot in the arm as rising vaccination rates improve mobility and reduce the risk of further lockdowns, and as political leadership changes result in more fiscal stimulus: the Japanese election is due to be held before Nov. 28. Japanese equities look slightly more expensive than other regions such as the UK and Europe. We maintain our view that the Bank of Japan will significantly lag other central banks in normalizing policy.</p>\n<p><b>China</b></p>\n<p>We expect Chinese economic growth to berobust over the next 12 months, supported by a post-lockdown jump in consumer spending and incremental fiscal and monetary easing. Despite a big improvement in vaccination rates,COVID-19 outbreaks remain a riskgiven the Chinese government’s zero-tolerance approach. The major consumer technology companies have seen significant drops in stock prices recently due to more aggressive regulation. Some uncertainty remains around thepath of future regulation, especially as it relates to technology companies, and as a result we expect investors will remain cautious on Chinese equities in the coming months. The property market, particularly property developers as recently highlighted by Evergrande’s debt crisis, remains a risk that we are monitoring closely.</p>\n<p><b>Canada</b></p>\n<p>Canada leads the G71countries in terms of the vaccination rollout, which should minimize the risk of large-scale lockdowns over winter. The delta variant has taken an economic toll, however, with industry consensus projections now predicting 5% GDP growth in 2021 versus estimates of more than 6% just three months ago. Even so, growth remains above-trend and the odds of additional fiscal expenditures to support the economy have increased. This means that weaker growth due to COVID-19 is unlikely to change the Bank of Canada's (BoC) tightening bias.</p>\n<p>Tapering of asset purchasesshould be complete by the end of the first quarter of 2022. BoC Governor Tiff Macklem has indicated that the reinvestment phase of the bonds held by the central bank will commence once quantitative easing has ended. This should generate an estimated C$1 billion in weekly bond purchases, down from the current pace of C$2 billion. The BoC will likely only consider shrinking its balance sheet after it has started lifting interest rates. The BoC projects that the output gap will close sometime over the second half of 2022, and that rate hikes will be considered after economic slack has disappeared. We believe that the timeline may be a tad aggressive, and a delay to 2023 for liftoff is more likely. This would better align the Canadian central bank with its American counterpart.</p>\n<p><b>Australia/New Zealand</b></p>\n<p>The Australian economy is set to return to life, with lockdowns likely to be eased in October and November. Consumer and business balance sheets continue to look healthy, which should facilitate a strong recovery. The reopening of the international border in 2022 will provide a further boost. Fiscal policy has supported the economy through the downturn, and there is potential for further stimulus in the lead-up to the federal election, which is due before the end of 2022. The Reserve Bank of Australia has begun the process of tapering its bond-purchase program, but we expect that a rise in the cash rate is unlikely until at least the second half of 2023.</p>\n<p>New Zealand’s most recent lockdown will drag on Q3 GDP, but similar to Australia, we expect a solid rebound as the economy reopens. The government aims to provide a vaccine to all adults by the end of 2021, after which borders will gradually reopen. This will provide a boost, particularly to tourism-exposed sectors. Despite having recently put off hiking interest rates due to the recent lockdown, we expect the Reserve Bank of New Zealand will start raising rates this year. Even though they have significantly underperformed global equities this year, New Zealand equities still screen as relatively expensive compared to other regions.</p>\n<p><b>Asset-class preferences</b></p>\n<p>Our cycle, value and sentiment investment decision-making process in late September 2021 has a moderately positive medium-term view on global equities. Value is expensive across most markets except for UK equities, which are near fair value. The cycle is risk-asset supportive for the medium-term. The major economies still have spare capacity and inflation pressures appear transitory, caused by COVID-19-related supply shortages. Rate hikes by the U.S. Fed seem unlikely before the second half of 2023. Sentiment, after reaching overbought levels earlier in the year, has returned to more neutral levels.</p>\n<p><b>COMPOSITE CONTRARIAN INDICATOR: SENTIMENT SHIFTS TOWARD NEUTRAL</b></p>\n<p><img src=\"https://static.tigerbbs.com/5c527955abbc9e770d200c1d709f80d8\" tg-width=\"1280\" tg-height=\"982\" referrerpolicy=\"no-referrer\"></p>\n<ul>\n <li>We prefer<b>non-U.S. equities</b>to U.S. equities. Stronger economic growth and steeper yield curves after the third-quarter slowdown should favor undervalued cyclical value stocks over expensive technology and growth stocks. Relative to the U.S., the rest of the world is overweight cyclical value stocks.</li>\n <li><b>Emerging markets equities</b>have been relatively poor performers this year, but there are some encouraging signs. The vaccine rollout across EM has accelerated and policy easing in China should soon boost the economic growth outlook.China’s regulatory crackdownhas caused significant underperformance by Chinese technology companies, but this should be less of a headwind going forward now that it is priced in.</li>\n <li><b>High yield</b>and<b>investment grade credit</b>are expensive on a spread basis but have support from a positive cycle view that accommodates corporate profit growth and keeps default rates low. U.S. dollar-denominated<b>emerging markets debt</b>is close to fair value in spread terms and will gain support on U.S. dollar weakness.</li>\n <li><b>Government bonds</b>are expensive, and yields should come under upward pressure as output gaps close and central banks look to taper back asset purchases. We expect the 10-year U.S. Treasury yield to rise toward 1.75% in coming months.</li>\n <li><b>Real assets</b>: Real Estate Investment Trusts (REITs) have significantly outperformed Global Listed Infrastructure (GLI) so far this year, to the extent that REITS are now expensive relative to GLI. Both should benefit from the pandemic recovery, but GLI has some catch-up potential. GLI should benefit from the global re-opening boosting domestic and international travel.<b>Commodities</b>have been the best-performing asset class this year amid strong demand and supply bottlenecks. The gains have been led by industrial metals and energy. The pace of increase should ease as supply issues are resolved, butcommodities should retain supportfrom above-trend global demand.</li>\n <li>The<b>U.S. dollar</b>has been supported this year by expectations for early Fed tightening and U.S. economic growth leadership. It should weaken as global growth leadership rotates away from the U.S. and toward Europe and other developed economies. The dollar typically gains during global downturns and declines in the recovery phase. The main beneficiary is likely to be the<b>euro</b>, which is still undervalued. We also believe<b>British sterling</b>and the economically sensitive<i>commodity currencies</i>—the<b>Australian dollar</b>, the<b>New Zealand dollar</b>and the<b>Canadian dollar</b>—can make further gains, although these currencies are not undervalued from a longer-term perspective.</li>\n</ul>\n<p><b>ASSET PERFORMANCE SINCE THE BEGINNING OF 2021</b></p>\n<p><img src=\"https://static.tigerbbs.com/50e253becd38bd122d9fc211e7b0f583\" tg-width=\"1280\" tg-height=\"982\" referrerpolicy=\"no-referrer\"></p>\n<p>1The Group of Seven is an inter-governmental political forum consisting of Canada, France, Germany, Italy, Japan, the United Kingdom and the United States.</p>\n<p><b>Important Information</b></p>\n<p>The views in this Global Market Outlook report are subject to change at any time based upon market or other conditions and are current as of September 27, 2021. While all material is deemed to be reliable, accuracy and completeness cannot be guaranteed.</p>\n<p>Please remember that all investments carry some level of risk, including the potential loss of principal invested. They do not typically grow at an even rate of return and may experience negative growth. As with any type of portfolio structuring, attempting to reduce risk and increase return could, at certain times, unintentionally reduce returns.</p>\n<p>Keep in mind that, like all investing, multi-asset investing does not assure a profit or protect against loss.</p>\n<p>No model or group of models can offer a precise estimate of future returns available from capital markets. We remain cautious that rational analytical techniques cannot predict extremes in financial behavior, such as periods of financial euphoria or investor panic. Our models rest on the assumptions of normal and rational financial behavior. Forecasting models are inherently uncertain, subject to change at any time based on a variety of factors and can be inaccurate. Russell believes that the utility of this information is highest in evaluating the relative relationships of various components of a globally diversified portfolio. As such, the models may offer insights into the prudence of over or under weighting those components from time to time or under periods of extreme dislocation. The models are explicitly not intended as market timing signals.</p>\n<p>Forecasting represents predictions of market prices and/or volume patterns utilizing varying analytical data. It is not representative of a projection of the stock market, or of any specific investment.</p>\n<p>Investment in global, international or emerging markets may be significantly affected by political or economic conditions and regulatory requirements in a particular country. Investments in non-U.S. markets can involve risks of currency fluctuation, political and economic instability, different accounting standards and foreign taxation. Such securities may be less liquid and more volatile. Investments in emerging or developing markets involve exposure to economic structures that are generally less diverse and mature, and political systems with less stability than in more developed countries.</p>\n<p>Currency investing involves risks including fluctuations in currency values, whether the home currency or the foreign currency. They can either enhance or reduce the returns associated with foreign investments.</p>\n<p>Investments in non-U.S. markets can involve risks of currency fluctuation, political and economic instability, different accounting standards and foreign taxation.</p>\n<p>Bond investors should carefully consider risks such as interest rate, credit, default and duration risks. Greater risk, such as increased volatility, limited liquidity, prepayment, non-payment and increased default risk, is inherent in portfolios that invest in high yield (“junk”) bonds or mortgage-backed securities, especially mortgage-backed securities with exposure to sub-prime mortgages. Generally, when interest rates rise, prices of fixed income securities fall. Interest rates in the United States are at, or near, historic lows, which may increase a Fund’s exposure to risks associated with rising rates. Investment in non-U.S. and emerging market securities is subject to the risk of currency fluctuations and to economic and political risks associated with such foreign countries.</p>\n<p>Performance quoted represents past performance and should not be viewed as a guarantee of future results.</p>\n<p>The FTSE 100 Index is a market-capitalization weighted index of UK-listed blue chip companies.</p>\n<p>The S&amp;P 500® Index, or the Standard &amp; Poor’s 500, is a stock market index based on the market capitalizations of 500 large companies having common stock listed on the NYSE or NASDAQ.</p>\n<p>The MSCI EMU Index (European Economic and Monetary Union) captures large and mid cap representation across the 10 developed markets countries in the EMU. With 246 constituents, the index covers approximately 85% of the free float-adjusted market capitalization of the EMU.</p>\n<p>Indexes are unmanaged and cannot be invested in directly.</p>\n<p>Copyright © Russell Investments 2021. All rights reserved. This material is proprietary and may not be reproduced, transferred, or distributed in any form without prior written permission from Russell Investments. It is delivered on an “as is” basis without warranty.</p>\n<p>Frank Russell Company is the owner of the Russell trademarks contained in this material and all trademark rights related to the Russell trademarks, which the members of the Russell Investments group of companies are permitted to use under license from Frank Russell Company. The members of the Russell Investments group of companies are not affiliated in any manner with Frank Russell Company or any entity operating under the “FTSE RUSSELL” brand.</p>\n<p>Products and services described on this website are intended for<b>United States residents only</b>. Nothing contained in this material is intended to constitute legal, tax, securities, or investment advice, nor an opinion regarding the appropriateness of any investment, nor a solicitation of any type. The general information contained on this website should not be acted upon without obtaining specific legal, tax, and investment advice from a licensed professional. Persons outside the United States may find more information about products and services available within their jurisdictions by going to Russell Investments' Worldwide site.</p>\n<p>Russell Investments is committed to ensuring digital accessibility for people with disabilities. We are continually improving the user experience for everyone, and applying the relevant accessibility standards.</p>\n<p>Russell Investments' ownership is composed of a majority stake held by funds managed by TA Associates, with a significant minority stake held by funds managed by Reverence Capital Partners. Russell Investments' employees and Hamilton Lane Advisors, LLC also hold minority, non-controlling, ownership stakes.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2021 Global Market Outlook - Q4 Update: Growing Pains</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2021 Global Market Outlook - Q4 Update: Growing Pains\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-30 09:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4457651-2021-global-market-outlook-q4-update-growing-pains><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Summary\n\nThe post-lockdown recovery has been powerful, and most developed economies have seen double-digit gross domestic product (GDP) rebounds from 2020 lows.\nThe reopening trade should resume in ...</p>\n\n<a href=\"https://seekingalpha.com/article/4457651-2021-global-market-outlook-q4-update-growing-pains\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SPY":"标普500ETF",".DJI":"道琼斯",".SPX":"S&P 500 Index",".IXIC":"NASDAQ Composite"},"source_url":"https://seekingalpha.com/article/4457651-2021-global-market-outlook-q4-update-growing-pains","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1104172212","content_text":"Summary\n\nThe post-lockdown recovery has been powerful, and most developed economies have seen double-digit gross domestic product (GDP) rebounds from 2020 lows.\nThe reopening trade should resume in coming months. The cyclical stocks that comprise the value factor are reporting stronger earnings upgrades than technology-heavy growth stocks, and the value factor is cheap compared to the growth factor.\nThe key risk is that the delta variant or similar proves resilient to vaccination or that infection rates escalate during the Northern Hemisphere winter.\n\nThe COVID-19 delta variant, inflation and central bank tapering are unnerving investors. We expect the pandemic-recovery trade to resume as inflation subsides, infection rates decline and tapering turns out to not equal tightening. Amid this backdrop, our outlook favors equities over bonds, the value factor over the growth factor and non-U.S. stocks over U.S. stocks.\nIntroduction\nThe post-lockdown recovery has transitioned from energetic youthfulness to awkward adolescence. It’s still growing, although at a slower pace, and there are worries about what happens next, particularly about monetary policy and the outlook for inflation. Theinflation spikehas been larger than expected, but we still think it istransitory, caused by base effects from when the U.S. consumer price index (CPI) fell during the lockdown last year and by temporary supply bottlenecks. Inflation may remain high over the remainder of 2021 but should decline in early 2022. This means that even though the U.S. Federal Reserve (Fed) is likely to begin tapering back on asset purchases before the end of the year, rate hikes are unlikely before the second half of 2023.\nAnother worry is thehighly contagious COVID-19 delta variant. The evidence so far is that vaccines are effective in preventing serious COVID-19 infections. Vaccination rates are accelerating globally, and emerging economies are catching up with developed markets. Infection rates appear to have peaked globally in early September. This means the reopening of economies should continue over the remainder of 2021. The onset of winter in the northern hemisphere will be a test, but the rollout of booster vaccination shots should help prevent widescale renewed lockdowns.\nThe conclusions from our cycle, value and sentiment (CVS) investment decision-making process are broadly unchanged from our previous quarterly report. Global equities remain expensive, with the very expensive U.S. market offsetting better value elsewhere. Sentiment is slightly overbought, but not close to dangerous levels of euphoria. The strong cycle delivers a preference for equities over bonds for at least the next 12 months, despite expensive valuations. It also reinforces our preference for thevalue equity factor over the growth factorand for non-U.S. equities to outperform the U.S. market.\nCycle still in recovery phase\nThe post-lockdown recovery has been powerful, and most developed economies have seen double-digit gross domestic product (GDP) rebounds from 2020 lows. Even so, we think the cycle is still in the recovery phase, although it is maturing. Despite strong growth, there is plenty of spare capacity. This can be seen in the employment-to-population ratio for prime-age workers in the United States. The chart below shows the ratio has recovered from the pandemic lows, but only to levels reached during the relatively mild recessions in the early 1990s and 2000s. We expect theU.S. labor-market recoveryshould still resemble a typical post-recession recovery over the next few quarters.\nU.S. EMPLOYMENT-POPULATION RATIO FOR PRIME-AGE WORKERS\n\nThe U.S. recovery, however, is more advanced than that of other developed economies. The following chart shows how far GDP has recovered, relative to the pre-COVID-19 peak in 2019. GDP is 0.8% higher in the U.S., although this level is still short relative to the pre-COVID-19 trend. GDP is 2.5% below 2019 levels in the euro area and 4.5% below in the United Kingdom. We expect more cyclical upside for economic growth outside the U.S., and this should allow market leadership to rotate toward the rest of the world.\nGDP IN Q2 2021 RELATIVE TO PRE-COVID-19 PEAK IN 2019\n\nTwo key indicators\nLast quarter, we listed two indicators that should offer a guide to the Fed’s expected reaction to the inflation spike.\nThe first is five-year/five-year breakeven inflation expectations, based on the pricing of Treasury Inflation Protected Securities (TIPS). This is the market’s forecast for average inflation over five years in five years’ time. It tells us that investors expect inflation will average 2.17% in the five years from late 2026 to late 2031. The TIPS yields are based on the CPI, while the Fed targets inflation as measured by the personal consumption expenditure (PCE) deflator. The two move together over time, but CPI inflation is generally around 0.25% higher than PCE inflation. A breakeven rate of 2.75% would suggest the market sees PCE inflation above 2.5% in five years’ time. Market inflation expectations are currently comfortably below the Fed’s worry point.\nWATCHPOINT INDICATOR #1: U.S. 5-YEAR/5-YEAR BREAKEVEN INFLATION RATE\n\nThe second indicator is the Atlanta Fed’s Wage Growth Tracker, and this has a less-comforting message about inflation risks. It reached 3.9% in August, which isclose to the 4% thresholdwhere we judge that the Fed will become concerned about the inflationary impact on the growth of wages. A breakdown shows that the spike has been mostly driven by wages for low-skilled, young people in the leisure and hospitality industry. This suggests the surge has been caused by temporary labor supply shortages and that wage pressures should subside as economic activity normalizes. This indicator, however, will be an important watchpoint over the next few months.\nWATCHPOINT INDICATOR #2: ATLANTA FED WAGE GROWTH TRACKER\n\nReopening trade still makes sense\nThe reopening trade, which lifts long-term interest rates and favors cyclical and value stocks over technology and growth stocks, worked well for several months following the vaccine announcement last November. Value outperformed growth and yield curves steepened. The trade has reversed in recent months, however, amid fears that the delta variant might derail the economic recovery. The impact has been magnified by short covering in bond markets as investors, who have been short or underweight, have been forced by the rally to buy back into the market, pushing bond yields even lower.\nThe reopening trade should resume in coming months. The cyclical stocks that comprise the value factor are reporting stronger earnings upgrades than technology-heavy growth stocks, and the value factor is cheap compared to the growth factor. Financial stocks comprise the largest sector in the MSCI World Value Index, and they should benefit from further yield-curve steepening, which boosts the profitability of banks. Long-term interest rates should rise as global growth remains above trend, delta-variant fears fade, the short squeeze unwinds and central banks begin tapering back on bond purchases.\nThe rotation in economic growth leadership away from the United States should also help the reopening trade. The rest of the world is overweight cyclical value stocks relative to the U.S., which has a higher weight to technology stocks.\nEmerging market (EM) equities have been poor performers since the vaccine announcement, but there are some encouraging signs. Initially, they were held back by the exposure to technology stocks in the MSCI Emerging Markets Index and the slow rollout of COVID-19 vaccines. More recently, they have come under pressure from the slowdown in the Chinese economy and theregulatory crackdown on Chinese tech companies. The vaccine rollout across emerging markets has accelerated and policy easing in China should soon improve the growth outlook. The path of Chinese regulation is harder to predict, but it is now largely priced in, with Chinese technology companies underperforming their global peers by nearly 50% from February 2021 through mid-September.\nThe resumption of the reopening trade should also result in U.S. dollar weakness. The U.S. Dollar Index (DXY) has traded sideways since the vaccine announcement. It should weaken once investors have confidence that delta-variant risks are subsiding and realize that the Fed is likely to remain dovish as inflation risks decline. The dollar typically gains during global downturns and declines in the recovery phase. Dollar weakness should support the performance of non-U.S. markets, particularly emerging markets.\nRisks: variants, inflation, China weakness\nThe key risk is that the delta variant or similar proves resilient to vaccination or that infection rates escalate during the Northern Hemisphere winter. The evidence so far is that vaccinations are highly effective in preventing serious illness. In Israel, booster shots appear to have slowed the rate of new cases.\nAnother watchpoint is inflation and the response of central banks. Our expectation is that this year’s inflation spike is mostly transitory and that the major central banks, led by the Fed, are still two years from raising interest rates.\nFinally, there is the risk of a sharper-than-expected slowdown in China.Credit growth has slowed this yearand the purchasing managers’ indexes (PMI) have trended lower. Monetary and fiscal policy have been eased, however, and senior officials have signaled that more stimulus is on the way. China policy direction and credit trends will be an important watchpoint over coming months.\nRegional snapshotsUnited States\nThe U.S. economy is likely to sustain above-trend growth into 2022. However, the easiest gains appear in the rear-view mirror at the end of the third quarter as the recovery phase of the business cycle matures. This is most visible for corporate earnings, where S&P 500® Index earnings-per-share already sit 20% above their previous cyclical high.\nStrong fundamentals have helped power the stock market to new highs. Early evidence that the delta-variant wave may be fading and the potential for greater vaccine access for children are positives for a more complete recovery in the quarters ahead. The Fedlooks poised to start tapering its asset purchasesaround the end of 2021. The timing of the first rate hike will then hinge on what happens to inflation next year. Our models suggest that inflation is likely to drop back below the Fed’s 2% target in 2022. If that is correct, the Fed is likely to remain on hold into the second half of 2023.\nWage inflation is a key risk to this view. It is running unusually strong for this stage of the cycle, and record hiring intentions from businesses could exhaust spare capacity in the year ahead. We expect the 10-year U.S. Treasury yield to rise moderately from 1.37% in mid-September to 1.75% in coming months.\nFiscal stimulus negotiations continue to grab headlines in Washington, D.C. Thetax provisions in these billsare likely to be the most impactful for financial markets. We estimate thathigher corporate taxescould subtract about four percentage points from S&P 500 earnings growth in 2022. This could create volatility and opportunity in markets. Given our strong cyclical outlook, our bias continues to be arisk-onpreference for equities over bonds for the medium-term.\nEurozone\nEuro area growthslowed through the third quarter but looks on track for a return to above-trend growth over the fourth quarter and into 2022. Vaccination rates are high, and the euro area has more catch-up potential than other major economies, particularly the United States. The euro area is also set to receive more fiscal support than other regions, with the European Union’s pandemic recovery fund only just starting to disburse stimulus, which will provide significant support in southern Europe. Polls in advance of Germany’s federal election on Sept. 26 suggested the electorate was moving toward the political left, which means the new government is likely to support expansionary fiscal policy and a continued dovish stance by the European Central Bank (ECB).\nThe MSCI EMU Index, which reflects the European Economic and Monetary Union, has performed broadly in line with the S&P 500 so far in 2021. We think it has potential to outperform in coming quarters. Europe’s exposure to financials and cyclically sensitive sectors such as industrials, materials and energy, and its relatively small exposure to technology, gives it the potential to outperform as delta-variant fears subside, economic activity picks up and yield curves in Europe steepen.\nUnited Kingdom\nAs of mid-year, UK GDP was still nearly 4.5% below its pre-pandemic peak. We see plenty of scope for strong catch-up growth as borders are fully reopened and activity normalizes. Supply bottlenecks and labor shortages have triggered a sharp rise in underlying inflation and created concerns that the Bank of England (BoE) may start rate hikes in the first half of 2022. We think the BoE is unlikely to be that aggressive. We expect inflation to decline in early 2022 as supply constraints ease, which should convince the BoE to delay rate hikes.\nThe FTSE 100 Index is the cheapest of the major developed equity markets in late 2021, and this should help it reflect higher returns than other markets over the next decade. Around 70% of UK corporate earnings come from offshore, so one near-term risk is that further strengthening of British sterling dampens earnings growth. The other risks are mostly around policy missteps, for example, early tightening by the Bank of England.\nJapan\nThe Japanese economy is expected to get a shot in the arm as rising vaccination rates improve mobility and reduce the risk of further lockdowns, and as political leadership changes result in more fiscal stimulus: the Japanese election is due to be held before Nov. 28. Japanese equities look slightly more expensive than other regions such as the UK and Europe. We maintain our view that the Bank of Japan will significantly lag other central banks in normalizing policy.\nChina\nWe expect Chinese economic growth to berobust over the next 12 months, supported by a post-lockdown jump in consumer spending and incremental fiscal and monetary easing. Despite a big improvement in vaccination rates,COVID-19 outbreaks remain a riskgiven the Chinese government’s zero-tolerance approach. The major consumer technology companies have seen significant drops in stock prices recently due to more aggressive regulation. Some uncertainty remains around thepath of future regulation, especially as it relates to technology companies, and as a result we expect investors will remain cautious on Chinese equities in the coming months. The property market, particularly property developers as recently highlighted by Evergrande’s debt crisis, remains a risk that we are monitoring closely.\nCanada\nCanada leads the G71countries in terms of the vaccination rollout, which should minimize the risk of large-scale lockdowns over winter. The delta variant has taken an economic toll, however, with industry consensus projections now predicting 5% GDP growth in 2021 versus estimates of more than 6% just three months ago. Even so, growth remains above-trend and the odds of additional fiscal expenditures to support the economy have increased. This means that weaker growth due to COVID-19 is unlikely to change the Bank of Canada's (BoC) tightening bias.\nTapering of asset purchasesshould be complete by the end of the first quarter of 2022. BoC Governor Tiff Macklem has indicated that the reinvestment phase of the bonds held by the central bank will commence once quantitative easing has ended. This should generate an estimated C$1 billion in weekly bond purchases, down from the current pace of C$2 billion. The BoC will likely only consider shrinking its balance sheet after it has started lifting interest rates. The BoC projects that the output gap will close sometime over the second half of 2022, and that rate hikes will be considered after economic slack has disappeared. We believe that the timeline may be a tad aggressive, and a delay to 2023 for liftoff is more likely. This would better align the Canadian central bank with its American counterpart.\nAustralia/New Zealand\nThe Australian economy is set to return to life, with lockdowns likely to be eased in October and November. Consumer and business balance sheets continue to look healthy, which should facilitate a strong recovery. The reopening of the international border in 2022 will provide a further boost. Fiscal policy has supported the economy through the downturn, and there is potential for further stimulus in the lead-up to the federal election, which is due before the end of 2022. The Reserve Bank of Australia has begun the process of tapering its bond-purchase program, but we expect that a rise in the cash rate is unlikely until at least the second half of 2023.\nNew Zealand’s most recent lockdown will drag on Q3 GDP, but similar to Australia, we expect a solid rebound as the economy reopens. The government aims to provide a vaccine to all adults by the end of 2021, after which borders will gradually reopen. This will provide a boost, particularly to tourism-exposed sectors. Despite having recently put off hiking interest rates due to the recent lockdown, we expect the Reserve Bank of New Zealand will start raising rates this year. Even though they have significantly underperformed global equities this year, New Zealand equities still screen as relatively expensive compared to other regions.\nAsset-class preferences\nOur cycle, value and sentiment investment decision-making process in late September 2021 has a moderately positive medium-term view on global equities. Value is expensive across most markets except for UK equities, which are near fair value. The cycle is risk-asset supportive for the medium-term. The major economies still have spare capacity and inflation pressures appear transitory, caused by COVID-19-related supply shortages. Rate hikes by the U.S. Fed seem unlikely before the second half of 2023. Sentiment, after reaching overbought levels earlier in the year, has returned to more neutral levels.\nCOMPOSITE CONTRARIAN INDICATOR: SENTIMENT SHIFTS TOWARD NEUTRAL\n\n\nWe prefernon-U.S. equitiesto U.S. equities. Stronger economic growth and steeper yield curves after the third-quarter slowdown should favor undervalued cyclical value stocks over expensive technology and growth stocks. Relative to the U.S., the rest of the world is overweight cyclical value stocks.\nEmerging markets equitieshave been relatively poor performers this year, but there are some encouraging signs. The vaccine rollout across EM has accelerated and policy easing in China should soon boost the economic growth outlook.China’s regulatory crackdownhas caused significant underperformance by Chinese technology companies, but this should be less of a headwind going forward now that it is priced in.\nHigh yieldandinvestment grade creditare expensive on a spread basis but have support from a positive cycle view that accommodates corporate profit growth and keeps default rates low. U.S. dollar-denominatedemerging markets debtis close to fair value in spread terms and will gain support on U.S. dollar weakness.\nGovernment bondsare expensive, and yields should come under upward pressure as output gaps close and central banks look to taper back asset purchases. We expect the 10-year U.S. Treasury yield to rise toward 1.75% in coming months.\nReal assets: Real Estate Investment Trusts (REITs) have significantly outperformed Global Listed Infrastructure (GLI) so far this year, to the extent that REITS are now expensive relative to GLI. Both should benefit from the pandemic recovery, but GLI has some catch-up potential. GLI should benefit from the global re-opening boosting domestic and international travel.Commoditieshave been the best-performing asset class this year amid strong demand and supply bottlenecks. The gains have been led by industrial metals and energy. The pace of increase should ease as supply issues are resolved, butcommodities should retain supportfrom above-trend global demand.\nTheU.S. dollarhas been supported this year by expectations for early Fed tightening and U.S. economic growth leadership. It should weaken as global growth leadership rotates away from the U.S. and toward Europe and other developed economies. The dollar typically gains during global downturns and declines in the recovery phase. The main beneficiary is likely to be theeuro, which is still undervalued. We also believeBritish sterlingand the economically sensitivecommodity currencies—theAustralian dollar, theNew Zealand dollarand theCanadian dollar—can make further gains, although these currencies are not undervalued from a longer-term perspective.\n\nASSET PERFORMANCE SINCE THE BEGINNING OF 2021\n\n1The Group of Seven is an inter-governmental political forum consisting of Canada, France, Germany, Italy, Japan, the United Kingdom and the United States.\nImportant Information\nThe views in this Global Market Outlook report are subject to change at any time based upon market or other conditions and are current as of September 27, 2021. While all material is deemed to be reliable, accuracy and completeness cannot be guaranteed.\nPlease remember that all investments carry some level of risk, including the potential loss of principal invested. They do not typically grow at an even rate of return and may experience negative growth. As with any type of portfolio structuring, attempting to reduce risk and increase return could, at certain times, unintentionally reduce returns.\nKeep in mind that, like all investing, multi-asset investing does not assure a profit or protect against loss.\nNo model or group of models can offer a precise estimate of future returns available from capital markets. We remain cautious that rational analytical techniques cannot predict extremes in financial behavior, such as periods of financial euphoria or investor panic. Our models rest on the assumptions of normal and rational financial behavior. Forecasting models are inherently uncertain, subject to change at any time based on a variety of factors and can be inaccurate. Russell believes that the utility of this information is highest in evaluating the relative relationships of various components of a globally diversified portfolio. As such, the models may offer insights into the prudence of over or under weighting those components from time to time or under periods of extreme dislocation. The models are explicitly not intended as market timing signals.\nForecasting represents predictions of market prices and/or volume patterns utilizing varying analytical data. It is not representative of a projection of the stock market, or of any specific investment.\nInvestment in global, international or emerging markets may be significantly affected by political or economic conditions and regulatory requirements in a particular country. Investments in non-U.S. markets can involve risks of currency fluctuation, political and economic instability, different accounting standards and foreign taxation. Such securities may be less liquid and more volatile. Investments in emerging or developing markets involve exposure to economic structures that are generally less diverse and mature, and political systems with less stability than in more developed countries.\nCurrency investing involves risks including fluctuations in currency values, whether the home currency or the foreign currency. They can either enhance or reduce the returns associated with foreign investments.\nInvestments in non-U.S. markets can involve risks of currency fluctuation, political and economic instability, different accounting standards and foreign taxation.\nBond investors should carefully consider risks such as interest rate, credit, default and duration risks. Greater risk, such as increased volatility, limited liquidity, prepayment, non-payment and increased default risk, is inherent in portfolios that invest in high yield (“junk”) bonds or mortgage-backed securities, especially mortgage-backed securities with exposure to sub-prime mortgages. Generally, when interest rates rise, prices of fixed income securities fall. Interest rates in the United States are at, or near, historic lows, which may increase a Fund’s exposure to risks associated with rising rates. Investment in non-U.S. and emerging market securities is subject to the risk of currency fluctuations and to economic and political risks associated with such foreign countries.\nPerformance quoted represents past performance and should not be viewed as a guarantee of future results.\nThe FTSE 100 Index is a market-capitalization weighted index of UK-listed blue chip companies.\nThe S&P 500® Index, or the Standard & Poor’s 500, is a stock market index based on the market capitalizations of 500 large companies having common stock listed on the NYSE or NASDAQ.\nThe MSCI EMU Index (European Economic and Monetary Union) captures large and mid cap representation across the 10 developed markets countries in the EMU. With 246 constituents, the index covers approximately 85% of the free float-adjusted market capitalization of the EMU.\nIndexes are unmanaged and cannot be invested in directly.\nCopyright © Russell Investments 2021. All rights reserved. This material is proprietary and may not be reproduced, transferred, or distributed in any form without prior written permission from Russell Investments. It is delivered on an “as is” basis without warranty.\nFrank Russell Company is the owner of the Russell trademarks contained in this material and all trademark rights related to the Russell trademarks, which the members of the Russell Investments group of companies are permitted to use under license from Frank Russell Company. The members of the Russell Investments group of companies are not affiliated in any manner with Frank Russell Company or any entity operating under the “FTSE RUSSELL” brand.\nProducts and services described on this website are intended forUnited States residents only. Nothing contained in this material is intended to constitute legal, tax, securities, or investment advice, nor an opinion regarding the appropriateness of any investment, nor a solicitation of any type. The general information contained on this website should not be acted upon without obtaining specific legal, tax, and investment advice from a licensed professional. Persons outside the United States may find more information about products and services available within their jurisdictions by going to Russell Investments' Worldwide site.\nRussell Investments is committed to ensuring digital accessibility for people with disabilities. We are continually improving the user experience for everyone, and applying the relevant accessibility standards.\nRussell Investments' ownership is composed of a majority stake held by funds managed by TA Associates, with a significant minority stake held by funds managed by Reverence Capital Partners. Russell Investments' employees and Hamilton Lane Advisors, LLC also hold minority, non-controlling, ownership stakes.","news_type":1},"isVote":1,"tweetType":1,"viewCount":85,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":696931071,"gmtCreate":1640593493923,"gmtModify":1640593494254,"author":{"id":"3554895157968981","authorId":"3554895157968981","name":"canoboi","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like and comment thanks","listText":"Like and comment thanks","text":"Like and comment thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/696931071","repostId":"2194177239","repostType":4,"repost":{"id":"2194177239","pubTimestamp":1640559609,"share":"https://www.laohu8.com/m/news/2194177239?lang=&edition=full","pubTime":"2021-12-27 07:00","market":"us","language":"en","title":"Santa Claus Rally watch: What to know this week","url":"https://stock-news.laohu8.com/highlight/detail?id=2194177239","media":"Yahoo Finance","summary":"As traders return from the holiday-shortened week, the price action heading into the new year will be closely monitored — especially given the relatively light economic data and earnings calendar for the coming days.The S&P 500  is entering the period known for ushering in the so-called Santa Claus Rally, or seasonally strong timeframe for stocks at the end of each year.According to data from LPL Financial, the Santa Claus Rally period encapsulates the seven days most likely to be higher in any ","content":"<p>As traders return from the holiday-shortened week, the price action heading into the new year will be closely monitored — especially given the relatively light economic data and earnings calendar for the coming days.</p>\n<p>The S&amp;P 500 (^GSPC) is entering the period known for ushering in the so-called Santa Claus Rally, or seasonally strong timeframe for stocks at the end of each year.</p>\n<p>The term, coined by Stock Trader's Almanac in the 1970s, encompasses the final five trading days of the year and first two sessions of the new year. This year, that Santa Claus Rally window is set to start on Monday, Dec. 27 — or the latest a Santa Claus rally has started in 11 years, due to the timing of the holidays this year.</p>\n<p>According to data from LPL Financial, the Santa Claus Rally period encapsulates the seven days most likely to be higher in any given year. Since 1950, the Santa Claus Rally period has produced a positive return for the S&amp;P 500 78.9% of the time, with an average return of 1.33%.</p>\n<p>“Why are these seven days so strong?” wrote Ryan Detrick, LPL Financial chief market strategist, in a note. “Whether optimism over a coming new year, holiday spending, traders on vacation, institutions squaring up their books — or the holiday spirit — the bottom line is that bulls tend to believe in Santa.”</p>\n<p>And if history is any indication, the absence of a Santa Claus Rally has also typically served as a harbinger of lower near-term returns.</p>\n<p>\"Going back to the mid-1990s, there have been only six times Santa failed to show in December. January was lower five of those six times, and the full year had a solid gain only once (in 2016, but a mini-bear market early in the year),\" Detrick added.</p>\n<p>“Considering the bear markets of 2000 and 2008 both took place after <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the rare instances that Santa failed to show makes believers out of us,\" he said. A bear market typically refers to when stocks drop at least 20% from recent record highs. \"Should this seasonally strong period miss the mark, it could be a warning sign.\"</p>\n<p>And this year, investors do have considerable additional concerns to mull heading into the new year. Though stocks closed out Thursday's session at fresh record highs before the long holiday weekend, December still marked a volatile month to start, with renewed concerns over the Omicron variant and the potential for tighter monetary policy from the Federal Reserve weighing on risk assets. Plus, prospects for more near-term fiscal support via the Biden administration's Build Back Better bill have dwindled, and inflation concerns spiked further. Last week, the Bureau of Economic Analysis reported core personal consumption expenditures (PCE) — the Fed's preferred inflation gauge — rose at a 4.7% year-over-year clip, or the fastest since 1983.</p>\n<p>\"If the U.S. was not battling the Omicron variant, U.S. stocks would be dancing higher as the Santa Claus Rally would have kept the climb going into uncharted territory,\" Edward Moya, chief market strategist at OANDA, wrote in a note last week. \"It is too early to say for sure if we will get a Santa Claus Rally, but given all the short-term risks of Fed tightening, Chinese weakness, fiscal support uncertainty and COVID, Wall Street is not complaining.\"</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1279eeacff5d764e6ff5b3e8f7a24f49\" tg-width=\"4000\" tg-height=\"2667\" referrerpolicy=\"no-referrer\"><span>A man in a Santa Claus costume gestures on the floor at the closing bell of the Dow Industrial Average at the New York Stock Exchange on December 5, 2019 in New York. (Photo by Bryan R. Smith / AFP) (Photo by BRYAN R. SMITH/AFP via Getty Images)BRYAN R. SMITH via Getty Images</span></p>\n<h2>Economic calendar</h2>\n<ul>\n <li><p><b>Monday: </b>Dallas Federal Reserve Manufacturing Activity Index, Dec. (13.0 expected, 11.8 in November)</p></li>\n <li><p><b>Tuesday: </b>FHFA House Price Index, month-over-month, October (0.9% in September); S&amp;P <a href=\"https://laohu8.com/S/CLGX\">CoreLogic</a> Case-Shiller 20 City Composite Index, month-over-month, October (0.9% expected, 0.96% in September); S&amp;P CoreLogic Case-Shiller 20 City Composite Index, year-over-year, October (18.6%. expected, 19.05% in September); S&amp;P CoreLogic Case-Shiller Home Price Index, year-over-year, November (19.51% in October); Richmond Fed Manufacturing Index, December (11 expected,11 in November)</p></li>\n <li><p><b>Wednesday: </b>Wholesale Inventories, month-over-month, November preliminary (1.7% expected, 2.3% in October); Advance Goods Trade Balance, November (-$89.0 billion expected, -$82.9 billion in October); Retail Inventories, month-over-month, November (0.5% expected, 0.1% in October); Pending Home Sales, month-over-month, November (0.5% expected, 7.5% in October)</p></li>\n <li><p><b>Thursday: </b>Initial jobless claims, week ended Dec. 25. (205,000 during prior week); Continuing claims, week ended Dec. 18 (1.859 million during prior week); MNI Chicago PMI, December (62.2 expected, 61.8 in November)</p></li>\n <li><p><b>Friday: </b><i>No notable reports scheduled for release</i></p></li>\n</ul>\n<h2>Earnings calendar</h2>\n<ul>\n <li><p><b>Monday: </b><i>No notable reports scheduled for release</i></p></li>\n <li><p><b>Tuesday: </b><i>No notable reports scheduled for release</i></p></li>\n <li><p><b>Wednesday: </b>FuelCell Energy Inc. (FCEL) before market open</p></li>\n <li><p><b>Thursday: </b><i>No notable reports scheduled for release</i></p></li>\n <li><p><b>Friday: </b><i>No notable reports scheduled for release</i></p></li>\n</ul>","source":"yahoofinance_au","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Santa Claus Rally watch: What to know this week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSanta Claus Rally watch: What to know this week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-27 07:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/santa-claus-rally-watch-what-to-know-this-week-142909627.html><strong>Yahoo Finance</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>As traders return from the holiday-shortened week, the price action heading into the new year will be closely monitored — especially given the relatively light economic data and earnings calendar for ...</p>\n\n<a href=\"https://finance.yahoo.com/news/santa-claus-rally-watch-what-to-know-this-week-142909627.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4096":"电气部件与设备","BK4541":"氢能源","SPY.AU":"SPDR® S&P 500® ETF Trust","FCEL":"燃料电池能源"},"source_url":"https://finance.yahoo.com/news/santa-claus-rally-watch-what-to-know-this-week-142909627.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2194177239","content_text":"As traders return from the holiday-shortened week, the price action heading into the new year will be closely monitored — especially given the relatively light economic data and earnings calendar for the coming days.\nThe S&P 500 (^GSPC) is entering the period known for ushering in the so-called Santa Claus Rally, or seasonally strong timeframe for stocks at the end of each year.\nThe term, coined by Stock Trader's Almanac in the 1970s, encompasses the final five trading days of the year and first two sessions of the new year. This year, that Santa Claus Rally window is set to start on Monday, Dec. 27 — or the latest a Santa Claus rally has started in 11 years, due to the timing of the holidays this year.\nAccording to data from LPL Financial, the Santa Claus Rally period encapsulates the seven days most likely to be higher in any given year. Since 1950, the Santa Claus Rally period has produced a positive return for the S&P 500 78.9% of the time, with an average return of 1.33%.\n“Why are these seven days so strong?” wrote Ryan Detrick, LPL Financial chief market strategist, in a note. “Whether optimism over a coming new year, holiday spending, traders on vacation, institutions squaring up their books — or the holiday spirit — the bottom line is that bulls tend to believe in Santa.”\nAnd if history is any indication, the absence of a Santa Claus Rally has also typically served as a harbinger of lower near-term returns.\n\"Going back to the mid-1990s, there have been only six times Santa failed to show in December. January was lower five of those six times, and the full year had a solid gain only once (in 2016, but a mini-bear market early in the year),\" Detrick added.\n“Considering the bear markets of 2000 and 2008 both took place after one of the rare instances that Santa failed to show makes believers out of us,\" he said. A bear market typically refers to when stocks drop at least 20% from recent record highs. \"Should this seasonally strong period miss the mark, it could be a warning sign.\"\nAnd this year, investors do have considerable additional concerns to mull heading into the new year. Though stocks closed out Thursday's session at fresh record highs before the long holiday weekend, December still marked a volatile month to start, with renewed concerns over the Omicron variant and the potential for tighter monetary policy from the Federal Reserve weighing on risk assets. Plus, prospects for more near-term fiscal support via the Biden administration's Build Back Better bill have dwindled, and inflation concerns spiked further. Last week, the Bureau of Economic Analysis reported core personal consumption expenditures (PCE) — the Fed's preferred inflation gauge — rose at a 4.7% year-over-year clip, or the fastest since 1983.\n\"If the U.S. was not battling the Omicron variant, U.S. stocks would be dancing higher as the Santa Claus Rally would have kept the climb going into uncharted territory,\" Edward Moya, chief market strategist at OANDA, wrote in a note last week. \"It is too early to say for sure if we will get a Santa Claus Rally, but given all the short-term risks of Fed tightening, Chinese weakness, fiscal support uncertainty and COVID, Wall Street is not complaining.\"\nA man in a Santa Claus costume gestures on the floor at the closing bell of the Dow Industrial Average at the New York Stock Exchange on December 5, 2019 in New York. (Photo by Bryan R. Smith / AFP) (Photo by BRYAN R. SMITH/AFP via Getty Images)BRYAN R. SMITH via Getty Images\nEconomic calendar\n\nMonday: Dallas Federal Reserve Manufacturing Activity Index, Dec. (13.0 expected, 11.8 in November)\nTuesday: FHFA House Price Index, month-over-month, October (0.9% in September); S&P CoreLogic Case-Shiller 20 City Composite Index, month-over-month, October (0.9% expected, 0.96% in September); S&P CoreLogic Case-Shiller 20 City Composite Index, year-over-year, October (18.6%. expected, 19.05% in September); S&P CoreLogic Case-Shiller Home Price Index, year-over-year, November (19.51% in October); Richmond Fed Manufacturing Index, December (11 expected,11 in November)\nWednesday: Wholesale Inventories, month-over-month, November preliminary (1.7% expected, 2.3% in October); Advance Goods Trade Balance, November (-$89.0 billion expected, -$82.9 billion in October); Retail Inventories, month-over-month, November (0.5% expected, 0.1% in October); Pending Home Sales, month-over-month, November (0.5% expected, 7.5% in October)\nThursday: Initial jobless claims, week ended Dec. 25. (205,000 during prior week); Continuing claims, week ended Dec. 18 (1.859 million during prior week); MNI Chicago PMI, December (62.2 expected, 61.8 in November)\nFriday: No notable reports scheduled for release\n\nEarnings calendar\n\nMonday: No notable reports scheduled for release\nTuesday: No notable reports scheduled for release\nWednesday: FuelCell Energy Inc. (FCEL) before market open\nThursday: No notable reports scheduled for release\nFriday: No notable reports scheduled for release","news_type":1},"isVote":1,"tweetType":1,"viewCount":727,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":873934049,"gmtCreate":1636827206365,"gmtModify":1636827206466,"author":{"id":"3554895157968981","authorId":"3554895157968981","name":"canoboi","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/873934049","repostId":"1102251183","repostType":4,"repost":{"id":"1102251183","pubTimestamp":1636772424,"share":"https://www.laohu8.com/m/news/1102251183?lang=&edition=full","pubTime":"2021-11-13 11:00","market":"us","language":"en","title":"Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.","url":"https://stock-news.laohu8.com/highlight/detail?id=1102251183","media":"Barrons","summary":"Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Mo","content":"<p>Pfizer’s&nbsp;chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that its Covid-19 antiviral had cut the risk of hospitalization by 89% in high-risk adults.</p>\n<p>“It can’t be just a random thing, that you’re able to beat this type of world record and get a grand slam at the same time by chance,” Dolsten said, scrambling sports metaphors as he sought to illustrate the magnitude of Pfizer’s twin wins: the development of a stunningly effective Covid-19 vaccine in just 10 months, followed a year later by the development of a similarly stunning Covid-19 antiviral.</p>\n<p>Two years ago, Pfizer (ticker: PFE) CEO Albert Bourla asked investors to take a big gamble on the research-and-development operation that Dolsten has rebuilt over the course of more than a decade. That bet is looking smarter than ever.</p>\n<p>Bourla has gotten rid of Pfizer’s off-patent drugs division and the last of its consumer health products, leaving behind a pure-play biopharma company that will live or die on the strength of Dolsten’s science.</p>\n<p>In a cover story in November 2019, <i>Barron’s</i> argued that Bourla and Dolsten could pull it off.</p>\n<p>The new antiviral data reaffirms the case for Pfizer that <i>Barron’s</i> made two years ago. Continuing to profit off the pandemic, however, brings new risks, as criticism grows over the global inequity in vaccine distribution. Low-income nations account for less than 1% of the more than seven billion doses administered worldwide. If distribution of Pfizer’s antiviral continues to favor wealthy nations, the company’s stock could ultimately suffer.</p>\n<p>Pfizer’s shares surged 10.9% the day the data came out, their best daily showing in at least 20 years. Still, with the stock now changing hands at around $50, investors continue to undervalue the company. Investors are pricing Pfizer at 12 times next year’s expected earnings, cheaper than peers like&nbsp;Johnson &amp; Johnson&nbsp;(JNJ) and&nbsp;Eli Lilly&nbsp;(LLY).</p>\n<p>The Pfizer discount can be attributed to concerns over the patent cliff the drugmaker faces at the end of the decade. The company stands to lose exclusivity over a handful of drugs that bring in billions in annual revenue.</p>\n<p>The worries are legitimate, but Pfizer’s scientific coup should give investors confidence that the company’s science can carry it safely over that cliff. It may take time for the market to catch up, but for long-term investors, it’s a promising opportunity.</p>\n<p>The success of the antiviral is the best illustration yet of Pfizer’s scientific prowess.</p>\n<p>While Pfizer’s Covid-19 vaccine came out of the labs of the German biotech&nbsp;BioNTech&nbsp;(BNTX), the new Covid-19 antiviral was whipped up by what Dolsten called a “dream team” of scientists at Pfizer’s own labs across the Northeast U.S.</p>\n<p>In the earliest days of the pandemic, Pfizer split its efforts between its collaboration with BioNTech on the vaccine and its quest for a Covid-19 pill. The vaccine effort operated on a huge scale; Dolsten called it a “mega team” that spanned the Atlantic.</p>\n<p>The antiviral project was a much smaller operation—a group of Pfizer experts operating with resources left over from the vaccine push.</p>\n<p>“The small molecule was more like a nimble, laser-focused, high-end team, with rather moderate resources,” Dolsten said.</p>\n<p>Dolsten gathered some of Pfizer’s most experienced scientists to work on the antiviral project, including its head of medicine design, Charlotte Allerton. The scientists started with work Pfizer had done years ago on a type of antiviral called a protease inhibitor.</p>\n<p>“[Pfizer’s] pharmaceutical R&amp;D is better than people had thought.”</p>\n<p>The protease inhibitors in the Pfizer library, however, had been administered intravenously, and had not worked well when delivered orally. The team had to figure out how to adapt the drugs to oral administration, a substantial undertaking.</p>\n<p>“They had to really create a lot of new chemistry,” Dolsten said. The scientists created 600 compounds to nail down the right drug, a process that might normally take years, and which they accomplished in a matter of months. “Four years turned into four months here,” he said.</p>\n<p>Pfizer started testing the pill in humans in March. It is now running a number of Phase 2/3 trials of the drug, including one for patients who are high risk, one for patients not high risk, and one as a prophylaxis for patients who have been exposed to the virus but aren’t yet sick. In the first readout, the drug looked substantially more effective than the Covid treatment pill from&nbsp;Merck&nbsp;(MRK).</p>\n<p>“It definitely helps prove the point that [Pfizer’s] pharmaceutical R&amp;D is better than people had thought,” says Louise Chen, an analyst at Cantor Fitzgerald, who has an Overweight rating and a $61 price target on the stock.</p>\n<p>Chen says that she doesn’t expect investors to come around to her way of thinking until there is more clarity on the durability of Covid-19 vaccine and pill sales, and the rest of the pipeline gets proved out.</p>\n<p>“There is not one event that I think will trigger a re-rating of the stock at the next level,” she says. “Until those things play out, I don’t think that it necessarily will.”</p>\n<p>That makes a bet on Pfizer a long-term play. In the meantime, the experience of&nbsp;Moderna&nbsp;(MRNA) in recent weeks is highlighting the potential for the vaccine makers to come under scrutiny over unequal distribution of vaccines.</p>\n<p>Biden administration officials have been increasingly frustrated with Moderna, calling on the company to ramp up production so it can offer more doses at not-for-profit prices to low-income countries, with one top official calling on the company to “step up.”</p>\n<p>Moderna shares are down more than 40% over the past three months.</p>\n<p>As the pandemic persists, Pfizer risks eroding the enormous goodwill it earned roughly a year ago when it introduced its Covid-19 vaccine. Earlier this month, Pfizer CEO Bourla blamed low-income countries for unfair vaccine distribution, telling <i>Barron’s</i> that it was their fault for not placing orders. Pfizer has sold a billion vaccine doses to the U.S. at a not-for-profit price to donate to poor countries, and says that a total of at least two billion doses will be delivered to low- and middle-income nations by the end of next year.</p>\n<p>When it comes to antivirals, Pfizer has said only that it will offer tiered pricing for poorer nations, the same approach it has taken with its vaccine.</p>\n<p>That contrasts sharply with Merck’s plan to make its own Covid-19 pill available to poor countries. Merck has signed a deal with a United Nations-backed group that will allow its pill to be licensed globally, with no royalties paid to Merck.</p>\n<p>Dolsten said that Pfizer is looking into licensing its pill under a similar mechanism as Merck’s. “We will look at those options,” he said. “By no means have we said we would do something different. We just want to make sure whoever will be involved gets the advice and skill to do this.”</p>\n<p>Such a step couldn’t come soon enough. Late last month, activists protested outside Bourla’s home, calling on Pfizer to share its vaccine manufacturing technology and to fill orders from low-income countries ahead of those from wealthy countries.</p>\n<p>An aggressive plan to share its antiviral would help stave off such criticism, keeping Pfizer in the relative good graces of Washington and allowing its impressive science to continue to drive the stock higher.</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-13 11:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/buy-pfizer-stock-covid-19-51636674652?mod=hp_LEAD_1><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that...</p>\n\n<a href=\"https://www.barrons.com/articles/buy-pfizer-stock-covid-19-51636674652?mod=hp_LEAD_1\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.barrons.com/articles/buy-pfizer-stock-covid-19-51636674652?mod=hp_LEAD_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1102251183","content_text":"Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that its Covid-19 antiviral had cut the risk of hospitalization by 89% in high-risk adults.\n“It can’t be just a random thing, that you’re able to beat this type of world record and get a grand slam at the same time by chance,” Dolsten said, scrambling sports metaphors as he sought to illustrate the magnitude of Pfizer’s twin wins: the development of a stunningly effective Covid-19 vaccine in just 10 months, followed a year later by the development of a similarly stunning Covid-19 antiviral.\nTwo years ago, Pfizer (ticker: PFE) CEO Albert Bourla asked investors to take a big gamble on the research-and-development operation that Dolsten has rebuilt over the course of more than a decade. That bet is looking smarter than ever.\nBourla has gotten rid of Pfizer’s off-patent drugs division and the last of its consumer health products, leaving behind a pure-play biopharma company that will live or die on the strength of Dolsten’s science.\nIn a cover story in November 2019, Barron’s argued that Bourla and Dolsten could pull it off.\nThe new antiviral data reaffirms the case for Pfizer that Barron’s made two years ago. Continuing to profit off the pandemic, however, brings new risks, as criticism grows over the global inequity in vaccine distribution. Low-income nations account for less than 1% of the more than seven billion doses administered worldwide. If distribution of Pfizer’s antiviral continues to favor wealthy nations, the company’s stock could ultimately suffer.\nPfizer’s shares surged 10.9% the day the data came out, their best daily showing in at least 20 years. Still, with the stock now changing hands at around $50, investors continue to undervalue the company. Investors are pricing Pfizer at 12 times next year’s expected earnings, cheaper than peers like Johnson & Johnson (JNJ) and Eli Lilly (LLY).\nThe Pfizer discount can be attributed to concerns over the patent cliff the drugmaker faces at the end of the decade. The company stands to lose exclusivity over a handful of drugs that bring in billions in annual revenue.\nThe worries are legitimate, but Pfizer’s scientific coup should give investors confidence that the company’s science can carry it safely over that cliff. It may take time for the market to catch up, but for long-term investors, it’s a promising opportunity.\nThe success of the antiviral is the best illustration yet of Pfizer’s scientific prowess.\nWhile Pfizer’s Covid-19 vaccine came out of the labs of the German biotech BioNTech (BNTX), the new Covid-19 antiviral was whipped up by what Dolsten called a “dream team” of scientists at Pfizer’s own labs across the Northeast U.S.\nIn the earliest days of the pandemic, Pfizer split its efforts between its collaboration with BioNTech on the vaccine and its quest for a Covid-19 pill. The vaccine effort operated on a huge scale; Dolsten called it a “mega team” that spanned the Atlantic.\nThe antiviral project was a much smaller operation—a group of Pfizer experts operating with resources left over from the vaccine push.\n“The small molecule was more like a nimble, laser-focused, high-end team, with rather moderate resources,” Dolsten said.\nDolsten gathered some of Pfizer’s most experienced scientists to work on the antiviral project, including its head of medicine design, Charlotte Allerton. The scientists started with work Pfizer had done years ago on a type of antiviral called a protease inhibitor.\n“[Pfizer’s] pharmaceutical R&D is better than people had thought.”\nThe protease inhibitors in the Pfizer library, however, had been administered intravenously, and had not worked well when delivered orally. The team had to figure out how to adapt the drugs to oral administration, a substantial undertaking.\n“They had to really create a lot of new chemistry,” Dolsten said. The scientists created 600 compounds to nail down the right drug, a process that might normally take years, and which they accomplished in a matter of months. “Four years turned into four months here,” he said.\nPfizer started testing the pill in humans in March. It is now running a number of Phase 2/3 trials of the drug, including one for patients who are high risk, one for patients not high risk, and one as a prophylaxis for patients who have been exposed to the virus but aren’t yet sick. In the first readout, the drug looked substantially more effective than the Covid treatment pill from Merck (MRK).\n“It definitely helps prove the point that [Pfizer’s] pharmaceutical R&D is better than people had thought,” says Louise Chen, an analyst at Cantor Fitzgerald, who has an Overweight rating and a $61 price target on the stock.\nChen says that she doesn’t expect investors to come around to her way of thinking until there is more clarity on the durability of Covid-19 vaccine and pill sales, and the rest of the pipeline gets proved out.\n“There is not one event that I think will trigger a re-rating of the stock at the next level,” she says. “Until those things play out, I don’t think that it necessarily will.”\nThat makes a bet on Pfizer a long-term play. In the meantime, the experience of Moderna (MRNA) in recent weeks is highlighting the potential for the vaccine makers to come under scrutiny over unequal distribution of vaccines.\nBiden administration officials have been increasingly frustrated with Moderna, calling on the company to ramp up production so it can offer more doses at not-for-profit prices to low-income countries, with one top official calling on the company to “step up.”\nModerna shares are down more than 40% over the past three months.\nAs the pandemic persists, Pfizer risks eroding the enormous goodwill it earned roughly a year ago when it introduced its Covid-19 vaccine. Earlier this month, Pfizer CEO Bourla blamed low-income countries for unfair vaccine distribution, telling Barron’s that it was their fault for not placing orders. Pfizer has sold a billion vaccine doses to the U.S. at a not-for-profit price to donate to poor countries, and says that a total of at least two billion doses will be delivered to low- and middle-income nations by the end of next year.\nWhen it comes to antivirals, Pfizer has said only that it will offer tiered pricing for poorer nations, the same approach it has taken with its vaccine.\nThat contrasts sharply with Merck’s plan to make its own Covid-19 pill available to poor countries. Merck has signed a deal with a United Nations-backed group that will allow its pill to be licensed globally, with no royalties paid to Merck.\nDolsten said that Pfizer is looking into licensing its pill under a similar mechanism as Merck’s. “We will look at those options,” he said. “By no means have we said we would do something different. We just want to make sure whoever will be involved gets the advice and skill to do this.”\nSuch a step couldn’t come soon enough. Late last month, activists protested outside Bourla’s home, calling on Pfizer to share its vaccine manufacturing technology and to fill orders from low-income countries ahead of those from wealthy countries.\nAn aggressive plan to share its antiviral would help stave off such criticism, keeping Pfizer in the relative good graces of Washington and allowing its impressive science to continue to drive the stock higher.","news_type":1},"isVote":1,"tweetType":1,"viewCount":175,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698588186,"gmtCreate":1640448827048,"gmtModify":1640448827341,"author":{"id":"3554895157968981","authorId":"3554895157968981","name":"canoboi","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like and comment thanks","listText":"Like and comment thanks","text":"Like and comment thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/698588186","repostId":"2193317305","repostType":4,"repost":{"id":"2193317305","pubTimestamp":1640399660,"share":"https://www.laohu8.com/m/news/2193317305?lang=&edition=full","pubTime":"2021-12-25 10:34","market":"us","language":"en","title":"Can This Top Blue Chip Stock Handle Soaring Inflation?","url":"https://stock-news.laohu8.com/highlight/detail?id=2193317305","media":"Motley Fool","summary":"We are in strange times right now, so how companies navigate the current environment is vital to their success.","content":"<p>In the month of November, the Consumer Price Index, a widely used measure of inflation, jumped 6.8% from a year ago. Sparked by supply-chain disruptions and labor shortages across the economy, it was the highest increase in almost 40 years.&nbsp;</p>\n<p>For a company like&nbsp;<b>Home Depot</b>&nbsp;(NYSE:HD) that has done extremely well during the pandemic, the threat of rising costs is a real challenge heading into the new year, having possibly negative implications ahead of what is traditionally a busy spring and summer for the&nbsp;business.&nbsp;</p>\n<p>Continue reading to find out how this&nbsp;blue chip stock&nbsp;is dealing with the current situation.&nbsp;</p>\n<h2>Lumber prices are going back up&nbsp;</h2>\n<p>A major commodity that has a meaningful&nbsp;impact&nbsp;on Home Depot's&nbsp;business&nbsp;is lumber. From April 2020 to May 2021,&nbsp;lumber prices skyrocketed&nbsp;to nearly $1,700 per thousand board feet, an all-time record. Prices came down over the following few months, but they shot up again from mid-November to mid-December, settling at just over $1,000 per thousand board feet today. This is still extremely high from a historical perspective.&nbsp;</p>\n<p>\"Lumber is a driver of projects throughout the business, and that certainly carries on,\" Chief Executive Officer Craig Menear highlighted on the company's third-quarter earnings call. During Home Depot's fiscal second quarter that ended Aug. 1 (when lumber prices were sky-high), the company posted record quarterly sales of $41.1 billion. The gross margin of 33.2%, while down slightly from previous quarters, was still very healthy and in line with past results.&nbsp;</p>\n<p>This is a positive indicator of Home Depot's ability to handle the unpredictable price swings with a core commodity like lumber. As prices soared, unit sales fell. Even so, the business reported a historic quarter. Now, as lumber prices rise, especially ahead of the busy home-building and remodeling season in the spring and summer, don't be surprised if lumber unit sales start to drop again.&nbsp;</p>\n<p>Nonetheless, other product categories like outdoor garden, appliances, and kitchen and bath should be strong. And thanks to a robust housing market, characterized by low interest rates, consumers are increasingly looking to undertake renovation projects to boost the value of their existing homes. This underlying trend supports demand for the products and services Home Depot offers.&nbsp;</p>\n<p>\"We have effectively managed inflationary environments in the past, and we feel good about our ability to continue managing through the current environment,\" said President and Chief Operating Officer Ted Decker on the latest conference call with Wall Street analysts.</p>\n<h2>Home Depot's success is&nbsp;undeniable&nbsp;</h2>\n<p>One of Home Depot's overarching objectives is to be the low-cost provider in the home improvement industry. This means that the business wants to lag competitors when raising prices and lead when reducing prices. Obviously, this negatively impacts profitability in the near term as the company is hesitant to pass higher costs on to consumers.&nbsp;</p>\n<p>But if we look at Home Depot's historical performance, we see that this is definitely the right strategy to take. Over the past several years, while revenue has grown in the mid-single digits on a yearly basis, net income has soared as a result of expanding margins. In fiscal 2015, profit totaled $7 billion. Over the trailing-12-month period, it was almost $16 billion.&nbsp;</p>\n<p>And the business is popular among contractors and other professionals, who account for roughly 45% of sales. Instead of immediately passing on higher input costs, which could alienate these high-value customers and push them to competitors, Home Depot understands that building long-term relationships with them is crucial to the success of the company. Sacrificing margin in unusual times like today to keep customers loyal is the right move.&nbsp;</p>\n<p>The current economic environment is full of uncertainties with issues like the omicron coronavirus variant and tightening monetary policy receiving the bulk of investors' attention. When it comes to inflation in particular, I have no reason to believe that Home Depot won't be able to step up to whatever challenges 2022 brings. &nbsp;</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Can This Top Blue Chip Stock Handle Soaring Inflation?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCan This Top Blue Chip Stock Handle Soaring Inflation?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-25 10:34 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/24/can-top-blue-chip-stock-handle-soaring-inflation/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In the month of November, the Consumer Price Index, a widely used measure of inflation, jumped 6.8% from a year ago. Sparked by supply-chain disruptions and labor shortages across the economy, it was ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/24/can-top-blue-chip-stock-handle-soaring-inflation/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4566":"资本集团","BK4083":"家庭装潢零售","BK4567":"ESG概念","HD":"家得宝","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4534":"瑞士信贷持仓","BK4550":"红杉资本持仓","BK4504":"桥水持仓"},"source_url":"https://www.fool.com/investing/2021/12/24/can-top-blue-chip-stock-handle-soaring-inflation/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2193317305","content_text":"In the month of November, the Consumer Price Index, a widely used measure of inflation, jumped 6.8% from a year ago. Sparked by supply-chain disruptions and labor shortages across the economy, it was the highest increase in almost 40 years. \nFor a company like Home Depot (NYSE:HD) that has done extremely well during the pandemic, the threat of rising costs is a real challenge heading into the new year, having possibly negative implications ahead of what is traditionally a busy spring and summer for the business. \nContinue reading to find out how this blue chip stock is dealing with the current situation. \nLumber prices are going back up \nA major commodity that has a meaningful impact on Home Depot's business is lumber. From April 2020 to May 2021, lumber prices skyrocketed to nearly $1,700 per thousand board feet, an all-time record. Prices came down over the following few months, but they shot up again from mid-November to mid-December, settling at just over $1,000 per thousand board feet today. This is still extremely high from a historical perspective. \n\"Lumber is a driver of projects throughout the business, and that certainly carries on,\" Chief Executive Officer Craig Menear highlighted on the company's third-quarter earnings call. During Home Depot's fiscal second quarter that ended Aug. 1 (when lumber prices were sky-high), the company posted record quarterly sales of $41.1 billion. The gross margin of 33.2%, while down slightly from previous quarters, was still very healthy and in line with past results. \nThis is a positive indicator of Home Depot's ability to handle the unpredictable price swings with a core commodity like lumber. As prices soared, unit sales fell. Even so, the business reported a historic quarter. Now, as lumber prices rise, especially ahead of the busy home-building and remodeling season in the spring and summer, don't be surprised if lumber unit sales start to drop again. \nNonetheless, other product categories like outdoor garden, appliances, and kitchen and bath should be strong. And thanks to a robust housing market, characterized by low interest rates, consumers are increasingly looking to undertake renovation projects to boost the value of their existing homes. This underlying trend supports demand for the products and services Home Depot offers. \n\"We have effectively managed inflationary environments in the past, and we feel good about our ability to continue managing through the current environment,\" said President and Chief Operating Officer Ted Decker on the latest conference call with Wall Street analysts.\nHome Depot's success is undeniable \nOne of Home Depot's overarching objectives is to be the low-cost provider in the home improvement industry. This means that the business wants to lag competitors when raising prices and lead when reducing prices. Obviously, this negatively impacts profitability in the near term as the company is hesitant to pass higher costs on to consumers. \nBut if we look at Home Depot's historical performance, we see that this is definitely the right strategy to take. Over the past several years, while revenue has grown in the mid-single digits on a yearly basis, net income has soared as a result of expanding margins. In fiscal 2015, profit totaled $7 billion. Over the trailing-12-month period, it was almost $16 billion. \nAnd the business is popular among contractors and other professionals, who account for roughly 45% of sales. Instead of immediately passing on higher input costs, which could alienate these high-value customers and push them to competitors, Home Depot understands that building long-term relationships with them is crucial to the success of the company. Sacrificing margin in unusual times like today to keep customers loyal is the right move. \nThe current economic environment is full of uncertainties with issues like the omicron coronavirus variant and tightening monetary policy receiving the bulk of investors' attention. When it comes to inflation in particular, I have no reason to believe that Home Depot won't be able to step up to whatever challenges 2022 brings.","news_type":1},"isVote":1,"tweetType":1,"viewCount":619,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":605893068,"gmtCreate":1639140384143,"gmtModify":1639140384427,"author":{"id":"3554895157968981","authorId":"3554895157968981","name":"canoboi","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like and comment. Thanks","listText":"Like and comment. Thanks","text":"Like and comment. Thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/605893068","repostId":"1160479644","repostType":4,"isVote":1,"tweetType":1,"viewCount":621,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":699279794,"gmtCreate":1639824888317,"gmtModify":1639824888635,"author":{"id":"3554895157968981","authorId":"3554895157968981","name":"canoboi","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like n comment. Thks","listText":"Like n comment. Thks","text":"Like n comment. Thks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/699279794","repostId":"1116106959","repostType":4,"repost":{"id":"1116106959","pubTimestamp":1639785552,"share":"https://www.laohu8.com/m/news/1116106959?lang=&edition=full","pubTime":"2021-12-18 07:59","market":"us","language":"en","title":"Wall Street ends down after mostly negative week","url":"https://stock-news.laohu8.com/highlight/detail?id=1116106959","media":"Reuters","summary":" - Wall Street finished lower on Friday, weighed down by Big Tech as investors worried about the Omicron coronavirus variant and digested the Federal Reserve's decision to end its pandemic-era stimulus faster.All three main U.S. stock indexes ended with a decline for the week after the Fed on Wednesday signaled three quarter-percentage-point interest rate hikes by the end of 2022 to combat surging inflation.Nvidia dropped 2.1% and Alphabet lost 1.9%, both weighing on the S&P 500 and Nasdaq.The S","content":"<p>(Reuters) - Wall Street finished lower on Friday, weighed down by Big Tech as investors worried about the Omicron coronavirus variant and digested the Federal Reserve's decision to end its pandemic-era stimulus faster.</p>\n<p>All three main U.S. stock indexes ended with a decline for the week after the Fed on Wednesday signaled three quarter-percentage-point interest rate hikes by the end of 2022 to combat surging inflation.</p>\n<p>Nvidia dropped 2.1% and Alphabet lost 1.9%, both weighing on the S&amp;P 500 and Nasdaq.</p>\n<p>The S&amp;P 500 growth index lost 0.7% and the value index declined 1.4%.</p>\n<p>All of the 11 major S&amp;P 500 sector indexes fell, with financials leading the way down with a 2.3% drop. Energy lost 2.2%.</p>\n<p>Adding to uncertainty, Pfizer said on Friday the pandemic could extend through next year. European countries geared up for further travel and social restrictions and a study warned that the rapidly spreading Omicron coronavirus variant was five times more likely to reinfect people than its predecessor, Delta.</p>\n<p>Traders also pointed to year-end tax selling and the simultaneous expiration of stock options, stock index futures and index options contracts - known as triple witching - as potential causes for volatility.</p>\n<p>\"It's a big options expiration day,\" said Joe Saluzzi, co-manager of trading at Themis Trading in Chatham, New Jersey. \"And now you draw on top of that some Omicron, and you've got volatility, and I think it creates a lot of uncertainty amongst investors. Where are you going to position for the end of the year?\"</p>\n<p>Heavyweight growth stocks including Nvidia and Microsoft have outperformed the broader market in 2021, while the Philadelphia SE Semiconductor index has surged about 35%. The benchmark S&amp;P 500 index gained around 23% in the same period.</p>\n<p>In Friday's session, the Dow Jones Industrial Average fell 1.48% to end at 35,365.44 points, while the S&amp;P 500 lost 1.03% to 4,620.64.</p>\n<p>The Nasdaq Composite dropped 0.07% to 15,169.68.</p>\n<p>On a positive note, the small-cap Russell 2000 index rallied 1% after having fallen more than 10% from a record high in early November.</p>\n<p>With options expiring, volume on U.S. exchanges jumped to 16.6 billion shares, far above the 11.9 billion average over the last 20 trading days.</p>\n<p>For the week, the S&amp;P 500 fell 1.9%, the Dow lost 1.7% and the Nasdaq declined 2.9%.</p>\n<p>In Friday's session, Oracle tumbled 6.4% after the Wall Street Journal reported the enterprise software maker is in talks to buy electronic medical records company Cerner in a deal that could be valued at $30 billion. Shares of Cerner surged 12.9%.</p>\n<p>FedEx Corp rose almost 5% after the delivery firm reinstated its original fiscal 2022 forecast on Thursday, even as persistent labor woes chipped away profits.</p>\n<p>Declining issues outnumbered advancing ones on the NYSE by a 1.50-to-1 ratio; on Nasdaq, a 1.16-to-1 ratio favored advancers.</p>\n<p>The S&amp;P 500 posted 22 new 52-week highs and seven new lows; the Nasdaq Composite recorded 28 new highs and 341 new lows.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wall Street ends down after mostly negative week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWall Street ends down after mostly negative week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-18 07:59 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/us-stocks-wall-street-ends-212015460.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Reuters) - Wall Street finished lower on Friday, weighed down by Big Tech as investors worried about the Omicron coronavirus variant and digested the Federal Reserve's decision to end its pandemic-...</p>\n\n<a href=\"https://finance.yahoo.com/news/us-stocks-wall-street-ends-212015460.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite",".SPX":"S&P 500 Index",".DJI":"道琼斯"},"source_url":"https://finance.yahoo.com/news/us-stocks-wall-street-ends-212015460.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1116106959","content_text":"(Reuters) - Wall Street finished lower on Friday, weighed down by Big Tech as investors worried about the Omicron coronavirus variant and digested the Federal Reserve's decision to end its pandemic-era stimulus faster.\nAll three main U.S. stock indexes ended with a decline for the week after the Fed on Wednesday signaled three quarter-percentage-point interest rate hikes by the end of 2022 to combat surging inflation.\nNvidia dropped 2.1% and Alphabet lost 1.9%, both weighing on the S&P 500 and Nasdaq.\nThe S&P 500 growth index lost 0.7% and the value index declined 1.4%.\nAll of the 11 major S&P 500 sector indexes fell, with financials leading the way down with a 2.3% drop. Energy lost 2.2%.\nAdding to uncertainty, Pfizer said on Friday the pandemic could extend through next year. European countries geared up for further travel and social restrictions and a study warned that the rapidly spreading Omicron coronavirus variant was five times more likely to reinfect people than its predecessor, Delta.\nTraders also pointed to year-end tax selling and the simultaneous expiration of stock options, stock index futures and index options contracts - known as triple witching - as potential causes for volatility.\n\"It's a big options expiration day,\" said Joe Saluzzi, co-manager of trading at Themis Trading in Chatham, New Jersey. \"And now you draw on top of that some Omicron, and you've got volatility, and I think it creates a lot of uncertainty amongst investors. Where are you going to position for the end of the year?\"\nHeavyweight growth stocks including Nvidia and Microsoft have outperformed the broader market in 2021, while the Philadelphia SE Semiconductor index has surged about 35%. The benchmark S&P 500 index gained around 23% in the same period.\nIn Friday's session, the Dow Jones Industrial Average fell 1.48% to end at 35,365.44 points, while the S&P 500 lost 1.03% to 4,620.64.\nThe Nasdaq Composite dropped 0.07% to 15,169.68.\nOn a positive note, the small-cap Russell 2000 index rallied 1% after having fallen more than 10% from a record high in early November.\nWith options expiring, volume on U.S. exchanges jumped to 16.6 billion shares, far above the 11.9 billion average over the last 20 trading days.\nFor the week, the S&P 500 fell 1.9%, the Dow lost 1.7% and the Nasdaq declined 2.9%.\nIn Friday's session, Oracle tumbled 6.4% after the Wall Street Journal reported the enterprise software maker is in talks to buy electronic medical records company Cerner in a deal that could be valued at $30 billion. Shares of Cerner surged 12.9%.\nFedEx Corp rose almost 5% after the delivery firm reinstated its original fiscal 2022 forecast on Thursday, even as persistent labor woes chipped away profits.\nDeclining issues outnumbered advancing ones on the NYSE by a 1.50-to-1 ratio; on Nasdaq, a 1.16-to-1 ratio favored advancers.\nThe S&P 500 posted 22 new 52-week highs and seven new lows; the Nasdaq Composite recorded 28 new highs and 341 new lows.","news_type":1},"isVote":1,"tweetType":1,"viewCount":473,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":825369426,"gmtCreate":1634202190527,"gmtModify":1634202190677,"author":{"id":"3554895157968981","authorId":"3554895157968981","name":"canoboi","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like and comment thanks","listText":"Like and comment thanks","text":"Like and comment thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/825369426","repostId":"1131725095","repostType":4,"repost":{"id":"1131725095","pubTimestamp":1634201775,"share":"https://www.laohu8.com/m/news/1131725095?lang=&edition=full","pubTime":"2021-10-14 16:56","market":"us","language":"en","title":"Palantir: Strong Upside Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=1131725095","media":"Seeking Alpha","summary":"Summary\n\nPalantir's growth strategy in the commercial business is bearing fruit, showing that there ","content":"<p><b>Summary</b></p>\n<ul>\n <li>Palantir's growth strategy in the commercial business is bearing fruit, showing that there is a lot of potential to increase its customer base.</li>\n <li>This is a strong support for annual revenue growth of 20-30% in the next four years, justifying its high valuation multiples.</li>\n <li>My price target is $40.75 per share by end-2024, implying more than 70% upside potential over the next three years.</li>\n</ul>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/02d7c2e5739d48a7457788f40f66148c\" tg-width=\"1536\" tg-height=\"1024\" width=\"100%\" height=\"auto\"><span>Michael Vi/iStock Editorial via Getty Images</span></p>\n<p><b>Palantir Technologies</b>(PLTR) is a great growth play with plenty of upside over the next three years, even assuming more conservative assumptions than its own guidance.</p>\n<p><b>Background</b></p>\n<p>I&nbsp;covered Palantir&nbsp;a few months ago, and I’m bullish on its stock as I see the company very well positioned to grow strongly over the medium to long term. This is driven by its software that is quite unique and should lead to strong customer demand over the coming years, as the need to interpret and analyzed big datasets is only expected to rise in the future.</p>\n<p>Nevertheless, there is also a lot of hype about this company and investors should be aware that Palantir is still a small company and its business is in a very early growth phase, thus&nbsp;I don’t see Palantir&nbsp;becoming one of the big tech companies over the next decade.</p>\n<p>This expectation is justified by Palantir’s business model, which is focused on government and large corporate and therefore is not easily scalable. Indeed, the company only had 169 customers at the end of June, a relatively small number of customers due to its historical focus on large clients.</p>\n<p>As I’ve discussed in previous articles, I invest mainly in secular growth companies in a few investing themes, namely semiconductors, electric vehicles, digital payments, 5G and big data. In this last theme, I see Palantir as one of the best picks, and in this article, I do an update on its investment case.</p>\n<p><b>Recent Earnings &amp; Estimates</b></p>\n<p>Since my last article, Palantir has released&nbsp;Q2 2021 earnings, maintain a very good operating momentum. Its revenues in the quarter amounted to $376 million, up by 49% YoY. This strong growth was driven largely by its U.S. commercial business that reported exponential growth, up by 90% YoY.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f8ee3d7d0ef8a5d56f850d7e219ca013\" tg-width=\"640\" tg-height=\"340\" width=\"100%\" height=\"auto\"><span>Source: Palantir.</span></p>\n<p>This growth rate in Palantir’s commercial business is impressive, but not necessarily unexpected. While Palantir has focused historically on governments and large corporations as its key customers, the company has been changing its strategy and has recruited, in recent months, salespeople to target smaller and medium-sized companies.</p>\n<p>In Q1 2021, Palantir had recruited about 50 dedicated salespeople and this has translated quite rapidly in new customer acquisitions and higher revenue in a relatively short period of time. In Q2, the company added 20 net new customers and total commercial customers increased by 32% QoQ, while in the first six months of the year its commercial customer count increased by 61%. I think this is a strong signal that Palantir offers a good value proposition to customers of different sizes, boding quite well for its growth in the next few years.</p>\n<p>Indeed, Palantir’s edge is to offer a software that is used to analyze big datasets, so that users can make better decisions regarding their needs and projects. Palantir’s software is viewed as a central operating system for customer’s data, which usually can be spread across a large number of teams and departments and possibly in different countries.</p>\n<p>The strong growth reported in the last quarter on the commercial business side is clearly a demonstration that Palantir can leverage its software to a much larger customer base, making me even more bullish as the company can gain a lot of customers both in the U.S. and abroad for years to come.</p>\n<p>This is supported by Palantir’s push to hire more salespeople, with the company hiring 60 additional salespeople in Q2, and more expected until the end of the year. This means that revenue growth in the commercial business is not expected to slow down in the next few quarters, boding very well for overall revenue growth.</p>\n<p>On the government side, Palantir’s revenues increased by 66% YoY in Q2 2021 to $232 million, also a very strong growth rate, and this growth is expected to remain at a strong pace in the near future. For instance, Palantir has recentlybeen selectedby the U.S. Army for the delivery of the Army’s Intelligence data fabric and analytics foundation in a new contract valued at $823 million, for a period of four years, being a good tailwind for revenue growth in coming years.</p>\n<p>Its total commercial revenue increased by 28% YoY to $144 million in Q2 2021, which means that the majority of commercial revenues are generated in international markets and therefore the potential for revenue growth in the U.S. is still largely untapped.</p>\n<p>Beyond revenue growth, Palantir is also improving meaningfully its profitability and has achieved an adjusted operating margin (which excludes stock-based compensation) of 31% in the last quarter, much higher than in Q2 2020. Even though Palantir is not expected to report profits in the short term, from an operating standpoint, it is improving its margins due to a larger scale, showing that its business has operating leverage. As the company gains more customers and increases revenue at a higher rate than expenses, operating margins should continue to rise being a key factor for achieving break-even in the next few years.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/7214b3ada30c61fad0ea54b4ca066bb2\" tg-width=\"444\" tg-height=\"453\" width=\"100%\" height=\"auto\"><span>Source: Palantir.</span></p>\n<p>During the first six months of 2021, Palantir’s revenues were up by 49% YoY to $717 million, thus Palantir is on path to generate annual revenues of around $1.4-$1.5 billion in 2021. Current consensus is for $1.51 billion in revenues this year, which seems possible to beat as the company has reported higher growth than was expected in the two previous quarters.</p>\n<p>Regarding its cash flow generation, Palantir is also showing a good performance, given that it has raised its free cash flow guidance to about $300 million in 2021, while previously expecting some $150 million, benefiting from new customers and contracts that have upfront payments. This is supported by its ‘order backlog’, or what the company calls its remaining deal value, which amounted to more than $3.4 billion at the end of June.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/cf2e97080f2de2d05a69d9ac075b6994\" tg-width=\"318\" tg-height=\"262\" width=\"100%\" height=\"auto\"><span>Source: Palantir.</span></p>\n<p>Going forward, Palantir is expected to maintain strong revenue growth, even though it is estimated to drop below +30% YoY in the next couple of years. This may be too conservative, given that Palantir is not showing any signs of slowing down in both the government and commercial businesses, which gives the company a good margin to beat medium-term expectations.</p>\n<p>This provides a strong backdrop for Palantir to achieve annual revenue growth of 30%+ during the next four years and reach its target of $4 billion in revenues by 2025. However, as the company becomes larger I’m expecting lower revenue growth than Palantir’s goal, forecasting annual revenue growth of 20%-25% by 2024 and 2025. Being conservative, this leads to around $3.8 billion in revenue by 2025, slightly lower than the company’s $4 billion goal.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/8399716c34af6fc6abd62e9cf7cb59ed\" tg-width=\"494\" tg-height=\"288\" width=\"100%\" height=\"auto\"><span>Source: Bloomberg and author’s calculations.</span></p>\n<p><b>Valuation</b></p>\n<p>As I’ve explained in previous articles, my valuation approach is to look into the next few years of revenues and earnings rather than just focus on this year or the next, to see if the stock has upside potential over a time frame of 2-4 years. Therefore, I’ll use 2025 estimates to see if Palantir is currently undervalued or not, and use its historical valuation based on its revenue multiple as the company is still not profitable in its bottom-line.</p>\n<p>Palantir’s trading history is limited, as the company performed its IPO in 2020, but has traded at about 24x EV/revenues over the past year. Assuming that Palantir will have a slightly lower valuation multiple in the future, as its growth rates decrease in the coming years, I think it is reasonable to assume a 20x EV/revenue multiple by 2024. Note that this is a strong de-rate from its current&nbsp;valuation&nbsp;of close to 30x revenues, hence this seems to be a conservative assumption.</p>\n<p>This methodology gives me a price target of $40.75 by end-2024, implying an upside potential of more than 70% over the next three years. This shows that Palantir has strong upside potential over the next three years and is currently a great play for long-term investors.</p>\n<p><b>Bottom Line</b></p>\n<p>Palantir has very good long-term growth prospects and its recent impressive growth in the U.S. commercial business provides evidence that Palantir is only starting to tap a very large market for the company. I was already bullish on Palantir, but its push for growth in the commercial business was ahead of my expectations, showing that its strategy is right and has a lot of potential to increase its customer base.</p>\n<p>This provides a strong support for annual revenue growth of 20%-30% in the next four years, and being conservative I see plenty of upside in the next few years, making Palantir a great growth play in the big data investment theme.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Palantir: Strong Upside Ahead</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPalantir: Strong Upside Ahead\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-14 16:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4459749-palantir-strong-upside-ahead><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Summary\n\nPalantir's growth strategy in the commercial business is bearing fruit, showing that there is a lot of potential to increase its customer base.\nThis is a strong support for annual revenue ...</p>\n\n<a href=\"https://seekingalpha.com/article/4459749-palantir-strong-upside-ahead\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PLTR":"Palantir Technologies Inc."},"source_url":"https://seekingalpha.com/article/4459749-palantir-strong-upside-ahead","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1131725095","content_text":"Summary\n\nPalantir's growth strategy in the commercial business is bearing fruit, showing that there is a lot of potential to increase its customer base.\nThis is a strong support for annual revenue growth of 20-30% in the next four years, justifying its high valuation multiples.\nMy price target is $40.75 per share by end-2024, implying more than 70% upside potential over the next three years.\n\nMichael Vi/iStock Editorial via Getty Images\nPalantir Technologies(PLTR) is a great growth play with plenty of upside over the next three years, even assuming more conservative assumptions than its own guidance.\nBackground\nI covered Palantir a few months ago, and I’m bullish on its stock as I see the company very well positioned to grow strongly over the medium to long term. This is driven by its software that is quite unique and should lead to strong customer demand over the coming years, as the need to interpret and analyzed big datasets is only expected to rise in the future.\nNevertheless, there is also a lot of hype about this company and investors should be aware that Palantir is still a small company and its business is in a very early growth phase, thus I don’t see Palantir becoming one of the big tech companies over the next decade.\nThis expectation is justified by Palantir’s business model, which is focused on government and large corporate and therefore is not easily scalable. Indeed, the company only had 169 customers at the end of June, a relatively small number of customers due to its historical focus on large clients.\nAs I’ve discussed in previous articles, I invest mainly in secular growth companies in a few investing themes, namely semiconductors, electric vehicles, digital payments, 5G and big data. In this last theme, I see Palantir as one of the best picks, and in this article, I do an update on its investment case.\nRecent Earnings & Estimates\nSince my last article, Palantir has released Q2 2021 earnings, maintain a very good operating momentum. Its revenues in the quarter amounted to $376 million, up by 49% YoY. This strong growth was driven largely by its U.S. commercial business that reported exponential growth, up by 90% YoY.\nSource: Palantir.\nThis growth rate in Palantir’s commercial business is impressive, but not necessarily unexpected. While Palantir has focused historically on governments and large corporations as its key customers, the company has been changing its strategy and has recruited, in recent months, salespeople to target smaller and medium-sized companies.\nIn Q1 2021, Palantir had recruited about 50 dedicated salespeople and this has translated quite rapidly in new customer acquisitions and higher revenue in a relatively short period of time. In Q2, the company added 20 net new customers and total commercial customers increased by 32% QoQ, while in the first six months of the year its commercial customer count increased by 61%. I think this is a strong signal that Palantir offers a good value proposition to customers of different sizes, boding quite well for its growth in the next few years.\nIndeed, Palantir’s edge is to offer a software that is used to analyze big datasets, so that users can make better decisions regarding their needs and projects. Palantir’s software is viewed as a central operating system for customer’s data, which usually can be spread across a large number of teams and departments and possibly in different countries.\nThe strong growth reported in the last quarter on the commercial business side is clearly a demonstration that Palantir can leverage its software to a much larger customer base, making me even more bullish as the company can gain a lot of customers both in the U.S. and abroad for years to come.\nThis is supported by Palantir’s push to hire more salespeople, with the company hiring 60 additional salespeople in Q2, and more expected until the end of the year. This means that revenue growth in the commercial business is not expected to slow down in the next few quarters, boding very well for overall revenue growth.\nOn the government side, Palantir’s revenues increased by 66% YoY in Q2 2021 to $232 million, also a very strong growth rate, and this growth is expected to remain at a strong pace in the near future. For instance, Palantir has recentlybeen selectedby the U.S. Army for the delivery of the Army’s Intelligence data fabric and analytics foundation in a new contract valued at $823 million, for a period of four years, being a good tailwind for revenue growth in coming years.\nIts total commercial revenue increased by 28% YoY to $144 million in Q2 2021, which means that the majority of commercial revenues are generated in international markets and therefore the potential for revenue growth in the U.S. is still largely untapped.\nBeyond revenue growth, Palantir is also improving meaningfully its profitability and has achieved an adjusted operating margin (which excludes stock-based compensation) of 31% in the last quarter, much higher than in Q2 2020. Even though Palantir is not expected to report profits in the short term, from an operating standpoint, it is improving its margins due to a larger scale, showing that its business has operating leverage. As the company gains more customers and increases revenue at a higher rate than expenses, operating margins should continue to rise being a key factor for achieving break-even in the next few years.\nSource: Palantir.\nDuring the first six months of 2021, Palantir’s revenues were up by 49% YoY to $717 million, thus Palantir is on path to generate annual revenues of around $1.4-$1.5 billion in 2021. Current consensus is for $1.51 billion in revenues this year, which seems possible to beat as the company has reported higher growth than was expected in the two previous quarters.\nRegarding its cash flow generation, Palantir is also showing a good performance, given that it has raised its free cash flow guidance to about $300 million in 2021, while previously expecting some $150 million, benefiting from new customers and contracts that have upfront payments. This is supported by its ‘order backlog’, or what the company calls its remaining deal value, which amounted to more than $3.4 billion at the end of June.\nSource: Palantir.\nGoing forward, Palantir is expected to maintain strong revenue growth, even though it is estimated to drop below +30% YoY in the next couple of years. This may be too conservative, given that Palantir is not showing any signs of slowing down in both the government and commercial businesses, which gives the company a good margin to beat medium-term expectations.\nThis provides a strong backdrop for Palantir to achieve annual revenue growth of 30%+ during the next four years and reach its target of $4 billion in revenues by 2025. However, as the company becomes larger I’m expecting lower revenue growth than Palantir’s goal, forecasting annual revenue growth of 20%-25% by 2024 and 2025. Being conservative, this leads to around $3.8 billion in revenue by 2025, slightly lower than the company’s $4 billion goal.\nSource: Bloomberg and author’s calculations.\nValuation\nAs I’ve explained in previous articles, my valuation approach is to look into the next few years of revenues and earnings rather than just focus on this year or the next, to see if the stock has upside potential over a time frame of 2-4 years. Therefore, I’ll use 2025 estimates to see if Palantir is currently undervalued or not, and use its historical valuation based on its revenue multiple as the company is still not profitable in its bottom-line.\nPalantir’s trading history is limited, as the company performed its IPO in 2020, but has traded at about 24x EV/revenues over the past year. Assuming that Palantir will have a slightly lower valuation multiple in the future, as its growth rates decrease in the coming years, I think it is reasonable to assume a 20x EV/revenue multiple by 2024. Note that this is a strong de-rate from its current valuation of close to 30x revenues, hence this seems to be a conservative assumption.\nThis methodology gives me a price target of $40.75 by end-2024, implying an upside potential of more than 70% over the next three years. This shows that Palantir has strong upside potential over the next three years and is currently a great play for long-term investors.\nBottom Line\nPalantir has very good long-term growth prospects and its recent impressive growth in the U.S. commercial business provides evidence that Palantir is only starting to tap a very large market for the company. I was already bullish on Palantir, but its push for growth in the commercial business was ahead of my expectations, showing that its strategy is right and has a lot of potential to increase its customer base.\nThis provides a strong support for annual revenue growth of 20%-30% in the next four years, and being conservative I see plenty of upside in the next few years, making Palantir a great growth play in the big data investment theme.","news_type":1},"isVote":1,"tweetType":1,"viewCount":265,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":699478262,"gmtCreate":1639884539295,"gmtModify":1639884539582,"author":{"id":"3554895157968981","authorId":"3554895157968981","name":"canoboi","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like and comment thanks","listText":"Like and comment thanks","text":"Like and comment thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/699478262","repostId":"1122414343","repostType":4,"repost":{"id":"1122414343","pubTimestamp":1639884070,"share":"https://www.laohu8.com/m/news/1122414343?lang=&edition=full","pubTime":"2021-12-19 11:21","market":"us","language":"en","title":"Novavax, Vir among healthcare gainers, Pfizer posts best rally in a decade","url":"https://stock-news.laohu8.com/highlight/detail?id=1122414343","media":"Seeking Alpha","summary":"The healthcare stocks in the S&P 500 outperformed all other sectors in the broader index with a ~2.5","content":"<p>The healthcare stocks in the S&amp;P 500 outperformed all other sectors in the broader index with a ~2.5% gain thanks mainly to M&amp;A prospects. <a href=\"https://laohu8.com/S/HCSG\">Healthcare</a> technology, along with names battling the resurgence of COVID-19, led the gainers while the overall index fell ~1.9%.</p>\n<p>Among stocks with more than $2B market capitalization and 100K average daily volume over the past week, <a href=\"https://laohu8.com/S/ARNA\">Arena Pharmaceuticals </a> dominated with a ~83.8% rise after <a href=\"https://laohu8.com/S/PFE\">Pfizer </a> agreed to acquire it in a ~$6.7B deal with 100% premium for the biotech. <a href=\"https://laohu8.com/S/CERN\">Cerner </a> also joined the M&amp;A-driven rally to gain ~20.7% over the week amid reports of a potential ~$30B bid from <a href=\"https://laohu8.com/S/ORCL\">Oracle </a> for the electronic-medical-records company.</p>\n<p>Vaccine developer, <a href=\"https://laohu8.com/S/NVAX\">Novavax </a> jumped ~30.5% as investors welcomed the WHO clearance for the company’s COVID-19 shot. Further gains for the Maryland-based biotech are likely when an expert panel of the European regulators is set to review the marketing authorization for the vaccine next week.</p>\n<p><a href=\"https://laohu8.com/S/BHVN\">Biohaven Pharmaceutical </a> posted a ~25.2% weekly rise after the company announced the approval for NURTEC ODT (rimegepant) in Israel, making it the first regulatory win for the migraine drug outside the U.S. Meanwhile, Vir Biotechnology (NASDAQ:VIR) surged ~23.7% to stand among best gainers for the second week this month. More data emerged this week confirming the Omicron-neutralizing effect of the company’s COVID-19 therapy developed in partnership with GlaxoSmithKline (NYSE:GSK). Rounding out the top five gainers, <a href=\"https://laohu8.com/S/ROIV\">Roivant Sciences </a> added ~22.6%.</p>\n<p>Notable gainer: <a href=\"https://laohu8.com/S/PFE\">Pfizer</a> (PFE) made headlines throughout the week, raising its sales guidance for the COVID-19 vaccine once again as the rapidly spreading Omicron variant highlighted the need for booster shots. Despite an abrupt end to its six-day rally on Friday, the <a href=\"https://laohu8.com/S/NWY\">New York</a>-based pharma giant with a ~12.7% rise recorded its best weekly gain since March 2009.</p>\n<p>Among worst performers of the week, two newly IPO’ed biotechs, Instil Bio (NASDAQ:TIL) and Exscientia (NASDAQ:EXAI), stood out, falling 19.3% and ~13.5%, respectively, despite their favorable ratings on Wall Street. Meanwhile, GoodRx Holdings (NASDAQ:GDRX), an operator of a price comparison platform for prescription medicine slumped ~15.6%.</p>\n<p>Last week’s best performer, <a href=\"https://laohu8.com/S/BHG\">Bright Health Group</a>, crashed ~13.1%, hurt by the sole Sell rating issued by <a href=\"https://laohu8.com/S/GS\">Goldman Sachs</a> even as the investment bank kicked off its coverage on managed care with largely positive views.</p>\n<p>Allogene Therapeutics (NASDAQ:ALLO) dropped ~12.3% after the company’s ASH presentations on Phase 1 data for experimental allogeneic <a href=\"https://laohu8.com/S/00699\">CAR</a> T therapies failed to excite investors, including Cathie Wood’s Ark Investment Management, which sold ~1.6M shares of the biotech several days later.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax, Vir among healthcare gainers, Pfizer posts best rally in a decade</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax, Vir among healthcare gainers, Pfizer posts best rally in a decade\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-19 11:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3781487-novavax-vir-among-healthcare-gainers-pfizer-posts-best-rally-in-a-decade><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The healthcare stocks in the S&P 500 outperformed all other sectors in the broader index with a ~2.5% gain thanks mainly to M&A prospects. Healthcare technology, along with names battling the ...</p>\n\n<a href=\"https://seekingalpha.com/news/3781487-novavax-vir-among-healthcare-gainers-pfizer-posts-best-rally-in-a-decade\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ARNA":"阿里那","CERN":"美国塞纳","BK4534":"瑞士信贷持仓","PFE":"辉瑞","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4550":"红杉资本持仓","BK4568":"美国抗疫概念","ORCL":"甲骨文","BK4007":"制药"},"source_url":"https://seekingalpha.com/news/3781487-novavax-vir-among-healthcare-gainers-pfizer-posts-best-rally-in-a-decade","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1122414343","content_text":"The healthcare stocks in the S&P 500 outperformed all other sectors in the broader index with a ~2.5% gain thanks mainly to M&A prospects. Healthcare technology, along with names battling the resurgence of COVID-19, led the gainers while the overall index fell ~1.9%.\nAmong stocks with more than $2B market capitalization and 100K average daily volume over the past week, Arena Pharmaceuticals  dominated with a ~83.8% rise after Pfizer  agreed to acquire it in a ~$6.7B deal with 100% premium for the biotech. Cerner  also joined the M&A-driven rally to gain ~20.7% over the week amid reports of a potential ~$30B bid from Oracle  for the electronic-medical-records company.\nVaccine developer, Novavax  jumped ~30.5% as investors welcomed the WHO clearance for the company’s COVID-19 shot. Further gains for the Maryland-based biotech are likely when an expert panel of the European regulators is set to review the marketing authorization for the vaccine next week.\nBiohaven Pharmaceutical  posted a ~25.2% weekly rise after the company announced the approval for NURTEC ODT (rimegepant) in Israel, making it the first regulatory win for the migraine drug outside the U.S. Meanwhile, Vir Biotechnology (NASDAQ:VIR) surged ~23.7% to stand among best gainers for the second week this month. More data emerged this week confirming the Omicron-neutralizing effect of the company’s COVID-19 therapy developed in partnership with GlaxoSmithKline (NYSE:GSK). Rounding out the top five gainers, Roivant Sciences  added ~22.6%.\nNotable gainer: Pfizer (PFE) made headlines throughout the week, raising its sales guidance for the COVID-19 vaccine once again as the rapidly spreading Omicron variant highlighted the need for booster shots. Despite an abrupt end to its six-day rally on Friday, the New York-based pharma giant with a ~12.7% rise recorded its best weekly gain since March 2009.\nAmong worst performers of the week, two newly IPO’ed biotechs, Instil Bio (NASDAQ:TIL) and Exscientia (NASDAQ:EXAI), stood out, falling 19.3% and ~13.5%, respectively, despite their favorable ratings on Wall Street. Meanwhile, GoodRx Holdings (NASDAQ:GDRX), an operator of a price comparison platform for prescription medicine slumped ~15.6%.\nLast week’s best performer, Bright Health Group, crashed ~13.1%, hurt by the sole Sell rating issued by Goldman Sachs even as the investment bank kicked off its coverage on managed care with largely positive views.\nAllogene Therapeutics (NASDAQ:ALLO) dropped ~12.3% after the company’s ASH presentations on Phase 1 data for experimental allogeneic CAR T therapies failed to excite investors, including Cathie Wood’s Ark Investment Management, which sold ~1.6M shares of the biotech several days later.","news_type":1},"isVote":1,"tweetType":1,"viewCount":672,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":823280536,"gmtCreate":1633629291082,"gmtModify":1633629291510,"author":{"id":"3554895157968981","authorId":"3554895157968981","name":"canoboi","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like and comment. Thanks","listText":"Like and comment. Thanks","text":"Like and comment. Thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/823280536","repostId":"2173944807","repostType":4,"isVote":1,"tweetType":1,"viewCount":377,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":692490252,"gmtCreate":1641127475987,"gmtModify":1641127476362,"author":{"id":"3554895157968981","authorId":"3554895157968981","name":"canoboi","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like n comment","listText":"Like n comment","text":"Like n comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/692490252","repostId":"2200444738","repostType":4,"isVote":1,"tweetType":1,"viewCount":843,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691843505,"gmtCreate":1640173699052,"gmtModify":1640173790397,"author":{"id":"3554895157968981","authorId":"3554895157968981","name":"canoboi","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like and comment thanks","listText":"Like and comment thanks","text":"Like and comment thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/691843505","repostId":"1130487812","repostType":4,"isVote":1,"tweetType":1,"viewCount":618,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":602554024,"gmtCreate":1639046354491,"gmtModify":1639046354731,"author":{"id":"3554895157968981","authorId":"3554895157968981","name":"canoboi","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like and comment. Thanks","listText":"Like and comment. Thanks","text":"Like and comment. Thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/602554024","repostId":"1154556769","repostType":4,"isVote":1,"tweetType":1,"viewCount":222,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":820780700,"gmtCreate":1633433112004,"gmtModify":1633433149790,"author":{"id":"3554895157968981","authorId":"3554895157968981","name":"canoboi","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like and comment. Thanks","listText":"Like and comment. Thanks","text":"Like and comment. Thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/820780700","repostId":"2173918281","repostType":4,"repost":{"id":"2173918281","pubTimestamp":1633432920,"share":"https://www.laohu8.com/m/news/2173918281?lang=&edition=full","pubTime":"2021-10-05 19:22","market":"us","language":"en","title":"1 Recent Advertising Tech IPO to Watch","url":"https://stock-news.laohu8.com/highlight/detail?id=2173918281","media":"Motley Fool","summary":"Here's an ad tech company you might not have heard of yet.","content":"<p>Advertising tech company <b>PubMatic</b> (NASDAQ:PUBM) isn't quite as well known as other ad tech stocks like <b>The Trade Desk</b> (NASDAQ:TTD), but it may be worth a closer look. In this <i>Fool Live</i> video clip,&nbsp;<b>recorded on Sept. 27</b>, Fool.com contributor Jon Quast gives viewers a rundown of PubMatic's business and why it's a recent IPO on his watch list.</p>\n<p><b>Jon Quast:</b> It's an advertising technology company and it's opposite of The Trade Desk. Many investors might be familiar with <b>Magnite</b>. This is a direct competitor to Magnite. Magnite is the larger player in the space, but PubMatic has gotten to where it is organically, whereas Magnite has gotten there through acquisitions. That's <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the things that's interesting to me. It's a usage-based software-as-a-service company.</p>\n<p>Basically it partners with publishers to fill their ad slots, and the more ad slots that there are, the more things that are being filled, the more its software as a service is being used, the more revenue it can generate. Some of the reasons that I like this and let me share my screen.</p>\n<p>Why is it not pulling up this? Well, let me just say that since I can't pull it up. The global market for digital ads is growing at a very fast rate. It's growing at about a 15% compound annual growth rate. That is something that you want to see for these players, $650 billion, just a massive market. As you would expect, PubMatic's revenue is growing fast, up 88% year over year in the most recent quarter. I'm going to try to show the right page this time.</p>\n<p>Here we go. This is from their investor presentation here, they've got a lot of customer growth right now, which is one of the reasons that I like it. This is the most recent quarter and it says that it has this is just one part of the business that's connected TV. It's partnered with 114 connected TV partners. That is up from just 80 connected TV partners in the previous quarter. That is massive growth quarter over quarter, so they're winning a lot of new customers.</p>\n<p>As a software-as-a-service company, they do track the net dollar-based retention rate. I think Brian Feroldi says that's the good one. That's the one that we want to see. This as the increasing customer spend over time, that includes customer churn. In 2019, their dollar-based retention rate was 109%, 2020 it was 122%. As of the most recent quarter, it was 150%. Customers are staying, they're growing their customer base and existing customers are spending a lot more over time.</p>\n<p>When you look at the management team here, this is also very interesting. Look here, we have co-founder and CEO, founder and chairman, co-founder, president of engineering. There's also another co-founder on the board of directors. This is a management team that kept a lot of its early founders. What's really interesting here is Amar Goel. He is the chairman. Like I said, he owns nine percent of the company. His brother Rajeev owns 8.6% of the company. This is a management team that is very much invested in this company. Glassdoor, Rajeev gets a 92% approval rating, 4.4 out of five stars on Glassdoor. These are as good of Glassdoor ratings as I have seen. This company appears to be a very strong workplace that really helps explain why their organic growth has been so great compared to Magnite.</p>\n<p>Now, when you look at the financials here, what I want to point out is that this is the gross margin up here that is very high, 75%, that is about as high as you can get for any company. Net profit margin, very profitable even though it's a small company. I think it's around $200 million in annual revenue, very small company, but a 21% bottom-line profit. Its cash and equivalents, this mark right here showing $90 million, in reality, they have some short-term marketable securities brings a total balance up to over $122 million and they have zero debt on the balance sheet. A very financially strong company.</p>\n<p>Right now, the stock has been hammered, I think over concerns over Google and <b>Apple </b>changing up the ad tech market and its valuation has really dropped low. If you look at its price-to-sales, less than eight times sales for a company that is highly profitable and growing fast. This P/E ratio here, that's not quite the right one. I think it's closer to 50, but still trading at a very decent valuation for a fast-growth company in a fast-growing market, that has really great fundamentals.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>1 Recent Advertising Tech IPO to Watch</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n1 Recent Advertising Tech IPO to Watch\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-05 19:22 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/10/05/1-recent-advertising-tech-ipo-to-watch/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Advertising tech company PubMatic (NASDAQ:PUBM) isn't quite as well known as other ad tech stocks like The Trade Desk (NASDAQ:TTD), but it may be worth a closer look. In this Fool Live video clip, ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/10/05/1-recent-advertising-tech-ipo-to-watch/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PUBM":"PubMatic, Inc."},"source_url":"https://www.fool.com/investing/2021/10/05/1-recent-advertising-tech-ipo-to-watch/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2173918281","content_text":"Advertising tech company PubMatic (NASDAQ:PUBM) isn't quite as well known as other ad tech stocks like The Trade Desk (NASDAQ:TTD), but it may be worth a closer look. In this Fool Live video clip, recorded on Sept. 27, Fool.com contributor Jon Quast gives viewers a rundown of PubMatic's business and why it's a recent IPO on his watch list.\nJon Quast: It's an advertising technology company and it's opposite of The Trade Desk. Many investors might be familiar with Magnite. This is a direct competitor to Magnite. Magnite is the larger player in the space, but PubMatic has gotten to where it is organically, whereas Magnite has gotten there through acquisitions. That's one of the things that's interesting to me. It's a usage-based software-as-a-service company.\nBasically it partners with publishers to fill their ad slots, and the more ad slots that there are, the more things that are being filled, the more its software as a service is being used, the more revenue it can generate. Some of the reasons that I like this and let me share my screen.\nWhy is it not pulling up this? Well, let me just say that since I can't pull it up. The global market for digital ads is growing at a very fast rate. It's growing at about a 15% compound annual growth rate. That is something that you want to see for these players, $650 billion, just a massive market. As you would expect, PubMatic's revenue is growing fast, up 88% year over year in the most recent quarter. I'm going to try to show the right page this time.\nHere we go. This is from their investor presentation here, they've got a lot of customer growth right now, which is one of the reasons that I like it. This is the most recent quarter and it says that it has this is just one part of the business that's connected TV. It's partnered with 114 connected TV partners. That is up from just 80 connected TV partners in the previous quarter. That is massive growth quarter over quarter, so they're winning a lot of new customers.\nAs a software-as-a-service company, they do track the net dollar-based retention rate. I think Brian Feroldi says that's the good one. That's the one that we want to see. This as the increasing customer spend over time, that includes customer churn. In 2019, their dollar-based retention rate was 109%, 2020 it was 122%. As of the most recent quarter, it was 150%. Customers are staying, they're growing their customer base and existing customers are spending a lot more over time.\nWhen you look at the management team here, this is also very interesting. Look here, we have co-founder and CEO, founder and chairman, co-founder, president of engineering. There's also another co-founder on the board of directors. This is a management team that kept a lot of its early founders. What's really interesting here is Amar Goel. He is the chairman. Like I said, he owns nine percent of the company. His brother Rajeev owns 8.6% of the company. This is a management team that is very much invested in this company. Glassdoor, Rajeev gets a 92% approval rating, 4.4 out of five stars on Glassdoor. These are as good of Glassdoor ratings as I have seen. This company appears to be a very strong workplace that really helps explain why their organic growth has been so great compared to Magnite.\nNow, when you look at the financials here, what I want to point out is that this is the gross margin up here that is very high, 75%, that is about as high as you can get for any company. Net profit margin, very profitable even though it's a small company. I think it's around $200 million in annual revenue, very small company, but a 21% bottom-line profit. Its cash and equivalents, this mark right here showing $90 million, in reality, they have some short-term marketable securities brings a total balance up to over $122 million and they have zero debt on the balance sheet. A very financially strong company.\nRight now, the stock has been hammered, I think over concerns over Google and Apple changing up the ad tech market and its valuation has really dropped low. If you look at its price-to-sales, less than eight times sales for a company that is highly profitable and growing fast. This P/E ratio here, that's not quite the right one. I think it's closer to 50, but still trading at a very decent valuation for a fast-growth company in a fast-growing market, that has really great fundamentals.","news_type":1},"isVote":1,"tweetType":1,"viewCount":63,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}